

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 20 %										
2022-001	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	79.476	3.065	3.86	64.000	95.000				
2022-001	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	83.300	1.418	1.70	67.000	100.000				
2022-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	86.750	1.299	1.50	69.000	104.000				
2022-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	87.605	2.870	3.28	70.000	105.000				
2022-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	25	76.080	3.110	4.09	61.000	91.000				
2022-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	69.857	2.531	3.62	56.000	84.000				
2022-001	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	87.074	4.634	5.32	70.000	104.000				
2022-001	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	92.000	4.583	4.98	74.000	110.000				
2022-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	30	77.100	1.814	2.35	62.000	93.000				
2022-001	11 MOD. IFCC	212 S. D. EXL	143 SIEMENS	10	87.200	4.045	4.64	70.000	105.000				
2022-001	13 ALA &aKETO	165 VITROS	155 ALTV	130	76.477	1.978	2.59	61.000	92.000				
2022-002	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	405.714	12.190	3.00	325.000	487.000				
2022-002	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	378.900	8.904	2.35	303.000	455.000				
2022-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	423.763	12.456	2.94	339.000	509.000				
2022-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	430.000	7.969	1.85	344.000	516.000				
2022-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	25	386.800	10.822	2.80	309.000	464.000				
2022-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	358.321	13.724	3.83	287.000	430.000				
2022-002	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	435.630	28.616	6.57	349.000	523.000				
2022-002	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	426.000	17.364	4.08	341.000	511.000				
2022-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	30	395.300	11.530	2.92	316.000	474.000				
2022-002	11 MOD. IFCC	212 S. D. EXL	143 SIEMENS	10	422.600	11.552	2.73	338.000	507.000				
2022-002	13 ALA &aKETO	165 VITROS	155 ALTV	130	370.414	10.809	2.92	296.000	444.000				
2022-003	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	372.500	8.292	2.23	298.000	447.000				
2022-003	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	350.300	7.239	2.07	280.000	420.000				
2022-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	399.000	16.386	4.11	319.000	479.000				
2022-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	77	387.132	10.347	2.67	310.000	465.000				
2022-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	25	349.520	10.439	2.99	280.000	419.000				

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-003	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	28	327.464	8.604	2.63	262.000	393.000	
2022-003	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	404.778	27.990	6.91	324.000	486.000	
2022-003	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	395.250	10.280	2.60	316.000	474.000	
2022-003	11 MOD. IFCC	203	ROCHE	93	ROCHE	30	357.967	9.711	2.71	286.000	430.000	
2022-003	11 MOD. IFCC	212	S. D. EXL	143	SIEMENS	10	382.400	13.858	3.62	306.000	459.000	
2022-003	13 ALA &aKETO	165	VITROS	155	ALTV	130	334.000	8.598	2.57	267.000	401.000	
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 20 %									
2022-004	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	21	140.619	4.865	3.46	112.000	169.000	
2022-004	10 KINETIC 37	215	B.C DXC	134	BECKM.COUL	10	141.800	2.482	1.75	113.000	170.000	
2022-004	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	153.079	4.596	3.00	122.000	184.000	
2022-004	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	152.750	4.969	3.25	122.000	183.000	
2022-004	11 MOD. IFCC	184	INTEGRA	93	ROCHE	25	135.875	5.085	3.74	109.000	163.000	
2022-004	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	28	124.643	3.686	2.96	100.000	150.000	
2022-004	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	155.556	6.142	3.95	124.000	187.000	
2022-004	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	162.500	4.153	2.56	130.000	195.000	
2022-004	11 MOD. IFCC	203	ROCHE	93	ROCHE	30	137.207	3.633	2.65	110.000	165.000	
2022-004	11 MOD. IFCC	212	S. D. EXL	143	SIEMENS	10	150.900	4.206	2.79	121.000	181.000	
2022-004	13 ALA &aKETO	165	VITROS	155	ALTV	130	133.302	3.841	2.88	107.000	160.000	
2022-005	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	21	18.000	2.655	14.75	14.000	22.000	
2022-005	10 KINETIC 37	215	B.C DXC	134	BECKM.COUL	10	26.700	1.100	4.12	21.000	32.000	
2022-005	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	21.750	2.046	9.41	17.000	26.000	
2022-005	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	21.908	2.116	9.66	18.000	26.000	
2022-005	11 MOD. IFCC	184	INTEGRA	93	ROCHE	25	16.042	0.841	5.24	13.000	19.000	
2022-005	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	28	15.321	0.467	3.05	12.000	18.000	
2022-005	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	18.222	2.079	11.41	15.000	22.000	
2022-005	11 MOD. IFCC	191	RX-DAYTONA	126	RANDOX	28	21.000	0.707	3.37	17.000	25.000	
2022-005	11 MOD. IFCC	203	ROCHE	93	ROCHE	30	17.033	0.836	4.91	14.000	20.000	
2022-005	11 MOD. IFCC	212	S. D. EXL	143	SIEMENS	10	21.700	1.418	6.53	17.000	26.000	
2022-005	13 ALA &aKETO	165	VITROS	155	ALTV	130	14.531	0.809	5.57	12.000	17.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
002	ALBUMIN			CLIA TEST ID #: 265								
				EVALUATION CRITERIA: TARGET VALUE		10 %						
2022-001	3	DYE BI-B.G	165	VITROS	63	KODAK	147	2.413	0.075	3.13	2.200	2.700
2022-001	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	35	2.535	0.090	3.56	2.300	2.800
2022-001	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	28	2.414	0.074	3.07	2.200	2.700
2022-001	3	DYE BI-B.G	191	RX-DAYTONA	126	RANDOX	31	2.490	0.109	4.37	2.200	2.700
2022-001	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	20	2.335	0.073	3.11	2.100	2.600
2022-001	3	DYE BI-B.G	199	Rx-IMOLA	126	RANDOX	10	2.580	0.098	3.80	2.300	2.800
2022-001	3	DYE BI-B.G	203	ROCHE	93	ROCHE	38	2.571	0.112	4.36	2.300	2.800
2022-001	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	81	2.228	0.069	3.09	2.000	2.500
2022-001	4	DYE BI-B.P	212	S. D. EXL	143	SIEMENS	13	2.262	0.074	3.26	2.000	2.500
2022-002	3	DYE BI-B.G	165	VITROS	63	KODAK	147	5.646	0.183	3.24	5.100	6.200
2022-002	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	35	5.347	0.138	2.58	4.800	5.900
2022-002	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	28	5.081	0.154	3.03	4.600	5.600
2022-002	3	DYE BI-B.G	191	RX-DAYTONA	126	RANDOX	31	5.145	0.217	4.21	4.600	5.700
2022-002	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	20	5.005	0.143	2.86	4.500	5.500
2022-002	3	DYE BI-B.G	199	Rx-IMOLA	126	RANDOX	10	5.310	0.202	3.81	4.800	5.800
2022-002	3	DYE BI-B.G	203	ROCHE	93	ROCHE	38	5.435	0.155	2.84	4.900	6.000
2022-002	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	81	5.031	0.154	3.06	4.500	5.500
2022-002	4	DYE BI-B.P	212	S. D. EXL	143	SIEMENS	13	5.069	0.120	2.37	4.600	5.600
2022-003	3	DYE BI-B.G	165	VITROS	63	KODAK	147	5.333	0.164	3.08	4.800	5.900
2022-003	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	35	5.068	0.139	2.74	4.600	5.600
2022-003	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	28	4.861	0.118	2.42	4.400	5.300
2022-003	3	DYE BI-B.G	191	RX-DAYTONA	126	RANDOX	31	4.877	0.191	3.92	4.400	5.400
2022-003	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	20	4.750	0.136	2.86	4.300	5.200
2022-003	3	DYE BI-B.G	199	Rx-IMOLA	126	RANDOX	10	4.920	0.204	4.15	4.400	5.400
2022-003	3	DYE BI-B.G	203	ROCHE	93	ROCHE	38	5.149	0.141	2.73	4.600	5.700
2022-003	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	81	4.721	0.143	3.03	4.200	5.200
2022-003	4	DYE BI-B.P	212	S. D. EXL	143	SIEMENS	13	4.700	0.184	3.91	4.200	5.200

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
002	ALBUMIN	CLIA TEST ID #: 265	EVALUATION CRITERIA: TARGET VALUE 10 %								
2022-004	3 DYE BI-B.G	165 VITROS	63 KODAK		147	3.029	0.103	3.42	2.700	3.300	
2022-004	3 DYE BI-B.G	184 INTEGRA	93 ROCHE		35	3.115	0.106	3.41	2.800	3.400	
2022-004	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN		28	2.961	0.094	3.17	2.700	3.300	
2022-004	3 DYE BI-B.G	191 RX-DAYTONA	126 RANDOX		31	3.027	0.129	4.26	2.700	3.300	
2022-004	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT		20	2.880	0.087	3.03	2.600	3.200	
2022-004	3 DYE BI-B.G	199 Rx-IMOLA	126 RANDOX		10	3.100	0.089	2.89	2.800	3.400	
2022-004	3 DYE BI-B.G	203 ROCHE	93 ROCHE		38	3.145	0.116	3.70	2.800	3.500	
2022-004	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS		81	2.764	0.084	3.02	2.500	3.000	
2022-004	4 DYE BI-B.P	212 S. D. EXL	143 SIEMENS		13	2.777	0.080	2.88	2.500	3.100	
2022-005	3 DYE BI-B.G	165 VITROS	63 KODAK		147	1.826	0.061	3.33	1.600	2.000	
2022-005	3 DYE BI-B.G	184 INTEGRA	93 ROCHE		35	1.921	0.058	3.04	1.700	2.100	
2022-005	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN		28	1.843	0.049	2.69	1.700	2.000	
2022-005	3 DYE BI-B.G	191 RX-DAYTONA	126 RANDOX		31	1.919	0.093	4.85	1.700	2.100	
2022-005	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT		20	1.770	0.064	3.62	1.600	1.900	
2022-005	3 DYE BI-B.G	199 Rx-IMOLA	126 RANDOX		10	1.990	0.054	2.71	1.800	2.200	
2022-005	3 DYE BI-B.G	203 ROCHE	93 ROCHE		38	1.961	0.074	3.80	1.800	2.200	
2022-005	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS		81	1.664	0.057	3.44	1.500	1.800	
2022-005	4 DYE BI-B.P	212 S. D. EXL	143 SIEMENS		13	1.669	0.082	4.92	1.500	1.800	
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE 30 %								
2022-001	3 COLORIMET.	184 INTEGRA	93 ROCHE		28	79.036	2.909	3.68	55.000	103.000	
2022-001	3 COLORIMET.	203 ROCHE	93 ROCHE		26	76.800	2.980	3.88	54.000	100.000	
2022-001	3 COLORIMET.	203 ROCHE	93 ROCHE		26	76.400	3.826	5.01	53.000	99.000	
2022-001	5 KINETIC 30	197 ARCHITECT	1 ABBOTT		10	71.900	6.024	8.38	50.000	93.000	
2022-001	6 KINETIC 37	165 VITROS	63 KODAK		147	85.113	4.353	5.11	60.000	111.000	
2022-001	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	60.200	4.512	7.50	42.000	78.000	
2022-001	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN		29	64.690	6.086	9.41	45.000	84.000	
2022-001	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX		25	67.833	5.603	8.26	47.000	88.000	
2022-001	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX		25	63.750	4.969	7.79	45.000	83.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-001	11	Modified I	38	SIEMENS DI	143	SIEMENS	76	79.547	4.467	5.62	56.000	103.000
2022-001	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	72.000	5.893	8.18	50.000	94.000
003	ALKALINE PHOSPHATE		CLIA TEST ID #: 275		EVALUATION CRITERIA: TARGET VALUE 30 %							
2022-002	3	COLORIMET.	184	INTEGRA	93	ROCHE	28	362.393	13.300	3.67	254.000	471.000
2022-002	3	COLORIMET.	203	ROCHE	93	ROCHE	26	349.400	13.676	3.91	245.000	454.000
2022-002	3	COLORIMET.	203	ROCHE	93	ROCHE	26	354.292	13.265	3.74	248.000	461.000
2022-002	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	323.200	12.952	4.01	226.000	420.000
2022-002	6	KINETIC 37	165	VITROS	63	KODAK	147	187.167	9.646	5.15	131.000	243.000
2022-002	6	KINETIC 37	215	B.C DXC	134	BECKM.COUL	10	270.600	19.780	7.31	189.000	352.000
2022-002	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	300.241	30.589	10.19	210.000	390.000
2022-002	9	ENZYMAT.37	191	RX-DAYTONA	126	RANDOX	25	277.500	16.576	5.97	194.000	361.000
2022-002	9	ENZYMAT.37	191	RX-DAYTONA	126	RANDOX	25	293.840	34.269	11.66	206.000	382.000
2022-002	11	Modified I	38	SIEMENS DI	143	SIEMENS	76	365.093	13.656	3.74	256.000	475.000
2022-002	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	324.636	25.684	7.91	227.000	422.000
2022-003	3	COLORIMET.	184	INTEGRA	93	ROCHE	28	329.857	13.437	4.07	231.000	429.000
2022-003	3	COLORIMET.	203	ROCHE	93	ROCHE	26	320.083	10.758	3.36	224.000	416.000
2022-003	3	COLORIMET.	203	ROCHE	93	ROCHE	26	319.000	14.381	4.51	223.000	415.000
2022-003	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	295.000	10.918	3.70	207.000	384.000
2022-003	6	KINETIC 37	165	VITROS	63	KODAK	147	185.340	9.542	5.15	130.000	241.000
2022-003	6	KINETIC 37	215	B.C DXC	134	BECKM.COUL	10	251.100	18.721	7.46	176.000	326.000
2022-003	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	273.000	25.395	9.30	191.000	355.000
2022-003	9	ENZYMAT.37	191	RX-DAYTONA	126	RANDOX	25	269.040	28.780	10.70	188.000	350.000
2022-003	9	ENZYMAT.37	191	RX-DAYTONA	126	RANDOX	25	253.750	17.283	6.81	178.000	330.000
2022-003	11	Modified I	38	SIEMENS DI	143	SIEMENS	76	332.560	10.979	3.30	233.000	432.000
2022-003	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	304.900	7.622	2.50	213.000	396.000
2022-004	3	COLORIMET.	184	INTEGRA	93	ROCHE	28	131.429	5.081	3.87	92.000	171.000
2022-004	3	COLORIMET.	203	ROCHE	93	ROCHE	26	127.200	5.706	4.49	89.000	165.000
2022-004	3	COLORIMET.	203	ROCHE	93	ROCHE	26	129.160	3.926	3.04	90.000	168.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2022-004	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	10	117.300	4.605	3.93	82.000	152.000			
2022-004	6 KINETIC 37	165 VITROS	63 KODAK	147	125.021	6.772	5.42	88.000	163.000			
2022-004	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	99.500	6.756	6.79	70.000	129.000			
2022-004	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	29	107.862	9.846	9.13	76.000	140.000			
2022-004	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX	25	104.500	5.852	5.60	73.000	136.000			
2022-004	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX	25	114.333	12.595	11.02	80.000	149.000			
2022-004	11 Modified I	38 SIEMENS DI	143 SIEMENS	76	132.068	4.589	3.48	92.000	172.000			
2022-004	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	11	119.182	9.291	7.80	83.000	155.000			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE 30 %									
2022-005	3 COLORIMET.	184 INTEGRA	93 ROCHE	28	26.714	1.385	5.18	19.000	35.000			
2022-005	3 COLORIMET.	203 ROCHE	93 ROCHE	26	26.000	0.849	3.26	18.000	34.000			
2022-005	3 COLORIMET.	203 ROCHE	93 ROCHE	26	25.600	1.356	5.30	18.000	33.000			
2022-005	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	10	23.700	2.193	9.25	17.000	31.000			
2022-005	6 KINETIC 37	165 VITROS	63 KODAK	147	36.517	2.711	7.43	26.000	47.000			
2022-005	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	20.100	1.300	6.47	14.000	26.000			
2022-005	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	29	21.379	2.235	10.45	15.000	28.000			
2022-005	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX	25	23.680	3.121	13.18	17.000	31.000			
2022-005	9 ENZYMAT.37	191 RX-DAYTONA	126 RANDOX	25	22.750	1.090	4.79	16.000	30.000			
2022-005	11 Modified I	38 SIEMENS DI	143 SIEMENS	76	27.013	2.831	10.48	19.000	35.000			
2022-005	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	11	24.364	2.532	10.39	17.000	32.000			
004	AMYLASE	CLIA TEST ID #: 285										
2022-001	3 ENZYM. 37C	165 VITROS	63 KODAK	87	48.046	4.766	9.92	34.000	62.000			
2022-001	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL	10	71.500	1.118	1.56	50.000	93.000			
2022-001	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	24	64.500	1.118	1.73	45.000	84.000			
2022-001	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	12	67.917	1.754	2.58	48.000	88.000			
2022-001	9 ENZ/COL.37	203 ROCHE	93 ROCHE	23	65.739	1.481	2.25	46.000	85.000			
2022-001	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	17	49.765	2.340	4.70	35.000	65.000			
2022-002	3 ENZYM. 37C	165 VITROS	63 KODAK	87	209.581	8.439	4.03	147.000	272.000			
2022-002	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL	10	314.100	4.763	1.52	220.000	408.000			

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-002	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	24	291.957	4.535	1.55	204.000	380.000		
2022-002	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	12	302.167	9.512	3.15	212.000	393.000		
2022-002	9 ENZ/COL.37	203 ROCHE	93 ROCHE	23	296.000	5.939	2.01	207.000	385.000		
2022-002	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	17	231.529	10.494	4.53	162.000	301.000		
004	AMYLASE	CLIA TEST ID #: 285	EVALUATION CRITERIA: TARGET VALUE 30 %								
2022-003	3 ENZYM. 37C	165 VITROS	63 KODAK	87	192.931	8.970	4.65	135.000	251.000		
2022-003	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL	10	287.700	4.670	1.62	201.000	374.000		
2022-003	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	24	267.708	4.623	1.73	187.000	348.000		
2022-003	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	12	273.167	8.163	2.99	191.000	355.000		
2022-003	9 ENZ/COL.37	203 ROCHE	93 ROCHE	23	268.174	7.637	2.85	188.000	349.000		
2022-003	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	17	210.941	9.564	4.53	148.000	274.000		
2022-004	3 ENZYM. 37C	165 VITROS	63 KODAK	87	80.407	4.895	6.09	56.000	105.000		
2022-004	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL	10	115.600	1.855	1.60	81.000	150.000		
2022-004	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	24	107.208	1.779	1.66	75.000	139.000		
2022-004	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	12	110.917	2.985	2.69	78.000	144.000		
2022-004	9 ENZ/COL.37	203 ROCHE	93 ROCHE	23	107.955	1.918	1.78	76.000	140.000		
2022-004	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	17	83.294	3.544	4.25	58.000	108.000		
2022-005	3 ENZYM. 37C	165 VITROS	63 KODAK	87	30.000	0.000	0.00	21.000	39.000		
2022-005	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL	10	24.900	0.831	3.34	17.000	32.000		
2022-005	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	24	21.125	0.725	3.43	15.000	27.000		
2022-005	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	12	25.333	0.624	2.46	18.000	33.000		
2022-005	9 ENZ/COL.37	203 ROCHE	93 ROCHE	23	24.364	0.568	2.33	17.000	32.000		
2022-005	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	17	15.941	0.998	6.26	11.000	21.000		
005	ASP. AMINO AST/SGOT	CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 20 %								
2022-001	1 ASPAR&KETO	165 VITROS	63 KODAK	142	111.482	4.169	3.74	89.000	134.000		
2022-001	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	80	100.203	3.362	3.35	80.000	120.000		
2022-001	5 ENZYMA.37C	212 S. D. EXL	143 SIEMENS	12	100.500	3.905	3.89	80.000	121.000		
2022-001	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	99.400	2.154	2.17	80.000	119.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2022-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	27	101.519	4.031	3.97	81.000	122.000			
2022-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	87.630	4.209	4.80	70.000	105.000			
2022-001	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	112.500	7.921	7.04	90.000	135.000			
2022-001	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	107.750	4.969	4.61	86.000	129.000			
2022-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	28	101.667	3.006	2.96	81.000	122.000			
2022-001	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	15	97.000	2.828	2.92	78.000	116.000			
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 20 %									
2022-002	1 ASPAR&KETO	165 VITROS	63 KODAK	142	588.421	23.704	4.03	471.000	706.000			
2022-002	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	80	426.101	12.549	2.95	341.000	511.000			
2022-002	5 ENZYMA.37C	212 S. D. EXL	143 SIEMENS	12	427.167	14.123	3.31	342.000	513.000			
2022-002	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	390.200	13.029	3.34	312.000	468.000			
2022-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	27	422.074	14.355	3.40	338.000	506.000			
2022-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	363.000	18.188	5.01	290.000	436.000			
2022-002	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	454.444	40.728	8.96	364.000	545.000			
2022-002	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	397.250	70.083	17.64	318.000	477.000			
2022-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	28	422.607	16.940	4.01	338.000	507.000			
2022-002	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	15	402.400	13.078	3.25	322.000	483.000			
2022-003	1 ASPAR&KETO	165 VITROS	63 KODAK	142	529.936	17.547	3.31	424.000	636.000			
2022-003	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	80	390.456	10.803	2.77	312.000	469.000			
2022-003	5 ENZYMA.37C	212 S. D. EXL	143 SIEMENS	12	388.333	13.487	3.47	311.000	466.000			
2022-003	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	365.800	11.418	3.12	293.000	439.000			
2022-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	27	385.111	14.690	3.81	308.000	462.000			
2022-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	334.667	15.210	4.54	268.000	402.000			
2022-003	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	423.074	32.263	7.63	338.000	508.000			
2022-003	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	385.750	53.096	13.76	309.000	463.000			
2022-003	11 MOD. IFCC	203 ROCHE	93 ROCHE	28	387.786	15.082	3.89	310.000	465.000			
2022-003	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	15	373.786	6.753	1.81	299.000	449.000			
2022-004	1 ASPAR&KETO	165 VITROS	63 KODAK	142	186.761	5.211	2.79	149.000	224.000			

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-004	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	80	161.772	4.392	2.71	129.000	194.000		
2022-004	5 ENZYMA.37C	212 S. D. EXL	143 SIEMENS	12	161.917	5.107	3.15	130.000	194.000		
2022-004	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	157.600	3.072	1.95	126.000	189.000		
2022-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE	27	163.577	6.789	4.15	131.000	196.000		
2022-004	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	141.556	6.291	4.44	113.000	170.000		
2022-004	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	180.000	13.818	7.68	144.000	216.000		
2022-004	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	153.250	34.795	22.70	123.000	184.000		
2022-004	11 MOD. IFCC	203 ROCHE	93 ROCHE	28	163.536	6.603	4.04	131.000	196.000		
2022-004	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	15	154.867	4.349	2.81	124.000	186.000		
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 20 %								
2022-005	1 ASPAR&KETO	165 VITROS	63 KODAK	142	44.357	1.488	3.36	35.000	53.000		
2022-005	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	80	39.772	1.814	4.56	32.000	48.000		
2022-005	5 ENZYMA.37C	212 S. D. EXL	143 SIEMENS	12	38.417	2.290	5.96	31.000	46.000		
2022-005	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	42.300	1.345	3.18	34.000	51.000		
2022-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE	27	39.222	1.474	3.76	31.000	47.000		
2022-005	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	34.704	1.356	3.91	28.000	42.000		
2022-005	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	43.643	3.598	8.24	35.000	52.000		
2022-005	11 MOD. IFCC	191 RX-DAYTONA	126 RANDOX	28	42.500	2.291	5.39	34.000	51.000		
2022-005	11 MOD. IFCC	203 ROCHE	93 ROCHE	28	39.571	1.178	2.98	32.000	47.000		
2022-005	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	15	37.733	0.998	2.64	30.000	45.000		
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305									
2022-001	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	80	0.807	0.045	5.58	0.650	0.970		
2022-001	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN	26	0.913	0.036	3.89	0.730	1.100		
2022-001	4 J-G WITH B	191 RX-DAYTONA	126 RANDOX	20	0.832	0.096	11.59	0.670	1.000		
2022-001	4 J-G WITH B	212 S. D. EXL	143 SIEMENS	11	0.839	0.069	8.23	0.670	1.010		
2022-001	5 J-G NO BK.	215 B.C DXC	134 BECKM.COUL	10	1.035	0.102	9.81	0.830	1.240		
2022-001	7 DIAZO-DYPH	165 VITROS	63 KODAK	142	0.841	0.091	10.81	0.670	1.010		
2022-001	7 DIAZO-DYPH	165 VITROS	63 KODAK	142	0.800	0.082	10.21	0.640	0.960		
2022-001	13 AZOBIL.	184 INTEGRA	93 ROCHE	15	0.729	0.032	4.37	0.580	0.870		
2022-001	13 AZOBIL.	203 ROCHE	93 ROCHE	25	0.710	0.027	3.84	0.570	0.850		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-001	18	COLORIMETR	203	ROCHE	93	ROCHE	12	0.738	0.049	6.59	0.590	0.890
2022-001	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	0.787	0.059	7.53	0.630	0.940
2022-001	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	0.808	0.092	11.38	0.650	0.970
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-002	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	5.412	0.239	4.42	4.330	6.490
2022-002	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	5.267	0.196	3.72	4.210	6.320
2022-002	4	J-G WITH B	191	RX-DAYTONA	126	RANDOX	20	5.425	0.468	8.62	4.340	6.510
2022-002	4	J-G WITH B	212	S. D. EXL	143	SIEMENS	11	5.569	0.218	3.92	4.460	6.680
2022-002	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	5.853	0.223	3.81	4.680	7.020
2022-002	7	DIAZO-DYPH	165	VITROS	63	KODAK	142	4.533	0.125	2.75	3.630	5.440
2022-002	7	DIAZO-DYPH	165	VITROS	63	KODAK	142	4.812	0.210	4.36	3.850	5.770
2022-002	13	AZOBIL.	184	INTEGRA	93	ROCHE	15	4.850	0.292	6.01	3.880	5.820
2022-002	13	AZOBIL.	203	ROCHE	93	ROCHE	25	4.780	0.160	3.36	3.820	5.740
2022-002	18	COLORIMETR	203	ROCHE	93	ROCHE	12	4.902	0.235	4.80	3.920	5.880
2022-002	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	5.069	0.266	5.24	4.060	6.080
2022-002	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	5.338	0.461	8.63	4.270	6.410
2022-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	4.899	0.178	3.63	3.920	5.880
2022-003	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	26	4.819	0.152	3.16	3.860	5.780
2022-003	4	J-G WITH B	191	RX-DAYTONA	126	RANDOX	20	4.984	0.306	6.14	3.990	5.980
2022-003	4	J-G WITH B	212	S. D. EXL	143	SIEMENS	11	4.950	0.249	5.04	3.960	5.940
2022-003	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	5.373	0.174	3.23	4.300	6.450
2022-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	142	4.376	0.212	4.85	3.500	5.250
2022-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	142	4.200	0.082	1.94	3.360	5.040
2022-003	13	AZOBIL.	184	INTEGRA	93	ROCHE	15	4.313	0.152	3.53	3.450	5.180
2022-003	13	AZOBIL.	203	ROCHE	93	ROCHE	25	4.359	0.173	3.98	3.490	5.230
2022-003	18	COLORIMETR	203	ROCHE	93	ROCHE	12	4.424	0.224	5.07	3.540	5.310
2022-003	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	4.592	0.245	5.34	3.670	5.510
2022-003	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	12	4.778	0.355	7.43	3.820	5.730

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
006	BILIRUBIN, TOTAL	CLIA TEST ID #: 305				EVALUATION CRITERIA: TARGET VALUE 20 %					
2022-004	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		80	1.665	0.081	4.86	1.330	2.000	
2022-004	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		26	1.768	0.098	5.52	1.410	2.120	
2022-004	4 J-G WITH B	191 RX-DAYTONA	126 RANDOX		20	1.661	0.106	6.41	1.330	1.990	
2022-004	4 J-G WITH B	212 S. D. EXL	143 SIEMENS		11	1.685	0.079	4.68	1.350	2.020	
2022-004	5 J-G NO BK.	215 B.C DXC	134 BECKM.COUL		10	1.912	0.119	6.21	1.530	2.290	
2022-004	7 DIAZO-DYPH	165 VITROS	63 KODAK		142	1.500	0.082	5.44	1.200	1.800	
2022-004	7 DIAZO-DYPH	165 VITROS	63 KODAK		142	1.584	0.107	6.73	1.270	1.900	
2022-004	13 AZOBIL.	184 INTEGRA	93 ROCHE		15	1.507	0.091	6.04	1.210	1.810	
2022-004	13 AZOBIL.	203 ROCHE	93 ROCHE		25	1.466	0.056	3.80	1.170	1.760	
2022-004	18 COLORIMETR	203 ROCHE	93 ROCHE		12	1.511	0.093	6.15	1.210	1.810	
2022-004	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	1.602	0.104	6.51	1.280	1.920	
2022-004	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	1.670	0.107	6.38	1.340	2.000	
2022-005	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		80	0.095	0.037	39.22	0.080	0.110	
2022-005	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		26	0.105	0.014	13.74	0.080	0.130	
2022-005	4 J-G WITH B	191 RX-DAYTONA	126 RANDOX		20	0.108	0.066	61.70	0.090	0.130	
2022-005	4 J-G WITH B	212 S. D. EXL	143 SIEMENS		11	0.073	0.035	48.73	0.060	0.090	
2022-005	5 J-G NO BK.	215 B.C DXC	134 BECKM.COUL		10	0.153	0.080	52.45	0.120	0.180	
2022-005	7 DIAZO-DYPH	165 VITROS	63 KODAK		142	0.172	0.073	42.53	0.140	0.210	
2022-005	7 DIAZO-DYPH	165 VITROS	63 KODAK		142	0.200	0.082	40.82	0.160	0.240	
2022-005	13 AZOBIL.	184 INTEGRA	93 ROCHE		15	0.072	0.080	110.44	0.060	0.090	
2022-005	13 AZOBIL.	203 ROCHE	93 ROCHE		25	0.148	0.028	18.73	0.120	0.180	
2022-005	18 COLORIMETR	203 ROCHE	93 ROCHE		12	0.146	0.025	16.90	0.120	0.180	
2022-005	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	0.090	0.029	31.78	0.070	0.110	
2022-005	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	0.100	0.000	0.00	0.080	0.120	
010	CALCIUM, TOTAL	CLIA TEST ID #: 345				EVALUATION CRITERIA: TARGET VALUE 1.00					
2022-001	3 ARSEN.-III	165 VITROS	63 KODAK		161	6.836	0.142	2.08	5.800	7.800	
2022-001	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN		30	6.893	0.177	2.57	5.900	7.900	
2022-001	3 ARSEN.-III	191 RX-DAYTONA	126 RANDOX		33	7.294	0.282	3.86	6.300	8.300	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-001	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	6.733	0.249	3.70	5.700	7.700
2022-001	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	6.850	0.189	2.76	5.900	7.900
2022-001	3	ARSEN.-III	199	Rx-IMOLA	126	RANDOX	10	7.310	0.176	2.40	6.300	8.300
2022-001	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	82	6.774	0.195	2.88	5.800	7.800
2022-001	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	16	6.938	0.291	4.20	5.900	7.900
2022-001	8	CRESOLPHT.	203	ROCHE	93	ROCHE	11	6.891	0.150	2.18	5.900	7.900
2022-001	8	CRESOLPHT.	212	S. D. EXL	143	SIEMENS	13	6.762	0.150	2.21	5.800	7.800
2022-001	14	ELECTRODE	215	B.C DXC	134	BECKM.COUL	10	6.980	0.117	1.67	6.000	8.000
2022-001	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	20	6.910	0.109	1.58	5.900	7.900
2022-001	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	26	7.054	0.174	2.46	6.100	8.100
010 CALCIUM, TOTAL			CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2022-002	3	ARSEN.-III	165	VITROS	63	KODAK	161	12.166	0.209	1.72	11.200	13.200
2022-002	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	30	12.814	0.284	2.21	11.800	13.800
2022-002	3	ARSEN.-III	191	RX-DAYTONA	126	RANDOX	33	12.621	0.520	4.12	11.600	13.600
2022-002	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	13.000	0.516	3.97	12.000	14.000
2022-002	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	13.178	0.850	6.45	12.200	14.200
2022-002	3	ARSEN.-III	199	Rx-IMOLA	126	RANDOX	10	12.900	0.539	4.17	11.900	13.900
2022-002	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	82	12.293	0.340	2.77	11.300	13.300
2022-002	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	16	12.569	0.380	3.03	11.600	13.600
2022-002	8	CRESOLPHT.	203	ROCHE	93	ROCHE	11	12.564	0.367	2.92	11.600	13.600
2022-002	8	CRESOLPHT.	212	S. D. EXL	143	SIEMENS	13	12.385	0.332	2.68	11.400	13.400
2022-002	14	ELECTRODE	215	B.C DXC	134	BECKM.COUL	10	12.090	0.255	2.11	11.100	13.100
2022-002	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	20	12.605	0.216	1.71	11.600	13.600
2022-002	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	26	12.619	0.349	2.76	11.600	13.600
2022-003	3	ARSEN.-III	165	VITROS	63	KODAK	161	11.696	0.199	1.70	10.700	12.700
2022-003	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	30	12.267	0.251	2.04	11.300	13.300
2022-003	3	ARSEN.-III	191	RX-DAYTONA	126	RANDOX	33	12.103	0.467	3.86	11.100	13.100
2022-003	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	12.033	1.257	10.45	11.000	13.000
2022-003	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	12.292	0.565	4.60	11.300	13.300

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2022-003	3	ARSEN.-III	199 Rx-IMOLA	126	RANDOX	10	12.080	0.412	3.41	11.100	13.100	
2022-003	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	82	11.684	0.318	2.72	10.700	12.700	
2022-003	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	16	11.869	0.422	3.56	10.900	12.900	
2022-003	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	11.855	0.274	2.31	10.900	12.900	
2022-003	8	CRESOLPHT.	212 S. D. EXL	143	SIEMENS	13	11.754	0.384	3.26	10.800	12.800	
2022-003	14	ELECTRODE	215 B.C DXC	134	BECKM.COUL	10	11.620	0.223	1.92	10.600	12.600	
2022-003	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	20	12.020	0.317	2.64	11.000	13.000	
2022-003	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	26	12.081	0.316	2.62	11.100	13.100	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2022-004	3	ARSEN.-III	165 VITROS	63	KODAK	161	7.954	0.174	2.19	7.000	9.000	
2022-004	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	30	8.040	0.187	2.33	7.000	9.000	
2022-004	3	ARSEN.-III	191 RX-DAYTONA	126	RANDOX	33	8.363	0.381	4.56	7.400	9.400	
2022-004	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	12	7.908	0.293	3.70	6.900	8.900	
2022-004	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	12	7.689	0.260	3.38	6.700	8.700	
2022-004	3	ARSEN.-III	199 Rx-IMOLA	126	RANDOX	10	8.380	0.248	2.96	7.400	9.400	
2022-004	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	82	7.823	0.223	2.85	6.800	8.800	
2022-004	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	16	8.000	0.276	3.45	7.000	9.000	
2022-004	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	7.955	0.271	3.41	7.000	9.000	
2022-004	8	CRESOLPHT.	212 S. D. EXL	143	SIEMENS	13	7.792	0.177	2.28	6.800	8.800	
2022-004	14	ELECTRODE	215 B.C DXC	134	BECKM.COUL	10	7.950	0.102	1.29	7.000	9.000	
2022-004	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	20	8.020	0.136	1.70	7.000	9.000	
2022-004	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	26	8.152	0.160	1.97	7.200	9.200	
2022-005	3	ARSEN.-III	165 VITROS	63	KODAK	161	5.676	0.135	2.37	4.700	6.700	
2022-005	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	30	5.717	0.137	2.39	4.700	6.700	
2022-005	3	ARSEN.-III	191 RX-DAYTONA	126	RANDOX	33	6.097	0.235	3.86	5.100	7.100	
2022-005	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	12	5.611	0.197	3.51	4.600	6.600	
2022-005	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	12	5.742	0.185	3.22	4.700	6.700	
2022-005	3	ARSEN.-III	199 Rx-IMOLA	126	RANDOX	10	6.070	0.142	2.34	5.100	7.100	
2022-005	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	82	5.746	0.187	3.26	4.700	6.700	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	16	5.750	0.173	3.01	4.800	6.800
2022-005	8	CRESOLPHT.	203	ROCHE	93	ROCHE	11	5.773	0.154	2.67	4.800	6.800
2022-005	8	CRESOLPHT.	212	S. D. EXL	143	SIEMENS	13	5.669	0.173	3.05	4.700	6.700
2022-005	14	ELECTRODE	215	B.C DXC	134	BECKM.COUL	10	5.900	0.077	1.31	4.900	6.900
2022-005	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	20	5.780	0.154	2.66	4.800	6.800
2022-005	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	26	5.873	0.172	2.93	4.900	6.900
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2022-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	38	90.079	2.299	2.55	86.000	95.000
2022-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	28	88.964	1.500	1.69	85.000	93.000
2022-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	18	91.722	1.557	1.70	87.000	96.000
2022-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	40	86.550	1.687	1.95	82.000	91.000
2022-001	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	89.800	1.400	1.56	85.000	94.000
2022-001	4	ISE UND-DI	165	VITROS	63	KODAK	84	90.687	1.803	1.99	86.000	95.000
2022-001	4	ISE UND-DI	165	VITROS	156	Kit 32	75	90.933	1.398	1.54	86.000	95.000
2022-001	4	ISE UND-DI	191	RX-DAYTONA	126	RANDOX	30	88.333	2.314	2.62	84.000	93.000
2022-001	4	ISE UND-DI	199	Rx-IMOLA	126	RANDOX	11	87.636	1.432	1.63	83.000	92.000
2022-001	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	79	88.410	1.597	1.81	84.000	93.000
2022-001	9	QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	88.154	1.167	1.32	84.000	93.000
2022-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	38	115.054	2.130	1.85	109.000	121.000
2022-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	28	109.037	1.598	1.47	104.000	114.000
2022-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	18	111.611	1.948	1.75	106.000	117.000
2022-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	40	110.231	2.303	2.09	105.000	116.000
2022-002	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	108.500	1.803	1.66	103.000	114.000
2022-002	4	ISE UND-DI	165	VITROS	63	KODAK	84	111.663	2.037	1.82	106.000	117.000
2022-002	4	ISE UND-DI	165	VITROS	156	Kit 32	75	112.230	1.466	1.31	107.000	118.000
2022-002	4	ISE UND-DI	191	RX-DAYTONA	126	RANDOX	30	111.862	1.870	1.67	106.000	117.000
2022-002	4	ISE UND-DI	199	Rx-IMOLA	126	RANDOX	11	112.455	2.350	2.09	107.000	118.000
2022-002	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	79	116.608	2.587	2.22	111.000	122.000
2022-002	9	QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	117.154	2.685	2.29	111.000	123.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
011	CHLORIDE	CLIA TEST ID #: 355	EVALUATION CRITERIA: TARGET VALUE 5 %								
2022-003	3 ISE DILUTE	184 INTEGRA	93 ROCHE		38	113.474	2.989	2.63	108.000	119.000	
2022-003	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		28	107.607	1.633	1.52	102.000	113.000	
2022-003	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		18	109.889	1.997	1.82	104.000	115.000	
2022-003	3 ISE DILUTE	203 ROCHE	93 ROCHE		40	107.850	2.535	2.35	102.000	113.000	
2022-003	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL		10	107.200	2.227	2.08	102.000	113.000	
2022-003	4 ISE UND-DI	165 VITROS	63 KODAK		84	109.783	1.791	1.63	104.000	115.000	
2022-003	4 ISE UND-DI	165 VITROS	156 Kit 32		75	110.554	1.612	1.46	105.000	116.000	
2022-003	4 ISE UND-DI	191 RX-DAYTONA	126 RANDOX		30	109.724	2.211	2.02	104.000	115.000	
2022-003	4 ISE UND-DI	199 Rx-IMOLA	126 RANDOX		11	108.455	2.571	2.37	103.000	114.000	
2022-003	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		79	113.671	2.220	1.95	108.000	119.000	
2022-003	9 QUICK LYTE	212 S. D. EXL	143 SIEMENS		13	113.923	2.526	2.22	108.000	120.000	
2022-004	3 ISE DILUTE	184 INTEGRA	93 ROCHE		38	95.289	1.932	2.03	91.000	100.000	
2022-004	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		28	93.250	1.214	1.30	89.000	98.000	
2022-004	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		18	95.389	1.603	1.68	91.000	100.000	
2022-004	3 ISE DILUTE	203 ROCHE	93 ROCHE		40	91.410	1.497	1.64	87.000	96.000	
2022-004	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL		10	94.200	1.536	1.63	89.000	99.000	
2022-004	4 ISE UND-DI	165 VITROS	63 KODAK		84	95.095	1.608	1.69	90.000	100.000	
2022-004	4 ISE UND-DI	165 VITROS	156 Kit 32		75	95.595	1.479	1.55	91.000	100.000	
2022-004	4 ISE UND-DI	191 RX-DAYTONA	126 RANDOX		30	92.800	2.197	2.37	88.000	97.000	
2022-004	4 ISE UND-DI	199 Rx-IMOLA	126 RANDOX		11	92.545	1.305	1.41	88.000	97.000	
2022-004	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		79	94.063	1.724	1.83	89.000	99.000	
2022-004	9 QUICK LYTE	212 S. D. EXL	143 SIEMENS		13	93.923	1.206	1.28	89.000	99.000	
2022-005	3 ISE DILUTE	184 INTEGRA	93 ROCHE		38	83.868	1.657	1.98	80.000	88.000	
2022-005	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		28	84.000	1.225	1.46	80.000	88.000	
2022-005	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		18	86.500	1.384	1.60	82.000	91.000	
2022-005	3 ISE DILUTE	203 ROCHE	93 ROCHE		40	81.050	1.717	2.12	77.000	85.000	
2022-005	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL		10	85.300	0.781	0.92	81.000	90.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-005	4	ISE UND-DI	165 VITROS	63	KODAK	84	86.159	1.573	1.83	82.000	90.000
2022-005	4	ISE UND-DI	165 VITROS	156	Kit 32	75	86.446	1.327	1.53	82.000	91.000
2022-005	4	ISE UND-DI	191 RX-DAYTONA	126	RANDOX	30	82.367	2.243	2.72	78.000	86.000
2022-005	4	ISE UND-DI	199 Rx-IMOLA	126	RANDOX	11	82.182	1.466	1.78	78.000	86.000
2022-005	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	79	81.557	1.300	1.59	77.000	86.000
2022-005	9	QUICK LYTE	212 S. D. EXL	143	SIEMENS	13	81.231	0.973	1.20	77.000	85.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365	EVALUATION CRITERIA: TARGET VALUE 10 %							
2022-001	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	79	131.987	4.168	3.16	119.000	145.000
2022-001	1	ENZYMATIC	165 VITROS	63	KODAK	150	131.260	4.467	3.40	118.000	144.000
2022-001	1	ENZYMATIC	184 INTEGRA	93	ROCHE	17	133.059	3.686	2.77	120.000	146.000
2022-001	1	ENZYMATIC	191 RX-DAYTONA	126	RANDOX	35	136.778	5.513	4.03	123.000	150.000
2022-001	1	ENZYMATIC	191 RX-DAYTONA	126	RANDOX	35	141.257	9.066	6.42	127.000	155.000
2022-001	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	14	135.714	3.493	2.57	122.000	149.000
2022-001	1	ENZYMATIC	203 ROCHE	93	ROCHE	22	136.818	3.651	2.67	123.000	151.000
2022-001	1	ENZYMATIC	212 S. D. EXL	143	SIEMENS	13	132.385	6.463	4.88	119.000	146.000
2022-001	1	ENZYMATIC	215 B.C DXC	134	BECKM.COUL	10	134.000	4.171	3.11	121.000	147.000
2022-001	1	ENZYMATIC	220 Medica E.	130	MEDICA	10	139.100	3.477	2.50	125.000	153.000
2022-001	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	28	132.107	3.039	2.30	119.000	145.000
2022-002	1	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	79	219.397	9.573	4.36	197.000	241.000
2022-002	1	ENZYMATIC	165 VITROS	63	KODAK	150	243.980	8.090	3.32	220.000	268.000
2022-002	1	ENZYMATIC	184 INTEGRA	93	ROCHE	17	222.353	5.940	2.67	200.000	245.000
2022-002	1	ENZYMATIC	191 RX-DAYTONA	126	RANDOX	35	239.829	13.696	5.71	216.000	264.000
2022-002	1	ENZYMATIC	191 RX-DAYTONA	126	RANDOX	35	229.333	7.846	3.42	206.000	252.000
2022-002	1	ENZYMATIC	197 ARCHITECT	1	ABBOTT	14	228.143	6.022	2.64	205.000	251.000
2022-002	1	ENZYMATIC	203 ROCHE	93	ROCHE	22	232.190	6.766	2.91	209.000	255.000
2022-002	1	ENZYMATIC	212 S. D. EXL	143	SIEMENS	13	219.769	11.470	5.22	198.000	242.000
2022-002	1	ENZYMATIC	215 B.C DXC	134	BECKM.COUL	10	226.700	10.050	4.43	204.000	249.000
2022-002	1	ENZYMATIC	220 Medica E.	130	MEDICA	10	231.600	7.186	3.10	208.000	255.000
2022-002	8	ENZYMATIC	186 BECK. COUL	76	AU-BECKMAN	28	222.148	7.054	3.18	200.000	244.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %					
2022-003	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		79	208.923	6.639	3.18	188.000	230.000	
2022-003	1 ENZYMATI	165 VITROS	63 KODAK		150	232.906	7.167	3.08	210.000	256.000	
2022-003	1 ENZYMATI	184 INTEGRA	93 ROCHE		17	211.176	5.216	2.47	190.000	232.000	
2022-003	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	225.333	9.452	4.19	203.000	248.000	
2022-003	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	228.543	13.046	5.71	206.000	251.000	
2022-003	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		14	217.857	5.592	2.57	196.000	240.000	
2022-003	1 ENZYMATI	203 ROCHE	93 ROCHE		22	221.636	4.686	2.11	199.000	244.000	
2022-003	1 ENZYMATI	212 S. D. EXL	143 SIEMENS		13	208.308	8.887	4.27	187.000	229.000	
2022-003	1 ENZYMATI	215 B.C DXC	134 BECKM.COUL		10	218.500	8.176	3.74	197.000	240.000	
2022-003	1 ENZYMATI	220 Medica E.	130 MEDICA		10	224.100	6.139	2.74	202.000	247.000	
2022-003	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		28	214.786	6.014	2.80	193.000	236.000	
2022-004	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		79	147.848	4.366	2.95	133.000	163.000	
2022-004	1 ENZYMATI	165 VITROS	63 KODAK		150	152.517	5.100	3.34	137.000	168.000	
2022-004	1 ENZYMATI	184 INTEGRA	93 ROCHE		17	149.706	4.184	2.79	135.000	165.000	
2022-004	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	159.765	9.283	5.81	144.000	176.000	
2022-004	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	157.667	5.578	3.54	142.000	173.000	
2022-004	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		14	153.000	4.259	2.78	138.000	168.000	
2022-004	1 ENZYMATI	203 ROCHE	93 ROCHE		22	154.909	3.919	2.53	139.000	170.000	
2022-004	1 ENZYMATI	212 S. D. EXL	143 SIEMENS		13	148.154	6.746	4.55	133.000	163.000	
2022-004	1 ENZYMATI	215 B.C DXC	134 BECKM.COUL		10	151.500	3.828	2.53	136.000	167.000	
2022-004	1 ENZYMATI	220 Medica E.	130 MEDICA		10	157.500	2.419	1.54	142.000	173.000	
2022-004	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		28	149.714	3.972	2.65	135.000	165.000	
2022-005	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		79	113.861	3.751	3.29	102.000	125.000	
2022-005	1 ENZYMATI	165 VITROS	63 KODAK		150	109.953	3.835	3.49	99.000	121.000	
2022-005	1 ENZYMATI	184 INTEGRA	93 ROCHE		17	113.313	3.669	3.24	102.000	125.000	
2022-005	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	118.556	4.833	4.08	107.000	130.000	
2022-005	1 ENZYMATI	191 RX-DAYTONA	126 RANDOX		35	120.400	7.184	5.97	108.000	132.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-005	1 ENZYMATI	197 ARCHITECT	1 ABBOTT	14	117.462	1.985	1.69	106.000	129.000		
2022-005	1 ENZYMATI	203 ROCHE	93 ROCHE	22	117.682	2.565	2.18	106.000	129.000		
2022-005	1 ENZYMATI	212 S. D. EXL	143 SIEMENS	13	114.769	4.627	4.03	103.000	126.000		
2022-005	1 ENZYMATI	215 B.C DXC	134 BECKM.COUL	10	113.700	2.685	2.36	102.000	125.000		
2022-005	1 ENZYMATI	220 Medica E.	130 MEDICA	10	119.300	3.822	3.20	107.000	131.000		
2022-005	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN	28	112.893	2.743	2.43	102.000	124.000		
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375	EVALUATION CRITERIA: TARGET VALUE 30 %								
2022-001	11 ENC.-COLO.	165 VITROS	63 KODAK	145	43.250	3.112	7.20	30.300	56.200		
2022-001	11 ENC.-COLO.	165 VITROS	63 KODAK	145	42.959	2.430	5.66	30.100	55.800		
2022-001	11 ENC.-COLO.	184 INTEGRA	93 ROCHE	33	49.303	2.114	4.29	34.500	64.100		
2022-001	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN	28	49.668	3.291	6.63	34.800	64.600		
2022-001	11 ENC.-COLO.	191 RX-DAYTONA	126 RANDOX	33	44.591	4.930	11.06	31.200	58.000		
2022-001	11 ENC.-COLO.	199 Rx-IMOLA	126 RANDOX	10	44.500	4.793	10.77	31.200	57.900		
2022-001	11 ENC.-COLO.	203 ROCHE	93 ROCHE	32	46.794	2.122	4.53	32.800	60.800		
2022-001	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	16	48.406	1.725	3.56	33.900	62.900		
2022-001	12 HOM-LQ.S.D	215 B.C DXC	134 BECKM.COUL	10	50.340	1.604	3.19	35.200	65.400		
2022-001	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	77	48.664	2.262	4.65	34.100	63.300		
2022-001	13 AMIN.W.E.Q	212 S. D. EXL	143 SIEMENS	13	49.769	2.189	4.40	34.800	64.700		
2022-002	11 ENC.-COLO.	165 VITROS	63 KODAK	145	74.692	4.690	6.28	52.300	97.100		
2022-002	11 ENC.-COLO.	165 VITROS	63 KODAK	145	72.500	2.872	3.96	50.800	94.300		
2022-002	11 ENC.-COLO.	184 INTEGRA	93 ROCHE	33	64.638	2.693	4.17	45.200	84.000		
2022-002	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN	28	80.232	5.499	6.85	56.200	104.300		
2022-002	11 ENC.-COLO.	191 RX-DAYTONA	126 RANDOX	33	69.055	8.452	12.24	48.300	89.800		
2022-002	11 ENC.-COLO.	199 Rx-IMOLA	126 RANDOX	10	69.370	5.405	7.79	48.600	90.200		
2022-002	11 ENC.-COLO.	203 ROCHE	93 ROCHE	32	61.703	2.803	4.54	43.200	80.200		
2022-002	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	16	76.619	2.809	3.67	53.600	99.600		
2022-002	12 HOM-LQ.S.D	215 B.C DXC	134 BECKM.COUL	10	79.910	2.804	3.51	55.900	103.900		
2022-002	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	77	51.525	3.134	6.08	36.100	67.000		
2022-002	13 AMIN.W.E.Q	212 S. D. EXL	143 SIEMENS	13	53.308	3.123	5.86	37.300	69.300		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
013	CHOLESTEROL, (HDL)	CLIA TEST ID #: 375	EVALUATION CRITERIA: TARGET VALUE	30 %							
2022-003	11 ENC.-COLO.	165 VITROS	63 KODAK		145	69.250	0.829	1.20	48.500	90.000	
2022-003	11 ENC.-COLO.	165 VITROS	63 KODAK		145	70.497	4.178	5.93	49.300	91.600	
2022-003	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		33	63.075	2.698	4.28	44.200	82.000	
2022-003	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		28	77.171	4.924	6.38	54.000	100.300	
2022-003	11 ENC.-COLO.	191 RX-DAYTONA	126 RANDOX		33	66.500	6.585	9.90	46.600	86.500	
2022-003	11 ENC.-COLO.	199 Rx-IMOLA	126 RANDOX		10	64.250	6.560	10.21	45.000	83.500	
2022-003	11 ENC.-COLO.	203 ROCHE	93 ROCHE		32	59.890	2.583	4.31	41.900	77.900	
2022-003	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT		16	73.281	2.738	3.74	51.300	95.300	
2022-003	12 HOM-LQ.S.D	215 B.C DXC	134 BECKM.COUL		10	76.700	2.880	3.76	53.700	99.700	
2022-003	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS		77	51.640	3.038	5.88	36.100	67.100	
2022-003	13 AMIN.W.E.Q	212 S. D. EXL	143 SIEMENS		13	52.385	2.788	5.32	36.700	68.100	
2022-004	11 ENC.-COLO.	165 VITROS	63 KODAK		145	47.500	2.062	4.34	33.300	61.800	
2022-004	11 ENC.-COLO.	165 VITROS	63 KODAK		145	47.783	2.572	5.38	33.400	62.100	
2022-004	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		33	52.476	2.262	4.31	36.700	68.200	
2022-004	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		28	55.025	3.743	6.80	38.500	71.500	
2022-004	11 ENC.-COLO.	191 RX-DAYTONA	126 RANDOX		33	49.825	5.097	10.23	34.900	64.800	
2022-004	11 ENC.-COLO.	199 Rx-IMOLA	126 RANDOX		10	47.580	4.236	8.90	33.300	61.900	
2022-004	11 ENC.-COLO.	203 ROCHE	93 ROCHE		32	49.935	2.527	5.06	35.000	64.900	
2022-004	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT		16	53.956	1.730	3.21	37.800	70.100	
2022-004	12 HOM-LQ.S.D	215 B.C DXC	134 BECKM.COUL		10	55.830	1.673	3.00	39.100	72.600	
2022-004	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS		77	50.079	2.270	4.53	35.100	65.100	
2022-004	13 AMIN.W.E.Q	212 S. D. EXL	143 SIEMENS		13	51.385	2.203	4.29	36.000	66.800	
2022-005	11 ENC.-COLO.	165 VITROS	63 KODAK		145	37.750	1.785	4.73	26.400	49.100	
2022-005	11 ENC.-COLO.	165 VITROS	63 KODAK		145	39.034	2.258	5.78	27.300	50.700	
2022-005	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		33	44.906	2.219	4.94	31.400	58.400	
2022-005	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		28	43.789	2.354	5.38	30.700	56.900	
2022-005	11 ENC.-COLO.	191 RX-DAYTONA	126 RANDOX		33	40.315	4.964	12.31	28.200	52.400	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-005	11 ENC.-COLO.	199 Rx-IMOLA	126 RANDOX	10	38.350	3.534	9.22	26.800	49.900		
2022-005	11 ENC.-COLO.	203 ROCHE	93 ROCHE	32	42.713	1.967	4.61	29.900	55.500		
2022-005	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT	16	42.788	1.459	3.41	30.000	55.600		
2022-005	12 HOM-LQ.S.D	215 B.C DXC	134 BECKM.COUL	10	44.920	2.956	6.58	31.400	58.400		
2022-005	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS	77	46.669	2.206	4.73	32.700	60.700		
2022-005	13 AMIN.W.E.Q	212 S. D. EXL	143 SIEMENS	13	47.692	2.523	5.29	33.400	62.000		
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385	EVALUATION CRITERIA: TARGET VALUE 30 %								
2022-001	3 KINETIC 37	165 VITROS	63 KODAK	76	117.622	6.175	5.25	82.000	153.000		
2022-001	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	20	116.450	5.634	4.84	82.000	151.000		
2022-001	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL	10	134.400	2.245	1.67	94.000	175.000		
2022-001	8 Hexokinase	184 INTEGRA	93 ROCHE	12	133.583	3.095	2.32	94.000	174.000		
2022-001	8 Hexokinase	203 ROCHE	93 ROCHE	12	131.500	4.856	3.69	92.000	171.000		
2022-001	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	28	130.643	6.037	4.62	91.000	170.000		
2022-002	3 KINETIC 37	165 VITROS	63 KODAK	76	402.960	20.871	5.18	282.000	524.000		
2022-002	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	20	576.350	31.897	5.53	403.000	749.000		
2022-002	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL	10	618.200	14.811	2.40	433.000	804.000		
2022-002	8 Hexokinase	184 INTEGRA	93 ROCHE	12	631.583	21.395	3.39	442.000	821.000		
2022-002	8 Hexokinase	203 ROCHE	93 ROCHE	12	633.000	17.795	2.81	443.000	823.000		
2022-002	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	28	637.143	31.992	5.02	446.000	828.000		
2022-003	3 KINETIC 37	165 VITROS	63 KODAK	76	385.533	19.076	4.95	270.000	501.000		
2022-003	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	20	523.300	27.163	5.19	366.000	680.000		
2022-003	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL	10	570.400	14.814	2.60	399.000	742.000		
2022-003	8 Hexokinase	184 INTEGRA	93 ROCHE	12	570.167	25.429	4.46	399.000	741.000		
2022-003	8 Hexokinase	203 ROCHE	93 ROCHE	12	580.000	18.170	3.13	406.000	754.000		
2022-003	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	28	586.107	23.284	3.97	410.000	762.000		
2022-004	3 KINETIC 37	165 VITROS	63 KODAK	76	193.680	11.278	5.82	136.000	252.000		
2022-004	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	20	202.900	10.212	5.03	142.000	264.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-004	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL		10	231.000	4.195	1.82	162.000	300.000	
2022-004	8 Hexokinase	184 INTEGRA	93 ROCHE		12	229.333	7.375	3.22	161.000	298.000	
2022-004	8 Hexokinase	203 ROCHE	93 ROCHE		12	227.750	5.644	2.48	159.000	296.000	
2022-004	9 SIEMENS	38 SIEMENS DI	143 SIEMENS		28	229.179	9.714	4.24	160.000	298.000	
014 CREATINE KINASE (CK)		CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 30 %							
2022-005	3 KINETIC 37	165 VITROS	63 KODAK		76	33.267	2.594	7.80	23.000	43.000	
2022-005	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN		20	29.050	2.132	7.34	20.000	38.000	
2022-005	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL		10	36.800	1.166	3.17	26.000	48.000	
2022-005	8 Hexokinase	184 INTEGRA	93 ROCHE		12	35.333	1.491	4.22	25.000	46.000	
2022-005	8 Hexokinase	203 ROCHE	93 ROCHE		12	35.417	2.100	5.93	25.000	46.000	
2022-005	9 SIEMENS	38 SIEMENS DI	143 SIEMENS		28	33.321	2.221	6.67	23.000	43.000	
016 CREATININE		CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}							
2022-001	3 AK. PIC. L	191 RX-DAYTONA	126 RANDOX		24	1.709	0.101	5.90	1.410	2.010	
2022-001	4 ENZYMATIC	220 Medica E.	130 MEDICA		10	1.907	0.106	5.58	1.610	2.210	
2022-001	6 KIN. ALK P	184 INTEGRA	93 ROCHE		22	1.914	0.074	3.88	1.610	2.210	
2022-001	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN		30	1.845	0.085	4.63	1.550	2.150	
2022-001	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT		19	1.827	0.078	4.27	1.530	2.130	
2022-001	6 KIN. ALK P	203 ROCHE	93 ROCHE		24	1.845	0.076	4.13	1.540	2.140	
2022-001	6 KIN. ALK P	215 B.C DXC	134 BECKM.COUL		10	1.915	0.085	4.45	1.620	2.220	
2022-001	8 IDMS-CREA	165 VITROS	63 KODAK		157	1.665	0.055	3.30	1.360	1.960	
2022-001	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS		75	1.916	0.082	4.26	1.620	2.220	
2022-001	11 IDMS Jaffe	212 S. D. EXL	143 SIEMENS		10	1.908	0.061	3.21	1.610	2.210	
2022-002	3 AK. PIC. L	191 RX-DAYTONA	126 RANDOX		24	5.625	0.450	8.00	4.780	6.470	
2022-002	4 ENZYMATIC	220 Medica E.	130 MEDICA		10	6.841	0.214	3.12	5.810	7.870	
2022-002	6 KIN. ALK P	184 INTEGRA	93 ROCHE		22	6.332	0.218	3.45	5.380	7.280	
2022-002	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN		30	6.612	0.327	4.94	5.620	7.600	
2022-002	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT		19	7.287	0.138	1.90	6.190	8.380	
2022-002	6 KIN. ALK P	203 ROCHE	93 ROCHE		24	6.334	0.267	4.22	5.380	7.280	
2022-002	6 KIN. ALK P	215 B.C DXC	134 BECKM.COUL		10	6.812	0.242	3.55	5.790	7.830	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-002	8	IDMS-CREA	165	VITROS	63	KODAK	157	5.440	0.159	2.91	4.620	6.260
2022-002	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	75	6.991	0.222	3.17	5.940	8.040
2022-002	11	IDMS Jaffe	212	S. D. EXL	143	SIEMENS	10	7.038	0.210	2.98	5.980	8.090
016 CREATININE			CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}							
2022-003	3	AK. PIC. L	191	RX-DAYTONA	126	RANDOX	24	5.298	0.357	6.74	4.500	6.090
2022-003	4	ENZYMATIC	220	Medica E.	130	MEDICA	10	6.392	0.240	3.76	5.430	7.350
2022-003	6	KIN. ALK P	184	INTEGRA	93	ROCHE	22	5.875	0.202	3.43	4.990	6.760
2022-003	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	30	6.134	0.212	3.45	5.210	7.050
2022-003	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	19	6.686	0.183	2.74	5.680	7.690
2022-003	6	KIN. ALK P	203	ROCHE	93	ROCHE	24	5.908	0.207	3.50	5.020	6.790
2022-003	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	6.271	0.259	4.13	5.330	7.210
2022-003	8	IDMS-CREA	165	VITROS	63	KODAK	157	5.108	0.143	2.80	4.340	5.870
2022-003	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	75	6.432	0.186	2.89	5.470	7.400
2022-003	11	IDMS Jaffe	212	S. D. EXL	143	SIEMENS	10	6.474	0.188	2.90	5.500	7.450
2022-004	3	AK. PIC. L	191	RX-DAYTONA	126	RANDOX	24	2.516	0.176	7.00	2.140	2.890
2022-004	4	ENZYMATIC	220	Medica E.	130	MEDICA	10	2.829	0.099	3.50	2.400	3.250
2022-004	6	KIN. ALK P	184	INTEGRA	93	ROCHE	22	2.809	0.115	4.10	2.390	3.230
2022-004	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	30	2.760	0.119	4.31	2.350	3.170
2022-004	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	19	2.852	0.064	2.26	2.420	3.280
2022-004	6	KIN. ALK P	203	ROCHE	93	ROCHE	24	2.777	0.070	2.50	2.360	3.190
2022-004	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	2.845	0.096	3.39	2.420	3.270
2022-004	8	IDMS-CREA	165	VITROS	63	KODAK	157	2.501	0.079	3.16	2.130	2.880
2022-004	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	75	2.886	0.092	3.20	2.450	3.320
2022-004	11	IDMS Jaffe	212	S. D. EXL	143	SIEMENS	10	2.884	0.082	2.84	2.450	3.320
2022-005	3	AK. PIC. L	191	RX-DAYTONA	126	RANDOX	24	0.943	0.060	6.33	0.640	1.240
2022-005	4	ENZYMATIC	220	Medica E.	130	MEDICA	10	0.975	0.059	6.05	0.680	1.280
2022-005	6	KIN. ALK P	184	INTEGRA	93	ROCHE	22	0.935	0.057	6.05	0.640	1.240
2022-005	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	30	0.890	0.038	4.21	0.590	1.190

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	19	0.794	0.026	3.30	0.490	1.090
2022-005	6	KIN. ALK P	203	ROCHE	93	ROCHE	24	0.868	0.038	4.41	0.570	1.170
2022-005	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	0.952	0.051	5.33	0.650	1.250
2022-005	8	IDMS-CREA	165	VITROS	63	KODAK	157	0.809	0.029	3.58	0.510	1.110
2022-005	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	75	0.863	0.061	7.01	0.560	1.160
2022-005	11	IDMS Jaffe	212	S. D. EXL	143	SIEMENS	10	0.845	0.045	5.27	0.550	1.150
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2022-001	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	53.900	1.578	2.93	48.000	60.000
2022-001	3	GL. OXI. C	165	VITROS	63	KODAK	167	55.048	1.834	3.33	49.000	61.000
2022-001	3	GL. OXI. C	213	SELECTRA P	150	ELITECH	10	60.200	1.470	2.44	54.000	66.000
2022-001	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	61.085	1.836	3.01	55.000	67.000
2022-001	5	HEXOKINASE	184	INTEGRA	93	ROCHE	11	58.000	1.414	2.44	52.000	64.000
2022-001	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	30	56.379	1.606	2.85	50.000	62.000
2022-001	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	63.000	4.546	7.22	57.000	69.000
2022-001	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	63.692	3.538	5.56	57.000	70.000
2022-001	5	HEXOKINASE	203	ROCHE	93	ROCHE	22	58.136	1.575	2.71	52.000	64.000
2022-001	5	HEXOKINASE	212	S. D. EXL	143	SIEMENS	13	59.923	2.615	4.36	54.000	66.000
2022-001	12	HEXOKINASE	184	INTEGRA	93	ROCHE	25	58.960	1.708	2.90	53.000	65.000
2022-001	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	18	55.167	1.384	2.51	49.000	61.000
2022-001	12	HEXOKINASE	203	ROCHE	93	ROCHE	17	57.118	1.711	3.00	51.000	63.000
2022-002	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	164.100	4.527	2.76	148.000	181.000
2022-002	3	GL. OXI. C	165	VITROS	63	KODAK	167	176.772	4.188	2.37	159.000	194.000
2022-002	3	GL. OXI. C	213	SELECTRA P	150	ELITECH	10	171.800	9.938	5.78	155.000	189.000
2022-002	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	175.037	6.051	3.46	158.000	193.000
2022-002	5	HEXOKINASE	184	INTEGRA	93	ROCHE	11	168.727	2.926	1.73	152.000	186.000
2022-002	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	30	165.067	6.582	3.99	149.000	182.000
2022-002	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	175.423	8.599	4.90	158.000	193.000
2022-002	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	169.000	2.944	1.74	152.000	186.000
2022-002	5	HEXOKINASE	203	ROCHE	93	ROCHE	22	170.773	5.317	3.11	154.000	188.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-002	5	HEXOKINASE	212	S. D. EXL	143	SIEMENS	13	173.308	5.165	2.98	156.000	191.000
2022-002	12	HEXOKINASE	184	INTEGRA	93	ROCHE	25	172.040	4.359	2.53	155.000	189.000
2022-002	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	18	164.722	3.633	2.21	148.000	181.000
2022-002	12	HEXOKINASE	203	ROCHE	93	ROCHE	17	171.000	6.739	3.94	154.000	188.000
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2022-003	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	152.500	3.722	2.44	137.000	168.000
2022-003	3	GL. OXI. C	165	VITROS	63	KODAK	167	163.138	3.977	2.44	147.000	179.000
2022-003	3	GL. OXI. C	213	SELECTRA P	150	ELITECH	10	159.900	7.300	4.57	144.000	176.000
2022-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	162.585	4.155	2.56	146.000	179.000
2022-003	5	HEXOKINASE	184	INTEGRA	93	ROCHE	11	158.455	4.869	3.07	143.000	174.000
2022-003	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	30	153.567	4.341	2.83	138.000	169.000
2022-003	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	152.000	7.789	5.12	137.000	167.000
2022-003	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	163.808	7.845	4.79	147.000	180.000
2022-003	5	HEXOKINASE	203	ROCHE	93	ROCHE	22	157.818	4.978	3.15	142.000	174.000
2022-003	5	HEXOKINASE	212	S. D. EXL	143	SIEMENS	13	160.231	4.806	3.00	144.000	176.000
2022-003	12	HEXOKINASE	184	INTEGRA	93	ROCHE	25	159.960	4.476	2.80	144.000	176.000
2022-003	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	18	153.059	2.155	1.41	138.000	168.000
2022-003	12	HEXOKINASE	203	ROCHE	93	ROCHE	17	157.824	4.105	2.60	142.000	174.000
2022-004	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	74.900	1.578	2.11	67.000	82.000
2022-004	3	GL. OXI. C	165	VITROS	63	KODAK	167	79.448	2.214	2.79	72.000	87.000
2022-004	3	GL. OXI. C	213	SELECTRA P	150	ELITECH	10	82.400	1.685	2.05	74.000	91.000
2022-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	82.420	1.955	2.37	74.000	91.000
2022-004	5	HEXOKINASE	184	INTEGRA	93	ROCHE	11	78.909	1.975	2.50	71.000	87.000
2022-004	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	30	77.033	2.415	3.14	69.000	85.000
2022-004	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	85.240	4.519	5.30	77.000	94.000
2022-004	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	81.000	5.099	6.30	73.000	89.000
2022-004	5	HEXOKINASE	203	ROCHE	93	ROCHE	22	79.045	2.477	3.13	71.000	87.000
2022-004	5	HEXOKINASE	212	S. D. EXL	143	SIEMENS	13	81.538	3.365	4.13	73.000	90.000
2022-004	12	HEXOKINASE	184	INTEGRA	93	ROCHE	25	80.520	2.265	2.81	72.000	89.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-004	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	18	76.444	1.832	2.40	69.000	84.000
2022-004	12	HEXOKINASE	203	ROCHE	93	ROCHE	17	78.500	1.118	1.42	71.000	86.000
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2022-005	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	33.100	1.300	3.93	27.000	39.000
2022-005	3	GL. OXI. C	165	VITROS	63	KODAK	167	33.773	1.189	3.52	28.000	40.000
2022-005	3	GL. OXI. C	213	SELECTRA P	150	ELITECH	10	37.900	1.700	4.49	32.000	44.000
2022-005	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	39.074	1.585	4.06	33.000	45.000
2022-005	5	HEXOKINASE	184	INTEGRA	93	ROCHE	11	36.182	1.527	4.22	30.000	42.000
2022-005	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	30	35.379	1.064	3.01	29.000	41.000
2022-005	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	40.667	2.867	7.05	35.000	47.000
2022-005	5	HEXOKINASE	191	RX-DAYTONA	126	RANDOX	26	42.115	2.082	4.94	36.000	48.000
2022-005	5	HEXOKINASE	203	ROCHE	93	ROCHE	22	36.136	1.140	3.15	30.000	42.000
2022-005	5	HEXOKINASE	212	S. D. EXL	143	SIEMENS	13	38.615	1.820	4.71	33.000	45.000
2022-005	12	HEXOKINASE	184	INTEGRA	93	ROCHE	25	36.720	1.078	2.94	31.000	43.000
2022-005	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	18	34.000	1.000	2.94	28.000	40.000
2022-005	12	HEXOKINASE	203	ROCHE	93	ROCHE	17	36.188	0.634	1.75	30.000	42.000
018	IRON, TOTAL	CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-001	4	COULOMETR.	165	VITROS	63	KODAK	15	89.200	4.460	5.00	71.000	107.000
2022-002	4	COULOMETR.	165	VITROS	63	KODAK	15	396.600	9.337	2.35	317.000	476.000
2022-003	4	COULOMETR.	165	VITROS	63	KODAK	15	360.533	9.694	2.69	288.000	433.000
2022-004	4	COULOMETR.	165	VITROS	63	KODAK	15	140.533	5.390	3.84	112.000	169.000
2022-005	4	COULOMETR.	165	VITROS	63	KODAK	15	42.267	4.312	10.20	34.000	51.000
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435										
2022-001	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	20	138.950	11.754	8.46	111.000	167.000
2022-001	3	KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	143.500	3.854	2.69	115.000	172.000
2022-001	6	NADH	184	INTEGRA	93	ROCHE	13	181.538	10.308	5.68	145.000	218.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-001	6 NADH	203	ROCHE	93	ROCHE	22	176.381	6.114	3.47	141.000	212.000		
2022-001	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	31	167.452	6.288	3.76	134.000	201.000		
2022-001	9 LDH1	165	VITROS	63	KODAK	68	212.940	5.579	2.62	170.000	256.000		
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435		EVALUATION CRITERIA: TARGET VALUE 20 %									
2022-002	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	20	617.800	58.980	9.55	494.000	741.000		
2022-002	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	584.900	25.785	4.41	468.000	702.000		
2022-002	6 NADH	184	INTEGRA	93	ROCHE	13	752.615	29.788	3.96	602.000	903.000		
2022-002	6 NADH	203	ROCHE	93	ROCHE	22	763.381	23.695	3.10	611.000	916.000		
2022-002	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	31	753.065	24.389	3.24	602.000	904.000		
2022-002	9 LDH1	165	VITROS	63	KODAK	68	854.250	47.489	5.56	683.000	1025.000		
2022-003	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	20	565.350	48.017	8.49	452.000	678.000		
2022-003	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	543.900	21.695	3.99	435.000	653.000		
2022-003	6 NADH	184	INTEGRA	93	ROCHE	13	698.846	29.357	4.20	559.000	839.000		
2022-003	6 NADH	203	ROCHE	93	ROCHE	22	696.714	23.721	3.40	557.000	836.000		
2022-003	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	31	692.258	20.352	2.94	554.000	831.000		
2022-003	9 LDH1	165	VITROS	63	KODAK	68	798.706	42.386	5.31	639.000	958.000		
2022-004	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	20	228.850	19.244	8.41	183.000	275.000		
2022-004	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	233.100	7.203	3.09	186.000	280.000		
2022-004	6 NADH	184	INTEGRA	93	ROCHE	13	294.615	12.493	4.24	236.000	354.000		
2022-004	6 NADH	203	ROCHE	93	ROCHE	22	286.857	10.366	3.61	229.000	344.000		
2022-004	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	31	278.710	10.337	3.71	223.000	334.000		
2022-004	9 LDH1	165	VITROS	63	KODAK	68	337.612	7.105	2.10	270.000	405.000		
2022-005	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	20	47.600	3.639	7.64	38.000	57.000		
2022-005	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	49.700	2.326	4.68	40.000	60.000		
2022-005	6 NADH	184	INTEGRA	93	ROCHE	13	65.385	3.127	4.78	52.000	78.000		
2022-005	6 NADH	203	ROCHE	93	ROCHE	22	62.381	2.420	3.88	50.000	75.000		
2022-005	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	31	56.516	5.951	10.53	45.000	68.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	9 LDH1	165	VITROS	63	KODAK	68	75.324	4.279	5.68	60.000	90.000	
021	MAGNESIUM	CLIA TEST ID #: 455				EVALUATION CRITERIA: TARGET VALUE 25 %						
2022-001	5 COLOR./K E	165	VITROS	63	KODAK	25	2.120	0.063	2.98	1.600	2.700	
2022-002	5 COLOR./K E	165	VITROS	63	KODAK	25	6.312	0.173	2.74	4.700	7.900	
2022-003	5 COLOR./K E	165	VITROS	63	KODAK	25	5.836	0.144	2.47	4.400	7.300	
2022-004	5 COLOR./K E	165	VITROS	63	KODAK	25	2.948	0.064	2.17	2.200	3.700	
2022-005	5 COLOR./K E	165	VITROS	63	KODAK	25	1.296	0.053	4.07	1.000	1.600	
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 1.00						
2022-001	3 ISE DILUT.	184	INTEGRA	93	ROCHE	36	2.806	0.053	1.89	1.800	3.800	
2022-001	3 ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	2.777	0.056	2.01	1.800	3.800	
2022-001	3 ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	2.806	0.054	1.92	1.800	3.800	
2022-001	3 ISE DILUT.	203	ROCHE	93	ROCHE	41	2.841	0.062	2.20	1.800	3.800	
2022-001	3 ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	2.730	0.078	2.86	1.700	3.700	
2022-001	4 ISE UNDIL.	165	VITROS	63	KODAK	86	2.802	0.051	1.80	1.800	3.800	
2022-001	4 ISE UNDIL.	165	VITROS	156	Kit 32	75	2.797	0.049	1.75	1.800	3.800	
2022-001	4 ISE UNDIL.	191	RX-DAYTONA	126	RANDOX	30	2.800	0.108	3.87	1.800	3.800	
2022-001	4 ISE UNDIL.	199	Rx-IMOLA	126	RANDOX	11	2.818	0.072	2.54	1.800	3.800	
2022-001	4 ISE UNDIL.	220	Medica E.	130	MEDICA	10	2.700	0.045	1.66	1.700	3.700	
2022-001	6 QUICK LYTE	38	SIEMENS DI	143	SIEMENS	79	2.719	0.054	1.97	1.700	3.700	
2022-001	6 QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	2.723	0.042	1.55	1.700	3.700	
2022-002	3 ISE DILUT.	184	INTEGRA	93	ROCHE	36	6.369	0.097	1.52	5.400	7.400	
2022-002	3 ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	6.241	0.116	1.86	5.200	7.200	
2022-002	3 ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	6.400	0.124	1.93	5.400	7.400	
2022-002	3 ISE DILUT.	203	ROCHE	93	ROCHE	41	6.373	0.110	1.72	5.400	7.400	
2022-002	3 ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	6.270	0.100	1.60	5.300	7.300	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-002	4	ISE UNLIL.	165 VITROS	63	KODAK	86	6.476	0.118	1.82	5.500	7.500
2022-002	4	ISE UNLIL.	165 VITROS	156	Kit 32	75	6.472	0.107	1.65	5.500	7.500
2022-002	4	ISE UNLIL.	191 RX-DAYTONA	126	RANLIX	30	6.230	0.193	3.11	5.200	7.200
2022-002	4	ISE UNLIL.	199 Rx-IMOLA	126	RANLIX	11	6.282	0.190	3.02	5.300	7.300
2022-002	4	ISE UNLIL.	220 Medica E.	130	MEDICA	10	6.340	0.150	2.36	5.300	7.300
2022-002	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	79	6.318	0.112	1.77	5.300	7.300
2022-002	6	QUICK LYTE	212 S. D. EXL	143	SIEMENS	13	6.338	0.127	2.01	5.300	7.300
022	POTASSIUM	CLIA TEST ID #: 465	EVALUATION CRITERIA: TARGET VALUE 1.00								
2022-003	3	ISE DILUT.	184 INTEGRA	93	ROCHE	36	5.977	0.110	1.84	5.000	7.000
2022-003	3	ISE DILUT.	186 BECK. COUL	76	AU-BECKMAN	30	5.866	0.084	1.44	4.900	6.900
2022-003	3	ISE DILUT.	197 ARCHITECT	1	ABBOTT	17	6.000	0.091	1.51	5.000	7.000
2022-003	3	ISE DILUT.	203 ROCHE	93	ROCHE	41	5.983	0.101	1.69	5.000	7.000
2022-003	3	ISE DILUT.	215 B.C DXC	134	BECKM.COUL	10	5.890	0.114	1.93	4.900	6.900
2022-003	4	ISE UNLIL.	165 VITROS	63	KODAK	86	6.067	0.111	1.84	5.100	7.100
2022-003	4	ISE UNLIL.	165 VITROS	156	Kit 32	75	6.065	0.104	1.71	5.100	7.100
2022-003	4	ISE UNLIL.	191 RX-DAYTONA	126	RANLIX	30	5.840	0.147	2.52	4.800	6.800
2022-003	4	ISE UNLIL.	199 Rx-IMOLA	126	RANLIX	11	5.818	0.221	3.80	4.800	6.800
2022-003	4	ISE UNLIL.	220 Medica E.	130	MEDICA	10	5.940	0.120	2.02	4.900	6.900
2022-003	6	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	79	5.931	0.092	1.56	4.900	6.900
2022-003	6	QUICK LYTE	212 S. D. EXL	143	SIEMENS	13	5.908	0.138	2.34	4.900	6.900
2022-004	3	ISE DILUT.	184 INTEGRA	93	ROCHE	36	3.464	0.071	2.06	2.500	4.500
2022-004	3	ISE DILUT.	186 BECK. COUL	76	AU-BECKMAN	30	3.447	0.067	1.94	2.400	4.400
2022-004	3	ISE DILUT.	197 ARCHITECT	1	ABBOTT	17	3.453	0.078	2.25	2.500	4.500
2022-004	3	ISE DILUT.	203 ROCHE	93	ROCHE	41	3.513	0.060	1.71	2.500	4.500
2022-004	3	ISE DILUT.	215 B.C DXC	134	BECKM.COUL	10	3.390	0.054	1.59	2.400	4.400
2022-004	4	ISE UNLIL.	165 VITROS	63	KODAK	86	3.488	0.058	1.67	2.500	4.500
2022-004	4	ISE UNLIL.	165 VITROS	156	Kit 32	75	3.485	0.065	1.87	2.500	4.500
2022-004	4	ISE UNLIL.	191 RX-DAYTONA	126	RANLIX	30	3.383	0.119	3.50	2.400	4.400
2022-004	4	ISE UNLIL.	199 Rx-IMOLA	126	RANLIX	11	3.455	0.078	2.26	2.500	4.500

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-004	4 ISE UNLIL.	220 Medica E.	130 MEDICA	10	3.340	0.066	1.99	2.300	4.300		
2022-004	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	79	3.391	0.054	1.58	2.400	4.400		
2022-004	6 QUICK LYTE	212 S. D. EXL	143 SIEMENS	13	3.408	0.062	1.81	2.400	4.400		
022 POTASSIUM		CLIA TEST ID #: 465	EVALUATION CRITERIA: TARGET VALUE 1.00								
2022-005	3 ISE DILUT.	184 INTEGRA	93 ROCHE	36	2.114	0.035	1.66	1.100	3.100		
2022-005	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN	30	2.148	0.050	2.33	1.100	3.100		
2022-005	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT	17	2.106	0.064	3.03	1.100	3.100		
2022-005	3 ISE DILUT.	203 ROCHE	93 ROCHE	41	2.178	0.056	2.59	1.200	3.200		
2022-005	3 ISE DILUT.	215 B.C DXC	134 BECKM.COUL	10	2.040	0.049	2.40	1.000	3.000		
2022-005	4 ISE UNLIL.	165 VITROS	63 KODAK	86	2.120	0.046	2.16	1.100	3.100		
2022-005	4 ISE UNLIL.	165 VITROS	156 Kit 32	75	2.112	0.049	2.31	1.100	3.100		
2022-005	4 ISE UNLIL.	191 RX-DAYTONA	126 RANDOX	30	2.133	0.132	6.21	1.100	3.100		
2022-005	4 ISE UNLIL.	199 Rx-IMOLA	126 RANDOX	11	2.182	0.103	4.71	1.200	3.200		
2022-005	4 ISE UNLIL.	220 Medica E.	130 MEDICA	10	2.040	0.092	4.49	1.000	3.000		
2022-005	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	79	2.021	0.046	2.29	1.000	3.000		
2022-005	6 QUICK LYTE	212 S. D. EXL	143 SIEMENS	13	2.031	0.046	2.27	1.000	3.000		
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2022-001	3 ISE DILUTE	184 INTEGRA	93 ROCHE	33	124.576	2.374	1.91	121.000	129.000		
2022-001	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	30	123.367	1.906	1.54	119.000	127.000		
2022-001	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	12	125.333	1.179	0.94	121.000	129.000		
2022-001	3 ISE DILUTE	203 ROCHE	93 ROCHE	34	124.235	1.800	1.45	120.000	128.000		
2022-001	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	123.500	2.202	1.78	120.000	128.000		
2022-001	4 ISE UNLIL.	165 VITROS	63 KODAK	80	123.925	1.889	1.52	120.000	128.000		
2022-001	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	123.882	1.646	1.33	120.000	128.000		
2022-001	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	125.250	0.829	0.66	121.000	129.000		
2022-001	4 ISE UNLIL.	191 RX-DAYTONA	126 RANDOX	25	124.680	2.328	1.87	121.000	129.000		
2022-001	4 ISE UNLIL.	199 Rx-IMOLA	126 RANDOX	11	124.364	1.611	1.30	120.000	128.000		
2022-001	4 ISE UNLIL.	220 Medica E.	130 MEDICA	10	124.100	2.625	2.12	120.000	128.000		
2022-001	5 IMT	197 ARCHITECT	1 ABBOTT	11	124.182	1.850	1.49	120.000	128.000		
2022-001	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	80	125.861	1.940	1.54	122.000	130.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-001	6	QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	125.385	2.058	1.64	121.000	129.000
023	SODIUM		CLIA TEST ID #: 475		EVALUATION CRITERIA: TARGET VALUE 4.00							
2022-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	33	159.364	2.496	1.57	155.000	163.000
2022-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	158.897	2.644	1.66	155.000	163.000
2022-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	161.917	1.706	1.05	158.000	166.000
2022-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	34	159.882	2.180	1.36	156.000	164.000
2022-002	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	160.100	2.071	1.29	156.000	164.000
2022-002	4	ISE UNLIL.	165	VITROS	63	KODAK	80	165.671	2.304	1.39	162.000	170.000
2022-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	168.250	2.385	1.42	164.000	172.000
2022-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	166.133	1.948	1.17	162.000	170.000
2022-002	4	ISE UNLIL.	191	RX-DAYTONA	126	RANLIL	25	160.680	3.663	2.28	157.000	165.000
2022-002	4	ISE UNLIL.	199	Rx-IMOLA	126	RANLIL	11	161.182	3.511	2.18	157.000	165.000
2022-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	161.500	3.041	1.88	158.000	166.000
2022-002	5	IMT	197	ARCHITECT	1	ABBOTT	11	161.909	3.315	2.05	158.000	166.000
2022-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	80	159.218	2.474	1.55	155.000	163.000
2022-002	6	QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	159.692	2.728	1.71	156.000	164.000
2022-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	33	156.485	3.854	2.46	152.000	160.000
2022-003	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	156.034	1.884	1.21	152.000	160.000
2022-003	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	158.833	1.993	1.25	155.000	163.000
2022-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	34	156.324	2.598	1.66	152.000	160.000
2022-003	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	157.300	2.410	1.53	153.000	161.000
2022-003	4	ISE UNLIL.	165	VITROS	63	KODAK	80	161.575	2.349	1.45	158.000	166.000
2022-003	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	161.987	2.212	1.37	158.000	166.000
2022-003	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	163.500	1.658	1.01	160.000	168.000
2022-003	4	ISE UNLIL.	191	RX-DAYTONA	126	RANLIL	25	157.080	3.110	1.98	153.000	161.000
2022-003	4	ISE UNLIL.	199	Rx-IMOLA	126	RANLIL	11	155.909	4.144	2.66	152.000	160.000
2022-003	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	159.100	2.809	1.77	155.000	163.000
2022-003	5	IMT	197	ARCHITECT	1	ABBOTT	11	156.727	2.378	1.52	153.000	161.000
2022-003	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	80	155.975	2.318	1.49	152.000	160.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-003	6 QUICK LYTE	212 S. D. EXL	143 SIEMENS	13	156.154	2.656	1.70	152.000	160.000		
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2022-004	3 ISE DILUTE	184 INTEGRA	93 ROCHE	33	131.364	2.556	1.95	127.000	135.000		
2022-004	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	30	131.300	1.810	1.38	127.000	135.000		
2022-004	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	12	131.833	1.344	1.02	128.000	136.000		
2022-004	3 ISE DILUTE	203 ROCHE	93 ROCHE	34	131.485	1.480	1.13	127.000	135.000		
2022-004	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	130.400	1.800	1.38	126.000	134.000		
2022-004	4 ISE UNLIL.	165 VITROS	63 KODAK	80	132.000	1.823	1.38	128.000	136.000		
2022-004	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	132.250	2.487	1.88	128.000	136.000		
2022-004	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	132.387	1.758	1.33	128.000	136.000		
2022-004	4 ISE UNLIL.	191 RX-DAYTONA	126 RANDOX	25	131.080	1.787	1.36	127.000	135.000		
2022-004	4 ISE UNLIL.	199 Rx-IMOLA	126 RANDOX	11	130.000	2.174	1.67	126.000	134.000		
2022-004	4 ISE UNLIL.	220 Medica E.	130 MEDICA	10	131.500	2.012	1.53	128.000	136.000		
2022-004	5 IMT	197 ARCHITECT	1 ABBOTT	11	131.455	1.305	0.99	127.000	135.000		
2022-004	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	80	132.463	1.897	1.43	128.000	136.000		
2022-004	6 QUICK LYTE	212 S. D. EXL	143 SIEMENS	13	132.538	1.737	1.31	129.000	137.000		
2022-005	3 ISE DILUTE	184 INTEGRA	93 ROCHE	33	115.500	1.820	1.58	112.000	120.000		
2022-005	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	30	115.367	1.494	1.30	111.000	119.000		
2022-005	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	12	115.833	1.213	1.05	112.000	120.000		
2022-005	3 ISE DILUTE	203 ROCHE	93 ROCHE	34	115.794	1.745	1.51	112.000	120.000		
2022-005	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	114.200	1.661	1.45	110.000	118.000		
2022-005	4 ISE UNLIL.	165 VITROS	63 KODAK	80	114.975	1.559	1.36	111.000	119.000		
2022-005	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	115.160	1.524	1.32	111.000	119.000		
2022-005	4 ISE UNLIL.	165 VITROS	156 Kit 32	76	115.500	1.118	0.97	112.000	120.000		
2022-005	4 ISE UNLIL.	191 RX-DAYTONA	126 RANDOX	25	116.320	2.395	2.06	112.000	120.000		
2022-005	4 ISE UNLIL.	199 Rx-IMOLA	126 RANDOX	11	116.273	2.136	1.84	112.000	120.000		
2022-005	4 ISE UNLIL.	220 Medica E.	130 MEDICA	10	116.600	1.744	1.50	113.000	121.000		
2022-005	5 IMT	197 ARCHITECT	1 ABBOTT	11	115.182	1.029	0.89	111.000	119.000		
2022-005	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	80	117.738	1.730	1.47	114.000	122.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	6	QUICK LYTE	212	S. D. EXL	143	SIEMENS	13	117.154	1.747	1.49	113.000	121.000
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 10 %						
2022-001	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	3.995	0.081	2.03	3.600	4.400
2022-001	1	BIURET	165	VITROS	63	KODAK	146	3.849	0.098	2.56	3.500	4.200
2022-001	1	BIURET	184	INTEGRA	93	ROCHE	25	3.736	0.135	3.62	3.400	4.100
2022-001	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	3.925	0.043	1.10	3.500	4.300
2022-001	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	3.785	0.129	3.41	3.400	4.200
2022-001	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	3.848	0.146	3.79	3.500	4.200
2022-001	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	4.000	0.000	0.00	3.600	4.400
2022-001	1	BIURET	197	ARCHITECT	1	ABBOTT	21	3.752	0.126	3.35	3.400	4.100
2022-001	1	BIURET	203	ROCHE	93	ROCHE	32	3.891	0.113	2.90	3.500	4.300
2022-001	1	BIURET	212	S. D. EXL	143	SIEMENS	13	3.992	0.127	3.18	3.600	4.400
2022-001	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	3.820	0.172	4.50	3.400	4.200
2022-002	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	8.713	0.222	2.55	7.800	9.600
2022-002	1	BIURET	165	VITROS	63	KODAK	146	7.960	0.219	2.75	7.200	8.800
2022-002	1	BIURET	184	INTEGRA	93	ROCHE	25	7.980	0.202	2.53	7.200	8.800
2022-002	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	8.241	0.419	5.09	7.400	9.100
2022-002	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	8.475	0.179	2.11	7.600	9.300
2022-002	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	8.500	0.294	3.46	7.700	9.400
2022-002	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	8.315	0.353	4.24	7.500	9.100
2022-002	1	BIURET	197	ARCHITECT	1	ABBOTT	21	8.550	0.163	1.90	7.700	9.400
2022-002	1	BIURET	203	ROCHE	93	ROCHE	32	8.272	0.248	3.00	7.400	9.100
2022-002	1	BIURET	212	S. D. EXL	143	SIEMENS	13	8.777	0.208	2.37	7.900	9.700
2022-002	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	8.400	0.190	2.26	7.600	9.200
2022-003	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	8.175	0.216	2.65	7.400	9.000
2022-003	1	BIURET	165	VITROS	63	KODAK	146	7.477	0.188	2.52	6.700	8.200
2022-003	1	BIURET	184	INTEGRA	93	ROCHE	25	7.500	0.183	2.44	6.800	8.300
2022-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	8.050	0.112	1.39	7.200	8.900

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	7.724	0.158	2.05	7.000	8.500
2022-003	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	7.791	0.266	3.42	7.000	8.600
2022-003	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	8.033	0.047	0.59	7.200	8.800
2022-003	1	BIURET	197	ARCHITECT	1	ABBOTT	21	8.000	0.141	1.77	7.200	8.800
2022-003	1	BIURET	203	ROCHE	93	ROCHE	32	7.778	0.231	2.98	7.000	8.600
2022-003	1	BIURET	212	S. D. EXL	143	SIEMENS	13	8.131	0.281	3.46	7.300	8.900
2022-003	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	7.850	0.143	1.82	7.100	8.600
024 TOTAL PROTEIN			CLIA TEST ID #: 485			EVALUATION CRITERIA: TARGET VALUE 10 %						
2022-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	4.886	0.100	2.05	4.400	5.400
2022-004	1	BIURET	165	VITROS	63	KODAK	146	4.636	0.122	2.64	4.200	5.100
2022-004	1	BIURET	184	INTEGRA	93	ROCHE	25	4.544	0.150	3.30	4.100	5.000
2022-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	4.627	0.153	3.31	4.200	5.100
2022-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	4.800	0.100	2.08	4.300	5.300
2022-004	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	4.733	0.047	1.00	4.300	5.200
2022-004	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	4.734	0.217	4.59	4.300	5.200
2022-004	1	BIURET	197	ARCHITECT	1	ABBOTT	21	4.640	0.102	2.20	4.200	5.100
2022-004	1	BIURET	203	ROCHE	93	ROCHE	32	4.748	0.119	2.50	4.300	5.200
2022-004	1	BIURET	212	S. D. EXL	143	SIEMENS	13	4.900	0.130	2.65	4.400	5.400
2022-004	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	4.690	0.137	2.93	4.200	5.200
2022-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	3.085	0.077	2.50	2.800	3.400
2022-005	1	BIURET	165	VITROS	63	KODAK	146	3.022	0.091	3.02	2.700	3.300
2022-005	1	BIURET	184	INTEGRA	93	ROCHE	25	2.848	0.094	3.31	2.600	3.100
2022-005	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	2.975	0.043	1.46	2.700	3.300
2022-005	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	27	2.946	0.155	5.26	2.700	3.200
2022-005	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	2.982	0.140	4.70	2.700	3.300
2022-005	1	BIURET	191	RX-DAYTONA	126	RANDOX	33	3.033	0.047	1.55	2.700	3.300
2022-005	1	BIURET	197	ARCHITECT	1	ABBOTT	21	2.862	0.090	3.14	2.600	3.100
2022-005	1	BIURET	203	ROCHE	93	ROCHE	32	3.022	0.086	2.83	2.700	3.300
2022-005	1	BIURET	212	S. D. EXL	143	SIEMENS	13	3.100	0.088	2.83	2.800	3.400

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-005	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	2.970	0.090	3.03	2.700	3.300
025	TRIGLYCERIDES		CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-001	2	ENZ. COLO.	165	VITROS	63	KODAK	150	117.201	3.584	3.06	88.000	147.000
2022-001	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	108.250	4.585	4.24	81.000	135.000
2022-001	2	ENZ. COLO.	203	ROCHE	93	ROCHE	19	109.000	2.513	2.31	82.000	136.000
2022-001	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	77	99.395	3.528	3.55	75.000	124.000
2022-001	4	ENZ. (GPD)	212	S. D. EXL	143	SIEMENS	14	98.143	3.889	3.96	74.000	123.000
2022-001	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	29	106.103	5.047	4.76	80.000	133.000
2022-001	9	GPO TRIND.	191	RX-DAYTONA	126	RANDOX	22	104.273	6.524	6.26	78.000	130.000
2022-001	9	GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	111.900	3.208	2.87	84.000	140.000
2022-001	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	22	111.955	3.711	3.31	84.000	140.000
2022-001	10	ENZYM. GPO	191	RX-DAYTONA	126	RANDOX	11	106.909	3.315	3.10	80.000	134.000
2022-001	10	ENZYM. GPO	203	ROCHE	93	ROCHE	21	108.619	2.886	2.66	81.000	136.000
2022-001	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	12	99.083	4.769	4.81	74.000	124.000
2022-002	2	ENZ. COLO.	165	VITROS	63	KODAK	150	263.230	6.938	2.64	197.000	329.000
2022-002	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	220.417	5.545	2.52	165.000	276.000
2022-002	2	ENZ. COLO.	203	ROCHE	93	ROCHE	19	220.421	4.945	2.24	165.000	276.000
2022-002	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	77	220.618	6.164	2.79	165.000	276.000
2022-002	4	ENZ. (GPD)	212	S. D. EXL	143	SIEMENS	14	221.143	6.197	2.80	166.000	276.000
2022-002	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	29	229.241	11.866	5.18	172.000	287.000
2022-002	9	GPO TRIND.	191	RX-DAYTONA	126	RANDOX	22	215.409	15.956	7.41	162.000	269.000
2022-002	9	GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	237.400	8.743	3.68	178.000	297.000
2022-002	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	22	224.909	7.603	3.38	169.000	281.000
2022-002	10	ENZYM. GPO	191	RX-DAYTONA	126	RANDOX	11	221.273	11.787	5.33	166.000	277.000
2022-002	10	ENZYM. GPO	203	ROCHE	93	ROCHE	21	221.476	8.478	3.83	166.000	277.000
2022-002	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	12	211.250	6.647	3.15	158.000	264.000
2022-003	2	ENZ. COLO.	165	VITROS	63	KODAK	150	247.123	6.327	2.56	185.000	309.000
2022-003	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	208.500	6.198	2.97	156.000	261.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-003	2 ENZ. COLO.	203 ROCHE	93 ROCHE		19	207.737	5.447	2.62	156.000	260.000	
2022-003	4 ENZ. (GPD)	38 SIEMENS DI	143 SIEMENS		77	208.805	6.447	3.09	157.000	261.000	
2022-003	4 ENZ. (GPD)	212 S. D. EXL	143 SIEMENS		14	205.500	5.961	2.90	154.000	257.000	
2022-003	9 GPO TRIND.	186 BECK. COUL	76 AU-BECKMAN		29	217.000	8.816	4.06	163.000	271.000	
2022-003	9 GPO TRIND.	191 RX-DAYTONA	126 RANDOX		22	203.273	13.981	6.88	152.000	254.000	
2022-003	9 GPO TRIND.	215 B.C DXC	134 BECKM.COUL		10	224.800	8.897	3.96	169.000	281.000	
2022-003	10 ENZYM. GPO	184 INTEGRA	93 ROCHE		22	213.864	7.534	3.52	160.000	267.000	
2022-003	10 ENZYM. GPO	191 RX-DAYTONA	126 RANDOX		11	211.364	11.834	5.60	159.000	264.000	
2022-003	10 ENZYM. GPO	203 ROCHE	93 ROCHE		21	208.571	6.551	3.14	156.000	261.000	
2022-003	11 GLY PO4 OX	197 ARCHITECT	1 ABBOTT		12	199.833	7.301	3.65	150.000	250.000	
025 TRIGLYCERIDES		CLIA TEST ID #: 495	EVALUATION CRITERIA: TARGET VALUE 25 %								
2022-004	2 ENZ. COLO.	165 VITROS	63 KODAK		150	144.685	4.262	2.95	109.000	181.000	
2022-004	2 ENZ. COLO.	184 INTEGRA	93 ROCHE		12	130.583	4.329	3.32	98.000	163.000	
2022-004	2 ENZ. COLO.	203 ROCHE	93 ROCHE		19	130.053	2.837	2.18	98.000	163.000	
2022-004	4 ENZ. (GPD)	38 SIEMENS DI	143 SIEMENS		77	122.787	3.974	3.24	92.000	153.000	
2022-004	4 ENZ. (GPD)	212 S. D. EXL	143 SIEMENS		14	122.286	2.763	2.26	92.000	153.000	
2022-004	9 GPO TRIND.	186 BECK. COUL	76 AU-BECKMAN		29	129.793	4.951	3.81	97.000	162.000	
2022-004	9 GPO TRIND.	191 RX-DAYTONA	126 RANDOX		22	126.476	7.908	6.25	95.000	158.000	
2022-004	9 GPO TRIND.	215 B.C DXC	134 BECKM.COUL		10	135.400	5.987	4.42	102.000	169.000	
2022-004	10 ENZYM. GPO	184 INTEGRA	93 ROCHE		22	133.864	3.923	2.93	100.000	167.000	
2022-004	10 ENZYM. GPO	191 RX-DAYTONA	126 RANDOX		11	131.000	7.361	5.62	98.000	164.000	
2022-004	10 ENZYM. GPO	203 ROCHE	93 ROCHE		21	129.524	3.911	3.02	97.000	162.000	
2022-004	11 GLY PO4 OX	197 ARCHITECT	1 ABBOTT		12	120.000	4.509	3.76	90.000	150.000	
2022-005	2 ENZ. COLO.	165 VITROS	63 KODAK		150	89.284	2.771	3.10	67.000	112.000	
2022-005	2 ENZ. COLO.	184 INTEGRA	93 ROCHE		12	84.333	3.590	4.26	63.000	105.000	
2022-005	2 ENZ. COLO.	203 ROCHE	93 ROCHE		19	84.842	2.621	3.09	64.000	106.000	
2022-005	4 ENZ. (GPD)	38 SIEMENS DI	143 SIEMENS		77	74.907	3.355	4.48	56.000	94.000	
2022-005	4 ENZ. (GPD)	212 S. D. EXL	143 SIEMENS		14	74.000	4.392	5.93	56.000	93.000	
2022-005	9 GPO TRIND.	186 BECK. COUL	76 AU-BECKMAN		29	82.607	3.098	3.75	62.000	103.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	9	GPO TRIND.	191	RX-DAYTONA	126	RANDOX	22	82.857	3.468	4.19	62.000	104.000
2022-005	9	GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	88.400	2.498	2.83	66.000	111.000
2022-005	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	22	87.273	2.750	3.15	65.000	109.000
2022-005	10	ENZYM. GPO	191	RX-DAYTONA	126	RANDOX	11	83.273	3.816	4.58	62.000	104.000
2022-005	10	ENZYM. GPO	203	ROCHE	93	ROCHE	21	85.048	2.380	2.80	64.000	106.000
2022-005	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	12	76.250	3.419	4.48	57.000	95.000
026	UREA NITROGEN (BUN)		CLIA	TEST ID #: 505	EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}							
2022-001	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	16.349	0.962	5.89	14.000	18.000
2022-001	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	17.000	0.667	3.92	15.000	19.000
2022-001	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	39	15.974	0.768	4.80	14.000	18.000
2022-001	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	29	16.483	0.500	3.03	14.000	18.000
2022-001	2	UREAS.GLDH	191	RX-DAYTONA	126	RANDOX	30	17.033	0.983	5.77	15.000	19.000
2022-001	2	UREAS.GLDH	191	RX-DAYTONA	126	RANDOX	30	16.333	0.471	2.89	14.000	18.000
2022-001	2	UREAS.GLDH	203	ROCHE	93	ROCHE	42	16.262	0.692	4.26	14.000	18.000
2022-001	2	UREAS.GLDH	212	S. D. EXL	143	SIEMENS	13	16.000	0.784	4.90	14.000	18.000
2022-001	8	UREASE QUI	165	VITROS	63	KODAK	163	14.224	0.546	3.84	12.000	16.000
2022-001	10	UREASE 37	220	Medica E.	130	MEDICA	10	14.800	3.628	24.51	13.000	17.000
2022-001	11	UREASE	197	ARCHITECT	1	ABBOTT	10	15.800	0.400	2.53	14.000	18.000
2022-002	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	42.000	2.309	5.50	38.000	46.000
2022-002	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	43.280	1.876	4.33	39.000	47.000
2022-002	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	39	42.436	1.516	3.57	39.000	46.000
2022-002	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	29	42.786	1.292	3.02	39.000	47.000
2022-002	2	UREAS.GLDH	191	RX-DAYTONA	126	RANDOX	30	41.667	1.700	4.08	38.000	45.000
2022-002	2	UREAS.GLDH	191	RX-DAYTONA	126	RANDOX	30	40.267	2.874	7.14	37.000	44.000
2022-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	42	42.381	1.379	3.25	39.000	46.000
2022-002	2	UREAS.GLDH	212	S. D. EXL	143	SIEMENS	13	42.462	1.906	4.49	39.000	46.000
2022-002	8	UREASE QUI	165	VITROS	63	KODAK	163	39.216	0.973	2.48	36.000	43.000
2022-002	10	UREASE 37	220	Medica E.	130	MEDICA	10	39.800	1.166	2.93	36.000	43.000
2022-002	11	UREASE	197	ARCHITECT	1	ABBOTT	10	43.500	1.360	3.13	40.000	47.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505	EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}								
2022-003	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	40.241	1.572	3.91	37.000	44.000	
2022-003	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	39.667	1.247	3.14	36.000	43.000	
2022-003	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		39	39.590	1.295	3.27	36.000	43.000	
2022-003	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		29	40.138	1.106	2.75	37.000	44.000	
2022-003	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX		30	38.400	2.430	6.33	35.000	42.000	
2022-003	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX		30	39.000	1.414	3.63	35.000	43.000	
2022-003	2 UREAS.GLDH	203 ROCHE	93 ROCHE		42	39.452	1.257	3.19	36.000	43.000	
2022-003	2 UREAS.GLDH	212 S. D. EXL	143 SIEMENS		13	39.308	2.300	5.85	36.000	43.000	
2022-003	8 UREASE QUI	165 VITROS	63 KODAK		163	36.352	0.828	2.28	33.000	40.000	
2022-003	10 UREASE 37	220 Medica E.	130 MEDICA		10	37.400	1.356	3.63	34.000	41.000	
2022-003	11 UREASE	197 ARCHITECT	1 ABBOTT		10	40.000	0.775	1.94	36.000	44.000	
2022-004	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	21.889	0.737	3.37	20.000	24.000	
2022-004	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	21.253	0.992	4.67	19.000	23.000	
2022-004	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		39	20.897	0.810	3.88	19.000	23.000	
2022-004	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		29	21.310	0.532	2.50	19.000	23.000	
2022-004	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX		30	21.333	0.471	2.21	19.000	23.000	
2022-004	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX		30	21.333	1.274	5.97	19.000	23.000	
2022-004	2 UREAS.GLDH	203 ROCHE	93 ROCHE		42	20.951	0.731	3.49	19.000	23.000	
2022-004	2 UREAS.GLDH	212 S. D. EXL	143 SIEMENS		13	20.923	1.141	5.45	19.000	23.000	
2022-004	8 UREASE QUI	165 VITROS	63 KODAK		163	18.685	0.593	3.17	17.000	21.000	
2022-004	10 UREASE 37	220 Medica E.	130 MEDICA		10	20.300	0.458	2.26	18.000	22.000	
2022-004	11 UREASE	197 ARCHITECT	1 ABBOTT		10	20.600	0.800	3.88	19.000	23.000	
2022-005	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	11.253	0.916	8.14	9.000	13.000	
2022-005	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		83	12.000	0.471	3.93	10.000	14.000	
2022-005	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		39	10.974	0.577	5.26	9.000	13.000	
2022-005	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		29	11.414	0.493	4.32	9.000	13.000	
2022-005	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX		30	11.867	0.846	7.13	10.000	14.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-005	2 UREAS.GLDH	191 RX-DAYTONA	126 RANDOX	30	11.333	0.471	4.16	9.000	13.000		
2022-005	2 UREAS.GLDH	203 ROCHE	93 ROCHE	42	11.262	0.580	5.15	9.000	13.000		
2022-005	2 UREAS.GLDH	212 S. D. EXL	143 SIEMENS	13	11.154	0.863	7.74	9.000	13.000		
2022-005	8 UREASE QUI	165 VITROS	63 KODAK	163	9.827	0.466	4.74	8.000	12.000		
2022-005	10 UREASE 37	220 Medica E.	130 MEDICA	10	11.200	0.400	3.57	9.000	13.000		
2022-005	11 UREASE	197 ARCHITECT	1 ABBOTT	10	10.900	0.300	2.75	9.000	13.000		
027 URIC ACID		CLIA TEST ID #: 515	EVALUATION CRITERIA: TARGET VALUE 17 %								
2022-001	2 URICASE	38 SIEMENS DI	143 SIEMENS	42	3.086	0.151	4.88	2.600	3.600		
2022-001	2 URICASE	165 VITROS	63 KODAK	100	3.094	0.080	2.58	2.600	3.600		
2022-001	2 URICASE	184 INTEGRA	93 ROCHE	16	3.144	0.141	4.49	2.600	3.700		
2022-001	2 URICASE	197 ARCHITECT	1 ABBOTT	11	3.182	0.072	2.25	2.600	3.700		
2022-001	2 URICASE	203 ROCHE	93 ROCHE	25	3.032	0.088	2.91	2.500	3.500		
2022-001	5 URICASE 37	186 BECK. COUL	76 AU-BECKMAN	21	3.210	0.106	3.32	2.700	3.800		
2022-001	5 URICASE 37	215 B.C DXC	134 BECKM.COUL	10	2.980	0.075	2.51	2.500	3.500		
2022-001	6 ENZY. COL	203 ROCHE	93 ROCHE	10	3.070	0.090	2.93	2.500	3.600		
2022-002	2 URICASE	38 SIEMENS DI	143 SIEMENS	42	10.668	0.263	2.46	8.900	12.500		
2022-002	2 URICASE	165 VITROS	63 KODAK	100	10.768	0.209	1.94	8.900	12.600		
2022-002	2 URICASE	184 INTEGRA	93 ROCHE	16	10.956	0.337	3.08	9.100	12.800		
2022-002	2 URICASE	197 ARCHITECT	1 ABBOTT	11	10.945	0.167	1.53	9.100	12.800		
2022-002	2 URICASE	203 ROCHE	93 ROCHE	25	10.480	0.329	3.14	8.700	12.300		
2022-002	5 URICASE 37	186 BECK. COUL	76 AU-BECKMAN	21	10.576	0.262	2.47	8.800	12.400		
2022-002	5 URICASE 37	215 B.C DXC	134 BECKM.COUL	10	9.560	0.191	2.00	7.900	11.200		
2022-002	6 ENZY. COL	203 ROCHE	93 ROCHE	10	10.510	0.284	2.71	8.700	12.300		
2022-003	2 URICASE	38 SIEMENS DI	143 SIEMENS	42	9.793	0.307	3.13	8.100	11.500		
2022-003	2 URICASE	165 VITROS	63 KODAK	100	9.937	0.192	1.93	8.200	11.600		
2022-003	2 URICASE	184 INTEGRA	93 ROCHE	16	10.038	0.350	3.48	8.300	11.700		
2022-003	2 URICASE	197 ARCHITECT	1 ABBOTT	11	10.091	0.227	2.25	8.400	11.800		
2022-003	2 URICASE	203 ROCHE	93 ROCHE	25	9.640	0.303	3.15	8.000	11.300		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-003	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	21	9.805	0.226	2.30	8.100	11.500
2022-003	5	URICASE 37	215	B.C DXC	134	BECKM.COUL	10	8.940	0.174	1.95	7.400	10.500
2022-003	6	ENZY. COL	203	ROCHE	93	ROCHE	10	9.730	0.261	2.68	8.100	11.400
027	URIC ACID	CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 17 %						
2022-004	2	URICASE	38	SIEMENS DI	143	SIEMENS	42	4.488	0.153	3.41	3.700	5.300
2022-004	2	URICASE	165	VITROS	63	KODAK	100	4.498	0.109	2.43	3.700	5.300
2022-004	2	URICASE	184	INTEGRA	93	ROCHE	16	4.631	0.165	3.56	3.800	5.400
2022-004	2	URICASE	197	ARCHITECT	1	ABBOTT	11	4.591	0.067	1.46	3.800	5.400
2022-004	2	URICASE	203	ROCHE	93	ROCHE	25	4.440	0.150	3.37	3.700	5.200
2022-004	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	21	4.595	0.095	2.07	3.800	5.400
2022-004	5	URICASE 37	215	B.C DXC	134	BECKM.COUL	10	4.310	0.054	1.25	3.600	5.000
2022-004	6	ENZY. COL	203	ROCHE	93	ROCHE	10	4.480	0.117	2.60	3.700	5.200
2022-005	2	URICASE	38	SIEMENS DI	143	SIEMENS	42	1.702	0.091	5.36	1.400	2.000
2022-005	2	URICASE	165	VITROS	63	KODAK	100	1.713	0.063	3.66	1.400	2.000
2022-005	2	URICASE	184	INTEGRA	93	ROCHE	16	1.675	0.066	3.95	1.400	2.000
2022-005	2	URICASE	197	ARCHITECT	1	ABBOTT	11	1.773	0.045	2.51	1.500	2.100
2022-005	2	URICASE	203	ROCHE	93	ROCHE	25	1.604	0.053	3.29	1.300	1.900
2022-005	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	21	1.776	0.061	3.43	1.500	2.100
2022-005	5	URICASE 37	215	B.C DXC	134	BECKM.COUL	10	1.600	0.000	0.00	1.300	1.900
2022-005	6	ENZY. COL	203	ROCHE	93	ROCHE	10	1.640	0.049	2.99	1.400	1.900
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-001	3	ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	10	66.800	1.939	2.90	53.000	80.000
2022-001	5	KINETIC 37	165	VITROS	63	KODAK	22	134.273	2.471	1.84	107.000	161.000
2022-002	3	ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	10	365.500	10.585	2.90	292.000	439.000
2022-002	5	KINETIC 37	165	VITROS	63	KODAK	22	573.000	15.147	2.64	458.000	688.000
2022-003	3	ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	10	334.900	7.635	2.28	268.000	402.000
2022-003	5	KINETIC 37	165	VITROS	63	KODAK	22	526.857	12.009	2.28	421.000	632.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2022-004	3 ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	10	124.100	3.176	2.56	99.000	149.000	
2022-004	5 KINETIC 37	165	VITROS	63	KODAK	22	237.273	5.284	2.23	190.000	285.000	
2022-005	3 ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	10	11.200	0.600	5.36	9.000	13.000	
2022-005	5 KINETIC 37	165	VITROS	63	KODAK	22	20.182	1.154	5.72	16.000	24.000	
136	LACTIC ACID											
2022-001	1 LACTATE-P.	165	VITROS	63	KODAK	19	1.083	0.050	4.62	0.900	1.300	
2022-001	1 LACTATE-P.	165	VITROS	63	KODAK	19	1.040	0.120	11.54	0.800	1.200	
2022-002	1 LACTATE-P.	165	VITROS	63	KODAK	19	7.920	0.117	1.47	6.300	9.500	
2022-002	1 LACTATE-P.	165	VITROS	63	KODAK	19	7.206	0.207	2.87	5.800	8.600	
2022-003	1 LACTATE-P.	165	VITROS	63	KODAK	19	6.561	0.195	2.97	5.200	7.900	
2022-003	1 LACTATE-P.	165	VITROS	63	KODAK	19	7.140	0.080	1.12	5.700	8.600	
2022-004	1 LACTATE-P.	165	VITROS	63	KODAK	19	2.200	0.000	0.00	1.800	2.600	
2022-004	1 LACTATE-P.	165	VITROS	63	KODAK	19	2.306	0.085	3.68	1.800	2.800	
2022-005	1 LACTATE-P.	165	VITROS	63	KODAK	19	0.478	0.092	19.18	0.400	0.600	
2022-005	1 LACTATE-P.	165	VITROS	63	KODAK	19	0.260	0.080	30.77	0.200	0.300	
137	LIPASE											
2022-001	1 COLORIMET.	203	ROCHE	93	ROCHE	14	27.857	1.959	7.03	22.000	33.000	
2022-001	2 ENZIMATIC	165	VITROS	63	KODAK	85	201.600	8.114	4.02	161.000	242.000	
2022-001	2 ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	31.700	3.523	11.11	25.000	38.000	
2022-001	2 ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	32.429	2.382	7.35	26.000	39.000	
2022-001	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	28.500	1.910	6.70	23.000	34.000	
2022-001	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	13	29.462	1.599	5.43	24.000	35.000	
2022-001	4 ENZ/COLOR	203	ROCHE	93	ROCHE	14	28.643	1.394	4.87	23.000	34.000	
2022-001	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	18	84.333	4.203	4.98	67.000	101.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
137	LIPASE	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-002	1	COLORIMET.	203	ROCHE	93	ROCHE	14	94.571	9.634	10.19	76.000	113.000
2022-002	2	ENZIMATIC	165	VITROS	63	KODAK	85	864.776	54.230	6.27	692.000	1038.000
2022-002	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	75.000	4.219	5.63	60.000	90.000
2022-002	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	104.286	5.599	5.37	83.000	125.000
2022-002	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	90.900	5.873	6.46	73.000	109.000
2022-002	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	13	102.308	4.140	4.05	82.000	123.000
2022-002	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	92.143	6.278	6.81	74.000	111.000
2022-002	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	18	286.056	13.414	4.69	229.000	343.000
2022-003	1	COLORIMET.	203	ROCHE	93	ROCHE	14	89.231	5.206	5.83	71.000	107.000
2022-003	2	ENZIMATIC	165	VITROS	63	KODAK	85	767.107	27.853	3.63	614.000	921.000
2022-003	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	72.200	3.516	4.87	58.000	87.000
2022-003	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	96.000	4.276	4.45	77.000	115.000
2022-003	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	85.400	5.953	6.97	68.000	102.000
2022-003	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	13	94.308	3.428	3.63	75.000	113.000
2022-003	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	84.929	5.958	7.02	68.000	102.000
2022-003	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	18	266.833	9.173	3.44	213.000	320.000
2022-004	1	COLORIMET.	203	ROCHE	93	ROCHE	14	40.714	3.825	9.40	33.000	49.000
2022-004	2	ENZIMATIC	165	VITROS	63	KODAK	85	334.369	11.258	3.37	267.000	401.000
2022-004	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	42.500	3.528	8.30	34.000	51.000
2022-004	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	45.857	2.587	5.64	37.000	55.000
2022-004	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	40.500	2.335	5.76	32.000	49.000
2022-004	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	13	43.308	1.488	3.44	35.000	52.000
2022-004	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	40.857	2.356	5.77	33.000	49.000
2022-004	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	18	122.944	4.778	3.89	98.000	148.000
2022-005	1	COLORIMET.	203	ROCHE	93	ROCHE	14	15.143	0.915	6.04	12.000	18.000
2022-005	2	ENZIMATIC	165	VITROS	63	KODAK	85	58.133	4.756	8.18	47.000	70.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-005	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	22.700	3.164	13.94	18.000	27.000
2022-005	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	18.286	1.666	9.11	15.000	22.000
2022-005	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	16.100	1.578	9.80	13.000	19.000
2022-005	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	13	15.000	1.414	9.43	12.000	18.000
2022-005	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	15.571	0.728	4.68	12.000	19.000
2022-005	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	18	44.944	3.257	7.25	36.000	54.000
138	PHOSPHORUS	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2022-001	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	42	2.460	0.086	3.50	2.000	3.000
2022-001	1	PHOSPHOMO.	165	VITROS	63	KODAK	91	2.530	0.098	3.86	2.000	3.000
2022-001	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	17	2.256	0.100	4.42	1.800	2.700
2022-001	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	18	2.239	0.111	4.97	1.800	2.700
2022-001	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	33	2.245	0.070	3.12	1.800	2.700
2022-001	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	2.250	0.112	4.97	1.800	2.700
2022-002	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	42	6.281	0.172	2.74	5.000	7.500
2022-002	1	PHOSPHOMO.	165	VITROS	63	KODAK	91	5.780	0.171	2.95	4.600	6.900
2022-002	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	17	5.965	0.153	2.57	4.800	7.200
2022-002	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	18	5.850	0.275	4.71	4.700	7.000
2022-002	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	33	5.979	0.151	2.53	4.800	7.200
2022-002	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	6.270	0.210	3.35	5.000	7.500
2022-003	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	42	5.848	0.162	2.77	4.700	7.000
2022-003	1	PHOSPHOMO.	165	VITROS	63	KODAK	91	5.412	0.147	2.71	4.300	6.500
2022-003	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	17	5.535	0.171	3.09	4.400	6.600
2022-003	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	18	5.472	0.228	4.17	4.400	6.600
2022-003	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	33	5.576	0.123	2.21	4.500	6.700
2022-003	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	5.830	0.224	3.84	4.700	7.000
2022-004	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	42	3.152	0.118	3.74	2.500	3.800
2022-004	1	PHOSPHOMO.	165	VITROS	63	KODAK	91	3.173	0.105	3.32	2.500	3.800

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-004	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	17	2.929	0.102	3.47	2.300	3.500
2022-004	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	18	2.906	0.143	4.93	2.300	3.500
2022-004	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	33	2.959	0.070	2.37	2.400	3.600
2022-004	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	3.020	0.075	2.48	2.400	3.600
138	PHOSPHORUS	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-005	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	42	1.666	0.093	5.56	1.300	2.000
2022-005	1	PHOSPHOMO.	165	VITROS	63	KODAK	91	1.790	0.093	5.20	1.400	2.100
2022-005	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	17	1.506	0.087	5.79	1.200	1.800
2022-005	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	18	1.544	0.101	6.55	1.200	1.900
2022-005	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	33	1.506	0.056	3.69	1.200	1.800
2022-005	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	1.500	0.100	6.67	1.200	1.800
169	CO2					EVALUATION CRITERIA: TARGET VALUE 3 SD						
2022-001	1	Generic Me	165	VITROS	63	KODAK	15	11.333	1.135	10.02	8.000	15.000
2022-001	1	Generic Me	184	INTEGRA	93	ROCHE	14	13.929	1.981	14.22	8.000	20.000
2022-001	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	13.174	2.119	16.09	7.000	20.000
2022-001	1	Generic Me	203	ROCHE	93	ROCHE	17	12.412	1.286	10.36	9.000	16.000
2022-001	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	66	14.682	2.583	17.59	7.000	22.000
2022-001	2	ENZYMATIC	165	VITROS	63	KODAK	65	12.369	1.535	12.41	8.000	17.000
2022-001	2	ENZYMATIC	165	VITROS	156	Kit 32	68	11.956	1.528	12.78	7.000	17.000
2022-001	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	11.333	2.321	20.48	4.000	18.000
2022-002	1	Generic Me	165	VITROS	63	KODAK	15	25.000	2.633	10.53	17.000	33.000
2022-002	1	Generic Me	184	INTEGRA	93	ROCHE	14	25.214	2.042	8.10	19.000	31.000
2022-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	28.227	2.953	10.46	19.000	37.000
2022-002	1	Generic Me	203	ROCHE	93	ROCHE	17	24.059	1.662	6.91	19.000	29.000
2022-002	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	66	28.636	2.638	9.21	21.000	37.000
2022-002	2	ENZYMATIC	165	VITROS	63	KODAK	65	25.754	2.475	9.61	18.000	33.000
2022-002	2	ENZYMATIC	165	VITROS	156	Kit 32	68	25.691	2.359	9.18	19.000	33.000
2022-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	25.500	2.986	11.71	17.000	34.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
169	CO2	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD									
2022-003	1	Generic Me	165 VITROS	63	KODAK	15	23.467	2.604	11.10	16.000	31.000		
2022-003	1	Generic Me	184 INTEGRA	93	ROCHE	14	24.000	1.890	7.87	18.000	30.000		
2022-003	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	23	26.391	2.059	7.80	20.000	33.000		
2022-003	1	Generic Me	203 ROCHE	93	ROCHE	17	23.059	1.589	6.89	18.000	28.000		
2022-003	2	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	66	26.106	2.425	9.29	19.000	33.000		
2022-003	2	ENZYMATIC	165 VITROS	63	KODAK	65	23.631	2.188	9.26	17.000	30.000		
2022-003	2	ENZYMATIC	165 VITROS	156	Kit 32	68	23.701	1.779	7.51	18.000	29.000		
2022-003	2	ENZYMATIC	203 ROCHE	93	ROCHE	12	22.167	1.818	8.20	17.000	28.000		
2022-004	1	Generic Me	165 VITROS	63	KODAK	15	13.733	1.914	13.93	8.000	19.000		
2022-004	1	Generic Me	184 INTEGRA	93	ROCHE	14	15.429	1.678	10.88	10.000	20.000		
2022-004	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	23	15.522	1.691	10.89	10.000	21.000		
2022-004	1	Generic Me	203 ROCHE	93	ROCHE	17	14.000	2.223	15.88	7.000	21.000		
2022-004	2	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	66	17.015	2.226	13.08	10.000	24.000		
2022-004	2	ENZYMATIC	165 VITROS	63	KODAK	65	14.047	1.473	10.49	10.000	18.000		
2022-004	2	ENZYMATIC	165 VITROS	156	Kit 32	68	14.000	1.486	10.62	10.000	18.000		
2022-004	2	ENZYMATIC	203 ROCHE	93	ROCHE	12	13.833	1.908	13.79	8.000	20.000		
2022-005	1	Generic Me	165 VITROS	63	KODAK	15	8.333	1.619	19.43	3.000	13.000		
2022-005	1	Generic Me	184 INTEGRA	93	ROCHE	14	10.571	1.591	15.05	6.000	15.000		
2022-005	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	23	10.391	1.132	10.89	7.000	14.000		
2022-005	1	Generic Me	203 ROCHE	93	ROCHE	17	9.529	1.786	18.74	4.000	15.000		
2022-005	2	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	66	12.076	1.812	15.00	7.000	18.000		
2022-005	2	ENZYMATIC	165 VITROS	63	KODAK	65	9.540	1.245	13.05	6.000	13.000		
2022-005	2	ENZYMATIC	165 VITROS	156	Kit 32	68	9.119	1.191	13.06	6.000	13.000		
2022-005	2	ENZYMATIC	203 ROCHE	93	ROCHE	12	9.750	1.639	16.81	5.000	15.000		
170	DIRECT BILIRUBIN	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}											
2022-001	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	0.278	0.047	16.78	0.100	0.400		
2022-001	11	SPECT. WIT	165 VITROS	63	KODAK	64	0.059	0.138	234.28	0	0.500		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-001	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	15	0.264	0.048	18.13	0.100	0.400
2022-001	16	DIAZO ENDP	215 B.C DXC	134	BECKM.COUL	10	0.300	0.000	0.00	0.200	0.400
170 DIRECT BILIRUBIN						CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}					
2022-002	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	1.920	0.069	3.61	1.500	2.300
2022-002	11	SPECT. WIT	165 VITROS	63	KODAK	64	1.343	0.192	14.33	0.800	1.900
2022-002	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	15	1.613	0.182	11.29	1.100	2.200
2022-002	16	DIAZO ENDP	215 B.C DXC	134	BECKM.COUL	10	1.820	0.040	2.20	1.500	2.200
2022-003	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	1.734	0.067	3.88	1.400	2.100
2022-003	11	SPECT. WIT	165 VITROS	63	KODAK	64	1.227	0.168	13.72	0.700	1.700
2022-003	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	15	1.480	0.168	11.36	1.000	2.000
2022-003	16	DIAZO ENDP	215 B.C DXC	134	BECKM.COUL	10	1.650	0.050	3.03	1.300	2.000
2022-004	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	0.589	0.032	5.39	0.500	0.700
2022-004	11	SPECT. WIT	165 VITROS	63	KODAK	64	0.152	0.204	133.76	0	0.800
2022-004	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	15	0.533	0.079	14.79	0.300	0.800
2022-004	16	DIAZO ENDP	215 B.C DXC	134	BECKM.COUL	10	0.600	0.000	0.00	0.500	0.700
2022-005	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	0.073	0.044	60.30	0	0.200
2022-005	11	SPECT. WIT	165 VITROS	63	KODAK	64	0.021	0.057	275.21	0	0.200
2022-005	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	15	0.200	0.037	18.26	0.100	0.300
2022-005	16	DIAZO ENDP	215 B.C DXC	134	BECKM.COUL	10	0.040	0.049	122.47	0	0.200

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
157 WHOLE BLOOD GLUCOSE						EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2022-101	20	ABBOT FREE		20	429.800	15.371	3.58	387.000	473.000		
2022-101	23	ABBOTT PRE		28	397.464	18.411	4.63	358.000	437.000		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-101	27	STAT SRIP.		44	283.442	22.237	7.85	255.000	312.000	
2022-101	33	AC.CHEK II		26	362.800	11.545	3.18	327.000	399.000	
2022-101	34	FREE STYL		47	432.043	26.205	6.07	389.000	475.000	
157 WHOLE BLOOD GLUCOSE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2022-102	20	ABBOT FREE		20	144.300	6.694	4.64	130.000	159.000	
2022-102	23	ABBOTT PRE		28	131.296	6.688	5.09	118.000	144.000	
2022-102	27	STAT SRIP.		44	122.419	6.638	5.42	110.000	135.000	
2022-102	33	AC.CHEK II		26	126.640	2.938	2.32	114.000	139.000	
2022-102	34	FREE STYL		47	144.435	7.854	5.44	130.000	159.000	
2022-103	20	ABBOT FREE		20	430.900	16.367	3.80	388.000	474.000	
2022-103	23	ABBOTT PRE		28	395.556	19.261	4.87	356.000	435.000	
2022-103	27	STAT SRIP.		44	279.023	21.239	7.61	251.000	307.000	
2022-103	33	AC.CHEK II		26	361.560	11.896	3.29	325.000	398.000	
2022-103	34	FREE STYL		47	433.489	29.560	6.82	390.000	477.000	
2022-104	20	ABBOT FREE		20	98.700	3.466	3.51	89.000	109.000	
2022-104	23	ABBOTT PRE		28	89.593	5.251	5.86	81.000	99.000	
2022-104	27	STAT SRIP.		44	86.091	5.195	6.03	77.000	95.000	
2022-104	33	AC.CHEK II		26	91.080	3.211	3.53	82.000	100.000	
2022-104	34	FREE STYL		47	99.283	5.119	5.16	89.000	109.000	
2022-105	20	ABBOT FREE		20	143.650	6.643	4.62	129.000	158.000	
2022-105	23	ABBOTT PRE		28	132.852	5.133	3.86	120.000	146.000	
2022-105	27	STAT SRIP.		44	121.814	6.303	5.17	110.000	134.000	
2022-105	33	AC.CHEK II		26	126.615	2.975	2.35	114.000	139.000	
2022-105	34	FREE STYL		47	145.596	8.123	5.58	131.000	160.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007	BLOOD GASES-pCO2		CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE	8	% OR 5.00	{GREATER}			
2022-051	265 ROCHE COBA				30	88.263	7.978	9.04	81.200	95.300
2022-052	265 ROCHE COBA				30	48.362	0.772	1.60	43.400	53.400
2022-053	265 ROCHE COBA				30	25.643	0.885	3.45	20.600	30.600
2022-054	265 ROCHE COBA				30	63.580	1.553	2.44	58.500	68.700
2022-055	265 ROCHE COBA				30	95.893	3.956	4.12	88.200	103.600
008	BLOOD GASES-pH		CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE	0.04					
2022-051	265 ROCHE COBA				30	7.075	0.011	0.16	7.035	7.115
2022-052	265 ROCHE COBA				30	7.369	0.004	0.06	7.329	7.409
2022-053	265 ROCHE COBA				30	7.581	0.007	0.09	7.541	7.621
2022-054	265 ROCHE COBA				30	7.196	0.007	0.10	7.156	7.236
2022-055	265 ROCHE COBA				30	7.070	0.010	0.15	7.030	7.110
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	3	SD				
2022-051	265 ROCHE COBA				30	80.137	8.920	11.13	53.400	106.900
2022-052	265 ROCHE COBA				30	107.100	2.903	2.71	98.400	115.800
2022-053	265 ROCHE COBA				30	182.107	4.651	2.55	168.200	196.100
2022-054	265 ROCHE COBA				30	332.443	19.765	5.95	273.100	391.700

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2022-055	265 ROCHE COBA			30	83.690	9.766	11.67	54.400	113.000	
SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 0								
2022-031	116 ROCHE COBA			16	17.125	1.649	9.63	12.200	22.100	
2022-031	149 ARC i2000s			10	15.630	1.114	7.12	12.300	19.000	
2022-032	116 ROCHE COBA			16	31.325	2.367	7.56	24.200	38.400	
2022-032	149 ARC i2000s			10	29.720	1.754	5.90	24.500	35.000	
2022-033	116 ROCHE COBA			16	33.456	2.645	7.91	25.500	41.400	
2022-033	149 ARC i2000s			10	32.230	2.111	6.55	25.900	38.600	
2022-034	116 ROCHE COBA			16	8.873	0.799	9.00	6.500	11.300	
2022-034	149 ARC i2000s			10	7.730	0.445	5.76	6.400	9.100	
2022-035	116 ROCHE COBA			16	13.100	1.321	10.08	9.100	17.100	
2022-035	149 ARC i2000s			10	11.610	0.664	5.72	9.600	13.600	
030	FREE THYROXINE	CLIA TEST ID #: 545								
2022-031	115 VITROS ECI			42	4.183	0.191	4.57	3.600	4.800	
2022-031	116 ROCHE COBA			47	1.872	0.094	5.01	1.600	2.200	
2022-031	125 B.C.ACCESS			45	1.541	0.101	6.54	1.200	1.800	
2022-031	149 ARC i2000s			24	1.421	0.064	4.53	1.200	1.600	
2022-031	160 SIEMENS EX			48	1.745	0.074	4.23	1.500	2.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2022-032	115 VITROS ECI			42	6.719	0.148	2.21	6.300	7.200	
2022-032	116 ROCHE COBA			47	3.202	0.162	5.05	2.700	3.700	
2022-032	125 B.C.ACCESS			45	2.259	0.113	5.02	1.900	2.600	
2022-032	149 ARC i2000s			24	2.329	0.114	4.88	2.000	2.700	
2022-032	160 SIEMENS EX			48	2.838	0.127	4.47	2.500	3.200	
2022-033	115 VITROS ECI			42	6.912	0.104	1.51	6.600	7.200	
2022-033	116 ROCHE COBA			47	3.387	0.201	5.92	2.800	4.000	
2022-033	125 B.C.ACCESS			45	2.348	0.118	5.01	2.000	2.700	
2022-033	149 ARC i2000s			24	2.454	0.115	4.70	2.100	2.800	
2022-033	160 SIEMENS EX			48	2.981	0.113	3.79	2.600	3.300	
2022-034	115 VITROS ECI			42	1.702	0.084	4.94	1.500	2.000	
2022-034	116 ROCHE COBA			47	0.980	0.071	7.25	0.800	1.200	
2022-034	125 B.C.ACCESS			45	0.925	0.064	6.96	0.700	1.100	
2022-034	149 ARC i2000s			24	0.763	0.048	6.35	0.600	0.900	
2022-034	160 SIEMENS EX			48	0.974	0.048	4.95	0.800	1.100	
2022-035	115 VITROS ECI			42	3.012	0.148	4.92	2.600	3.500	
2022-035	116 ROCHE COBA			47	1.457	0.077	5.29	1.200	1.700	
2022-035	125 B.C.ACCESS			45	1.273	0.069	5.39	1.100	1.500	
2022-035	149 ARC i2000s			24	1.092	0.049	4.52	0.900	1.200	
2022-035	160 SIEMENS EX			48	1.369	0.062	4.51	1.200	1.600	
032	hCG-QUANTITATIVE	CLIA TEST ID #: 555								
2022-031	115 VITROS ECI			18	910.389	29.834	3.28	820.900	999.900	
2022-031	116 ROCHE COBA			20	395.150	20.350	5.15	334.100	456.200	
2022-031	116 ROCHE COBA			20	532.355	34.042	6.39	430.200	634.500	
2022-031	125 B.C.ACCESS			12	370.675	17.532	4.73	318.100	423.300	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 30 ENDOCRINOLOGY

GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
032	hCG-QUANTITATIVE	CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2022-032	115 VITROS ECI			18	2642.222	104.985	3.97	2327.300	2957.200
2022-032	116 ROCHE COBA			20	1582.000	98.833	6.25	1285.500	1878.500
2022-032	116 ROCHE COBA			20	1095.933	61.891	5.65	910.300	1281.600
2022-032	125 B.C.ACCESS			12	805.783	32.789	4.07	707.400	904.200
2022-033	115 VITROS ECI			18	2906.072	104.566	3.60	2592.400	3219.800
2022-033	116 ROCHE COBA			20	1209.967	59.496	4.92	1031.500	1388.500
2022-033	116 ROCHE COBA			20	1762.474	92.806	5.27	1484.100	2040.900
2022-033	125 B.C.ACCESS			12	858.400	31.612	3.68	763.600	953.200
2022-034	115 VITROS ECI			18	2.394	0.024	0.98	2.300	2.500
2022-034	116 ROCHE COBA			20	0.605	0.246	40.64	0	1.300
2022-034	116 ROCHE COBA			20	1.800	0.917	50.92	0	4.500
2022-034	125 B.C.ACCESS			12	0.958	0.095	9.95	0.700	1.200
2022-035	115 VITROS ECI			18	453.678	16.888	3.72	403.000	504.300
2022-035	116 ROCHE COBA			20	192.800	21.846	11.33	127.300	258.300
2022-035	116 ROCHE COBA			20	262.065	15.213	5.80	216.400	307.700
2022-035	125 B.C.ACCESS			12	204.125	8.031	3.93	180.000	228.200
035	PROLACTIN	CLIA TEST ID #: 0							
2022-031	116 ROCHE COBA			18	15.028	0.642	4.27	13.100	17.000
2022-032	116 ROCHE COBA			18	37.789	1.801	4.77	32.400	43.200
2022-033	116 ROCHE COBA			18	41.289	2.041	4.94	35.200	47.400
2022-034	116 ROCHE COBA			18	3.553	0.329	9.27	2.600	4.500

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
035	PROLACTIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2022-035	116	ROCHE COBA			18	9.167	0.437	4.77	7.900	10.500
037	TESTOSTERONE									
2022-031	149	ARC i2000s			10	6.710	0.530	7.90	5.100	8.300
2022-032	149	ARC i2000s			10	14.520	1.474	10.15	10.100	18.900
2022-033	149	ARC i2000s			10	14.520	1.474	10.15	10.100	18.900
2022-034	149	ARC i2000s			10	0.920	0.060	6.52	0.700	1.100
2022-035	149	ARC i2000s			10	3.620	0.264	7.29	2.800	4.400
039	THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585							
2022-031	106	TOSOH AIA			14	3.350	0.297	8.87	2.500	4.200
2022-031	115	VITROS ECI			46	3.580	0.117	3.27	3.200	3.900
2022-031	116	ROCHE COBA			53	3.266	0.188	5.76	2.700	3.800
2022-031	125	B.C.ACCESS			59	2.859	0.153	5.35	2.400	3.300
2022-031	149	ARC i2000s			26	2.700	0.130	4.82	2.300	3.100
2022-031	160	SIEMENS EX			76	2.519	0.170	6.76	2.000	3.000
2022-031	160	SIEMENS EX			76	3.050	0.200	6.56	2.500	3.700
2022-032	106	TOSOH AIA			14	7.393	0.570	7.71	5.700	9.100
2022-032	115	VITROS ECI			46	8.144	0.342	4.20	7.100	9.200
2022-032	116	ROCHE COBA			53	6.832	0.363	5.32	5.700	7.900
2022-032	125	B.C.ACCESS			59	6.791	0.363	5.35	5.700	7.900
2022-032	149	ARC i2000s			26	6.358	0.343	5.40	5.300	7.400
2022-032	160	SIEMENS EX			76	6.725	0.460	6.84	5.300	8.100
2022-032	160	SIEMENS EX			76	5.692	0.360	6.32	4.600	6.800

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2022-033	106 TOSOH AIA		14	7.971	0.603	7.56	6.200	9.800	
2022-033	115 VITROS ECI		46	8.736	0.438	5.02	7.400	10.100	
2022-033	116 ROCHE COBA		53	7.340	0.435	5.93	6.000	8.600	
2022-033	125 B.C.ACCESS		59	7.359	0.316	4.29	6.400	8.300	
2022-033	149 ARC i2000s		26	6.854	0.349	5.09	5.800	7.900	
2022-033	160 SIEMENS EX		76	6.204	0.412	6.64	5.000	7.400	
2022-033	160 SIEMENS EX		76	7.275	0.452	6.21	5.900	8.600	
2022-034	106 TOSOH AIA		14	0.821	0.086	10.47	0.600	1.100	
2022-034	115 VITROS ECI		46	0.753	0.050	6.62	0.600	0.900	
2022-034	116 ROCHE COBA		53	0.994	0.074	7.49	0.800	1.200	
2022-034	125 B.C.ACCESS		59	0.760	0.053	6.91	0.600	0.900	
2022-034	149 ARC i2000s		26	0.688	0.032	4.64	0.600	0.800	
2022-034	160 SIEMENS EX		76	0.763	0.048	6.35	0.600	0.900	
2022-034	160 SIEMENS EX		76	0.717	0.055	7.68	0.600	0.900	
2022-035	106 TOSOH AIA		14	2.079	0.186	8.94	1.500	2.600	
2022-035	115 VITROS ECI		46	2.247	0.120	5.36	1.900	2.600	
2022-035	116 ROCHE COBA		53	2.160	0.126	5.85	1.800	2.500	
2022-035	125 B.C.ACCESS		59	1.815	0.088	4.84	1.600	2.100	
2022-035	149 ARC i2000s		26	1.712	0.093	5.45	1.400	2.000	
2022-035	160 SIEMENS EX		76	1.900	0.122	6.45	1.500	2.300	
2022-035	160 SIEMENS EX		76	1.661	0.113	6.80	1.300	2.000	
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2022-031	32 DADE DIME.		45	8.036	0.563	7.01	6.400	9.600	
2022-031	106 TOSOH AIA		11	7.336	0.882	12.03	5.900	8.800	
2022-031	115 VITROS ECI		38	6.834	0.314	4.59	5.500	8.200	
2022-031	116 ROCHE COBA		49	6.791	0.316	4.65	5.400	8.100	
2022-031	125 B.C.ACCESS		47	7.245	0.646	8.91	5.800	8.700	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-031	149	ARC i2000s		23	6.730	0.344	5.12	5.400	8.100	
2022-031	160	SIEMENS EX		12	8.017	0.511	6.38	6.400	9.600	
040	THYROXINE (T4)		CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2022-032	32	DADE DIME.		45	15.289	0.823	5.38	12.200	18.300	
2022-032	106	TOSOH AIA		11	12.491	0.985	7.88	10.000	15.000	
2022-032	115	VITROS ECI		38	12.741	0.487	3.83	10.200	15.300	
2022-032	116	ROCHE COBA		49	12.808	0.664	5.18	10.200	15.400	
2022-032	125	B.C.ACCESS		47	12.134	0.837	6.90	9.700	14.600	
2022-032	149	ARC i2000s		23	13.057	0.708	5.42	10.400	15.700	
2022-032	160	SIEMENS EX		12	15.408	0.884	5.73	12.300	18.500	
2022-033	32	DADE DIME.		45	16.298	1.011	6.20	13.000	19.600	
2022-033	106	TOSOH AIA		11	13.745	0.942	6.86	11.000	16.500	
2022-033	115	VITROS ECI		38	13.484	0.548	4.07	10.800	16.200	
2022-033	116	ROCHE COBA		49	13.876	0.847	6.10	11.100	16.700	
2022-033	125	B.C.ACCESS		47	12.689	0.875	6.89	10.200	15.200	
2022-033	149	ARC i2000s		23	14.113	0.893	6.32	11.300	16.900	
2022-033	160	SIEMENS EX		12	16.817	1.018	6.05	13.500	20.200	
2022-034	32	DADE DIME.		45	4.058	0.529	13.05	3.100	5.100	
2022-034	106	TOSOH AIA		11	3.582	0.351	9.80	2.600	4.600	
2022-034	115	VITROS ECI		38	3.426	0.165	4.81	2.400	4.400	
2022-034	116	ROCHE COBA		49	3.519	0.263	7.47	2.500	4.500	
2022-034	125	B.C.ACCESS		47	3.413	0.290	8.50	2.400	4.400	
2022-034	149	ARC i2000s		23	2.961	0.337	11.39	2.000	4.000	
2022-034	160	SIEMENS EX		12	3.917	0.406	10.36	2.900	4.900	
2022-035	32	DADE DIME.		45	6.193	0.443	7.15	5.000	7.400	
2022-035	106	TOSOH AIA		11	5.527	0.339	6.13	4.400	6.600	
2022-035	115	VITROS ECI		38	5.200	0.248	4.77	4.200	6.200	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022-035	116	ROCHE COBA		49	5.213	0.245	4.71	4.200	6.300
2022-035	125	B.C.ACCESS		47	5.496	0.423	7.70	4.400	6.600
2022-035	149	ARC i2000s		23	4.852	0.330	6.79	3.900	5.900
2022-035	160	SIEMENS EX		12	5.892	0.506	8.58	4.700	7.100
141	FOLATE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %					
2022-031	115	VITROS ECI		14	2.679	0.291	10.86	2.000	3.300
2022-031	115	VITROS ECI		14	3.525	0.217	6.14	2.600	4.400
2022-031	116	ROCHE COBA		18	2.967	0.403	13.58	2.200	3.700
2022-031	116	ROCHE COBA		18	2.711	0.445	16.40	2.000	3.400
2022-031	125	B.C.ACCESS		11	3.482	0.212	6.10	2.600	4.400
2022-031	149	ARC i2000s		12	3.300	0.438	13.27	2.500	4.100
2022-032	115	VITROS ECI		14	8.425	0.217	2.57	6.300	10.500
2022-032	115	VITROS ECI		14	8.171	0.797	9.75	6.100	10.200
2022-032	116	ROCHE COBA		18	7.672	1.084	14.12	5.800	9.600
2022-032	116	ROCHE COBA		18	8.867	0.858	9.67	6.700	11.100
2022-032	125	B.C.ACCESS		11	9.182	0.471	5.13	6.900	11.500
2022-032	149	ARC i2000s		12	9.300	0.917	9.86	7.000	11.600
2022-033	115	VITROS ECI		14	8.836	0.900	10.18	6.600	11.000
2022-033	115	VITROS ECI		14	9.125	0.349	3.83	6.800	11.400
2022-033	116	ROCHE COBA		18	8.733	1.266	14.49	6.600	10.900
2022-033	116	ROCHE COBA		18	8.544	1.127	13.19	6.400	10.700
2022-033	125	B.C.ACCESS		11	9.864	0.280	2.84	7.400	12.300
2022-033	149	ARC i2000s		12	10.225	1.019	9.97	7.700	12.800
2022-034	115	VITROS ECI		14	0.825	0.192	23.28	0.600	1.000
2022-034	115	VITROS ECI		14	0.929	0.162	17.47	0.700	1.200
2022-034	116	ROCHE COBA		18	0.467	0.047	10.10	0.400	0.600
2022-034	116	ROCHE COBA		18	2.000	0.000	0.00	1.500	2.500

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-034	125	B.C.ACCESS		11	0.655	0.178	27.15	0.500	0.800	
2022-034	149	ARC i2000s		12	1.208	0.766	63.43	0.900	1.500	
141	FOLATE			CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 25 %						
2022-035	115	VITROS ECI		14	1.707	0.187	10.95	1.300	2.100	
2022-035	115	VITROS ECI		14	2.200	0.200	9.09	1.700	2.800	
2022-035	116	ROCHE COBA		18	2.006	0.024	1.17	1.500	2.500	
2022-035	116	ROCHE COBA		18	1.600	0.245	15.31	1.200	2.000	
2022-035	125	B.C.ACCESS		11	2.118	0.127	5.98	1.600	2.600	
2022-035	149	ARC i2000s		12	1.842	0.403	21.88	1.400	2.300	
142	hLH (HUMAN LUT. HOR)									
2022-031	116	ROCHE COBA		14	20.350	0.978	4.81	15.300	25.400	
2022-032	116	ROCHE COBA		14	44.721	1.663	3.72	33.500	55.900	
2022-033	116	ROCHE COBA		14	48.036	2.208	4.60	36.000	60.000	
2022-034	116	ROCHE COBA		14	5.877	0.634	10.79	4.400	7.300	
2022-035	116	ROCHE COBA		14	13.171	0.602	4.57	9.900	16.500	

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART #	LABS #	"SF"	Score	
SAMPLE	RESULT	RESULT	RESULT	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2022-031	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100
2022-031	142	INSTANT VI		002	002	002	002	002 - POSITIVE	48	48	48	100
2022-031	150	AIM STEP		002	002	002	002	002 - POSITIVE	83	83	83	100
2022-031	164	HCG Alere		002	002	002	002	002 - POSITIVE	70	70	70	100
2022-031	165	Osom HCG C		002	002	002	002	002 - POSITIVE	22	22	22	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-031	166	FaStep		002 002	002 002		002 - POSITIVE	19	19	19	100		
2022-031	167	Tanner Sci		002 002	002 002		002 - POSITIVE	13	13	13	100		
	031	hCG-QUALITATIVE											
2022-032	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100		
2022-032	142	INSTANT VI		002 002	002 002		002 - POSITIVE	48	48	48	100		
2022-032	150	AIM STEP		002 002	002 002		002 - POSITIVE	83	83	83	100		
2022-032	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100		
2022-032	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100		
2022-032	166	FaStep		002 002	002 002		001 - NEGATIVE	19	1	18	0		
2022-032	166	FaStep		002 002	002 002		002 - POSITIVE	19	18	18	100		
2022-032	167	Tanner Sci		002 002	002 002		002 - POSITIVE	13	13	13	100		
2022-033	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100		
2022-033	142	INSTANT VI		002 002	002 002		002 - POSITIVE	48	48	48	100		
2022-033	150	AIM STEP		002 002	002 002		002 - POSITIVE	83	83	83	100		
2022-033	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100		
2022-033	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100		
2022-033	166	FaStep		002 002	002 002		002 - POSITIVE	19	19	19	100		
2022-033	167	Tanner Sci		002 002	002 002		002 - POSITIVE	13	13	13	100		
2022-034	113	BIO-SIGN		001 001	001 001		001 - NEGATIVE	22	22	22	100		
2022-034	142	INSTANT VI		001 001	001 001		001 - NEGATIVE	48	48	48	100		
2022-034	150	AIM STEP		001 001	001 001		001 - NEGATIVE	83	81	81	100		
2022-034	150	AIM STEP		001 001	001 001		002 - POSITIVE	83	2	81	0		
2022-034	164	HCG Alere		001 001	001 001		001 - NEGATIVE	70	70	70	100		
2022-034	165	Osom HCG C		001 001	001 001		001 - NEGATIVE	22	22	22	100		
2022-034	166	FaStep		001 001	001 001		001 - NEGATIVE	19	18	18	100		
2022-034	166	FaStep		001 001	001 001		002 - POSITIVE	19	1	18	0		
2022-034	167	Tanner Sci		001 001	001 001		001 - NEGATIVE	13	12	12	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-034	167	Tanner Sci		001	001	001	001	002 - POSITIVE	13	1	12	0
	031	hCG-QUALITATIVE										
2022-035	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100
2022-035	142	INSTANT VI		002	002	002	002	002 - POSITIVE	48	48	48	100
2022-035	150	AIM STEP		002	002	002	002	002 - POSITIVE	83	83	83	100
2022-035	164	HCG Alere		002	002	002	002	002 - POSITIVE	70	70	70	100
2022-035	165	Osom HCG C		002	002	002	002	002 - POSITIVE	22	22	22	100
2022-035	166	FaStep		002	002	002	002	001 - NEGATIVE	19	1	18	0
2022-035	166	FaStep		002	002	002	002	002 - POSITIVE	19	18	18	100
2022-035	167	Tanner Sci		002	002	002	002	001 - NEGATIVE	13	1	12	0
2022-035	167	Tanner Sci		002	002	002	002	002 - POSITIVE	13	12	12	100

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
	151	hCG ONLY QUALITATIVE										
2022-021	018	BIO SIGN		002	002	002	002	002 - POSITIVE	26	26	26	100
2022-021	112	ONE STEP D		002	002	002	002	002 - POSITIVE	10	10	10	100
2022-021	114	INSTANT VI		002	002	002	002	002 - POSITIVE	115	115	115	100
2022-021	118	AIM STEP		002	002	002	002	002 - POSITIVE	145	145	145	100
2022-021	130	ALERE HCG		002	002	002	002	002 - POSITIVE	86	86	86	100
2022-021	131	OSOM HCG		002	002	002	002	002 - POSITIVE	29	29	29	100
2022-021	133	FaStep		002	002	002	002	002 - POSITIVE	32	32	32	100
2022-021	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	58	58	58	100
2022-021	135	STANBIO 20		002	002	002	002	002 - POSITIVE	11	11	11	100
2022-021	136	CLARITY		002	002	002	002	002 - POSITIVE	10	10	10	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
151 hCG ONLY QUALITATIVE													
2022-022	018	BIO SIGN		001	001	001	001	001 - NEGATIVE	26	26	26	100	
2022-022	112	ONE STEP D		001	001	001	001	001 - NEGATIVE	10	10	10	100	
2022-022	114	INSTANT VI		001	001	001	001	001 - NEGATIVE	115	113	113	100	
2022-022	114	INSTANT VI		001	001	001	001	002 - POSITIVE	115	2	113	0	
2022-022	118	AIM STEP		001	001	001	001	001 - NEGATIVE	145	142	142	100	
2022-022	118	AIM STEP		001	001	001	001	002 - POSITIVE	145	3	142	0	
2022-022	130	ALERE HCG		001	001	001	001	001 - NEGATIVE	86	79	79	100	
2022-022	130	ALERE HCG		001	001	001	001	002 - POSITIVE	86	7	79	0	
2022-022	131	OSOM HCG		001	001	001	001	001 - NEGATIVE	29	29	29	100	
2022-022	133	FaStep		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2022-022	134	Tanner Sc.		001	001	001	001	001 - NEGATIVE	58	58	58	100	
2022-022	135	STANBIO 20		001	001	001	001	001 - NEGATIVE	11	11	11	100	
2022-022	136	CLARITY		001	001	001	001	001 - NEGATIVE	10	10	10	100	
2022-023	018	BIO SIGN		002	002	002	002	002 - POSITIVE	26	26	26	100	
2022-023	112	ONE STEP D		002	002	002	002	002 - POSITIVE	10	10	10	100	
2022-023	114	INSTANT VI		002	002	002	002	002 - POSITIVE	115	115	115	100	
2022-023	118	AIM STEP		002	002	002	002	002 - POSITIVE	145	145	145	100	
2022-023	130	ALERE HCG		002	002	002	002	002 - POSITIVE	86	86	86	100	
2022-023	131	OSOM HCG		002	002	002	002	002 - POSITIVE	29	29	29	100	
2022-023	133	FaStep		002	002	002	002	002 - POSITIVE	32	32	32	100	
2022-023	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	58	58	58	100	
2022-023	135	STANBIO 20		002	002	002	002	002 - POSITIVE	11	11	11	100	
2022-023	136	CLARITY		002	002	002	002	002 - POSITIVE	10	10	10	100	
2022-024	018	BIO SIGN		002	002	002	002	002 - POSITIVE	26	26	26	100	
2022-024	112	ONE STEP D		002	002	002	002	002 - POSITIVE	10	10	10	100	
2022-024	114	INSTANT VI		002	002	002	002	001 - NEGATIVE	115	1	114	0	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-024	114	INSTANT VI		002 002	002 002		002 - POSITIVE	115	114	114	100	
2022-024	118	AIM STEP		002 002	002 002		002 - POSITIVE	145	145	145	100	
2022-024	130	ALERE HCG		002 002	002 002		002 - POSITIVE	86	86	86	100	
2022-024	131	OSOM HCG		002 002	002 002		002 - POSITIVE	29	29	29	100	
2022-024	133	FaStep		002 002	002 002		002 - POSITIVE	32	32	32	100	
2022-024	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	58	58	58	100	
2022-024	135	STANBIO 20		002 002	002 002		002 - POSITIVE	11	11	11	100	
2022-024	136	CLARITY		002 002	002 002		002 - POSITIVE	10	10	10	100	
151 hCG ONLY QUALITATIVE												
2022-025	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	26	26	26	100	
2022-025	112	ONE STEP D		001 001	001 001		001 - NEGATIVE	10	10	10	100	
2022-025	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	115	113	113	100	
2022-025	114	INSTANT VI		001 001	001 001		002 - POSITIVE	115	2	113	0	
2022-025	118	AIM STEP		001 001	001 001		001 - NEGATIVE	145	140	140	100	
2022-025	118	AIM STEP		001 001	001 001		002 - POSITIVE	145	5	140	0	
2022-025	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	86	81	81	100	
2022-025	130	ALERE HCG		001 001	001 001		002 - POSITIVE	86	5	81	0	
2022-025	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	29	29	29	100	
2022-025	133	FaStep		001 001	001 001		001 - NEGATIVE	32	32	32	100	
2022-025	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	58	58	58	100	
2022-025	135	STANBIO 20		001 001	001 001		001 - NEGATIVE	11	11	11	100	
2022-025	136	CLARITY		001 001	001 001		001 - NEGATIVE	10	10	10	100	

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
173 T3 UPTAKE												
CLIA TEST ID #: 565												
EVALUATION CRITERIA: TARGET VALUE 3 SD												
2022-031	1 %U	84 VITROS ECI	1 25-35	25	54.428	1.729	3.18	49.240	59.620			

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-031	1 %U	91	B.C.ACCESS	2	35-45	27	49.367	2.955	5.99	40.500	58.230	
2022-031	2 TUV	95	Arc i2000s	3	0.7 - 1.2	16	0.826	0.046	5.62	0.690	0.960	
2022-031	4 %	32	DIMENSION	2	35-45	43	40.573	1.406	3.47	36.350	44.790	
2022-031	4 %	91	B.C.ACCESS	2	35-45	13	48.785	1.961	4.02	42.900	54.670	
2022-031	5 TBI	98	ROCHE COBA	4	0.8-1.3	47	0.764	0.077	10.07	0.530	0.990	
173 T3 UPTAKE		CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2022-032	1 %U	84	VITROS ECI	1	25-35	25	47.876	1.711	3.57	42.740	53.010	
2022-032	1 %U	91	B.C.ACCESS	2	35-45	27	44.374	2.410	5.43	37.140	51.600	
2022-032	2 TUV	95	Arc i2000s	3	0.7 - 1.2	16	1.085	0.053	4.84	0.930	1.240	
2022-032	4 %	32	DIMENSION	2	35-45	43	39.923	1.693	4.24	34.850	45.000	
2022-032	4 %	91	B.C.ACCESS	2	35-45	13	44.623	2.797	6.27	36.230	53.010	
2022-032	5 TBI	98	ROCHE COBA	4	0.8-1.3	47	0.623	0.081	13.04	0.380	0.870	
2022-033	1 %U	84	VITROS ECI	1	25-35	25	47.232	1.690	3.58	42.160	52.300	
2022-033	1 %U	91	B.C.ACCESS	2	35-45	27	43.796	2.264	5.17	37.000	50.590	
2022-033	2 TUV	95	Arc i2000s	3	0.7 - 1.2	16	1.124	0.071	6.28	0.910	1.340	
2022-033	4 %	32	DIMENSION	2	35-45	43	39.809	1.659	4.17	34.830	44.790	
2022-033	4 %	91	B.C.ACCESS	2	35-45	13	43.392	3.308	7.62	33.470	53.320	
2022-033	5 TBI	98	ROCHE COBA	4	0.8-1.3	47	0.611	0.072	11.82	0.390	0.830	
2022-034	1 %U	84	VITROS ECI	1	25-35	25	59.196	2.017	3.41	53.140	65.250	
2022-034	1 %U	91	B.C.ACCESS	2	35-45	27	53.463	3.016	5.64	44.410	62.510	
2022-034	2 TUV	95	Arc i2000s	3	0.7 - 1.2	16	0.601	0.040	6.68	0.480	0.720	
2022-034	4 %	32	DIMENSION	2	35-45	43	40.795	1.493	3.66	36.320	45.270	
2022-034	4 %	91	B.C.ACCESS	2	35-45	13	52.623	3.507	6.66	42.100	63.140	
2022-034	5 TBI	98	ROCHE COBA	4	0.8-1.3	47	0.866	0.060	6.94	0.690	1.050	
2022-035	1 %U	84	VITROS ECI	1	25-35	25	56.654	2.015	3.56	50.610	62.700	
2022-035	1 %U	91	B.C.ACCESS	2	35-45	27	51.563	2.937	5.70	42.750	60.370	
2022-035	2 TUV	95	Arc i2000s	3	0.7 - 1.2	16	0.720	0.049	6.84	0.570	0.870	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-035	4 %	32	DIMENSION	2	35-45	43	40.321	1.529	3.79	35.730	44.910		
2022-035	4 %	91	B.C.ACCESS	2	35-45	13	50.746	3.701	7.29	39.640	61.850		
2022-035	5 TBI	98	ROCHE COBA	4	0.8-1.3	47	0.815	0.069	8.41	0.610	1.020		

SPEC: 10 CHEMISTRY SUB: 40 TOXICOLOGY GRP: 60 TOXICOLOGY

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
043 DIGOXIN		CLIA TEST ID #: 645		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}									
2022-031	50 VITROS					14	0.879	0.077	8.79	0.700	1.100		
2022-032	50 VITROS					14	1.943	0.062	3.21	1.600	2.300		
2022-033	50 VITROS					14	2.064	0.097	4.71	1.700	2.500		
2022-034	50 VITROS					14	0.479	0.067	14.08	0.300	0.700		
2022-035	50 VITROS					14	0.671	0.080	11.85	0.500	0.900		
045 FERRITIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %									
2022-031	50 VITROS					18	65.506	3.621	5.53	49.100	81.900		
2022-031	90 ROCHE COBA					14	112.164	3.607	3.22	84.100	140.200		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
045	FERRITIN									
		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-032	50 VITROS			18	163.111	7.156	4.39	122.300	203.900	
2022-032	90 ROCHE COBA			14	270.521	9.713	3.59	202.900	338.200	
2022-033	50 VITROS			18	177.222	8.141	4.59	132.900	221.500	
2022-033	90 ROCHE COBA			14	291.750	8.919	3.06	218.800	364.700	
2022-034	50 VITROS			18	17.311	1.080	6.24	13.000	21.600	
2022-034	90 ROCHE COBA			14	30.621	3.490	11.40	23.000	38.300	
2022-035	50 VITROS			18	41.450	2.469	5.96	31.100	51.800	
2022-035	90 ROCHE COBA			14	70.393	2.971	4.22	52.800	88.000	
046	GENTAMICIN									
		CLIA TEST ID #: 665								
2022-031	50 VITROS			14	4.393	0.110	2.50	3.300	5.500	
2022-032	50 VITROS			14	13.050	0.534	4.09	9.800	16.300	
2022-033	50 VITROS			14	14.443	0.634	4.39	10.800	18.100	
2022-034	50 VITROS			14	0.600	0.000	0.00	0.500	0.800	
2022-035	50 VITROS			14	2.250	0.091	4.03	1.700	2.800	
050	PHENYTOIN									
		CLIA TEST ID #: 695								
2022-031	50 VITROS			14	8.157	0.399	4.90	6.100	10.200	
2022-031	92 ROCHE COBA			11	8.236	0.384	4.67	6.200	10.300	
2022-032	50 VITROS			14	24.421	1.236	5.06	18.300	30.500	
2022-032	92 ROCHE COBA			11	24.109	1.444	5.99	18.100	30.100	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 40 TOXICOLOGY

GRP: 60 TOXICOLOGY

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
050	PHENYTOIN			CLIA TEST ID #: 695						
				EVALUATION CRITERIA: TARGET VALUE 25 %						
2022-033	50	VITROS			14	27.364	2.212	8.08	20.500	34.200
2022-033	92	ROCHE COBA			11	26.700	2.003	7.50	20.000	33.400
2022-034	50	VITROS			14	3.000	0.000	0.00	2.300	3.800
2022-034	92	ROCHE COBA			11	0.800	0.000	0.00	0.600	1.000
2022-035	50	VITROS			14	3.879	0.257	6.62	2.900	4.800
2022-035	92	ROCHE COBA			11	4.273	0.186	4.36	3.200	5.300
054	THEOPHYLLINE			CLIA TEST ID #: 735						
2022-031	50	VITROS			12	18.833	0.641	3.40	14.100	23.500
2022-032	50	VITROS			12	46.383	1.964	4.23	34.800	58.000
2022-033	50	VITROS			12	50.658	2.382	4.70	38.000	63.300
2022-034	50	VITROS			12	1.967	0.366	18.61	1.500	2.500
2022-035	50	VITROS			12	10.292	0.417	4.05	7.700	12.900
127	VANCOMYCIN			CLIA TEST ID #: 0						
2022-031	50	VITROS			19	15.837	0.524	3.31	11.900	19.800
2022-031	92	ROCHE COBA			10	17.470	1.287	7.37	13.100	21.800
2022-032	50	VITROS			19	48.226	2.141	4.44	36.200	60.300
2022-032	92	ROCHE COBA			10	50.390	2.202	4.37	37.800	63.000
2022-033	50	VITROS			19	53.584	2.737	5.11	40.200	67.000
2022-033	92	ROCHE COBA			10	54.630	2.933	5.37	41.000	68.300

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
127	VANCOMYCIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %						
2022-034	50	VITROS		19	5.000	0.000	0.00	3.800	6.300		
2022-034	92	ROCHE COBA		10	4.000	0.000	0.00	3.000	5.000		
2022-035	50	VITROS		19	8.205	0.278	3.39	6.200	10.300		
2022-035	92	ROCHE COBA		10	8.730	0.496	5.68	6.500	10.900		
SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
065	URINA-PROTEIN QUANT.				EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2022-061	58	VITROS		43	5.262	0.847	16.09	0.300	10.300		
2022-061	62	DADE DIM.		39	14.803	1.072	7.24	9.800	19.800		
2022-061	79	BECK. COUL		15	4.427	0.727	16.42	0	9.400		
2022-061	93	ARCHITECT		19	6.706	0.417	6.22	1.700	11.700		
2022-061	95	INTEGRA		10	3.820	1.352	35.39	0	8.800		
2022-061	113	ROCHE COBA		31	4.081	0.694	17.02	0	9.100		
2022-061	139	S. EXL.200		17	15.265	1.378	9.02	10.300	20.300		
2022-062	58	VITROS		43	155.798	9.043	5.80	116.800	194.700		
2022-062	62	DADE DIM.		39	117.815	2.879	2.44	88.400	147.300		
2022-062	79	BECK. COUL		15	104.443	2.584	2.47	78.300	130.600		
2022-062	93	ARCHITECT		19	98.574	4.221	4.28	73.900	123.200		
2022-062	95	INTEGRA		10	89.020	7.128	8.01	66.800	111.300		
2022-062	113	ROCHE COBA		31	92.010	2.464	2.68	69.000	115.000		
2022-062	139	S. EXL.200		17	118.147	2.861	2.42	88.600	147.700		
2022-063	58	VITROS		43	134.988	10.499	7.78	101.200	168.700		

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-063	62	DADE DIM.		39	110.908	1.857	1.67	83.200	138.600
2022-063	79	BECK. COUL		15	102.173	3.461	3.39	76.600	127.700
2022-063	93	ARCHITECT		19	98.668	3.896	3.95	74.000	123.300
2022-063	95	INTEGRA		10	88.930	6.774	7.62	66.700	111.200
2022-063	113	ROCHE COBA		31	92.161	2.673	2.90	69.100	115.200
2022-063	139	S. EXL.200		17	111.318	1.719	1.54	83.500	139.100
065	URINA-PROTEIN QUANT.		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2022-064	58	VITROS		43	5.810	1.418	24.41	0.800	10.800
2022-064	62	DADE DIM.		39	23.474	1.664	7.09	17.600	29.300
2022-064	79	BECK. COUL		15	5.313	1.279	24.07	0.300	10.300
2022-064	93	ARCHITECT		19	7.189	1.498	20.83	2.200	12.200
2022-064	95	INTEGRA		10	2.220	0.813	36.64	0	7.200
2022-064	113	ROCHE COBA		31	3.790	0.618	16.30	0	8.800
2022-064	139	S. EXL.200		17	24.365	1.503	6.17	18.300	30.500
2022-065	58	VITROS		43	161.560	7.448	4.61	121.200	201.900
2022-065	62	DADE DIM.		39	119.436	1.445	1.21	89.600	149.300
2022-065	79	BECK. COUL		15	102.543	2.326	2.27	76.900	128.200
2022-065	93	ARCHITECT		19	102.479	4.810	4.69	76.900	128.100
2022-065	95	INTEGRA		10	92.720	7.258	7.83	69.500	115.900
2022-065	113	ROCHE COBA		31	95.868	2.486	2.59	71.900	119.800
2022-065	139	S. EXL.200		17	120.219	1.518	1.26	90.200	150.300
067	URI-SPECIFIC GRAVITY			EVALUATION CRITERIA: TARGET VALUE 3 SD					
2022-061	11	AMES NM10S		48	1.024	0.002	0.22	1.017	1.030
2022-061	13	BAYER CLI		33	1.022	0.003	0.29	1.013	1.031
2022-061	67	URISCAN		52	1.021	0.003	0.33	1.011	1.032
2022-061	71	ATLAS		11	1.030	0.002	0.19	1.024	1.036
2022-061	72	URS-9-TECO		96	1.022	0.003	0.32	1.012	1.032
2022-061	80	ROCHE (CHE		38	1.018	0.002	0.25	1.010	1.025
2022-061	89	AIMSTRIP		114	1.022	0.003	0.34	1.012	1.033

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-061	94	CLINITEK	106	1.023	0.003	0.30	1.014	1.032	
2022-061	102	ACON LAB	150	1.024	0.003	0.32	1.014	1.034	
2022-061	131	iCHEM VELO	29	1.027	0.001	0.09	1.024	1.029	
2022-061	135	Hybrido AU	12	1.025	0.001	0.10	1.022	1.028	
2022-061	138	URS-10T	10	1.021	0.006	0.57	1.004	1.039	
2022-061	140	MISSION A	53	1.023	0.003	0.32	1.014	1.033	
2022-061	145	CLINITEK	15	1.033	0.001	0.06	1.032	1.035	
2022-061	147	Mission120	34	1.023	0.002	0.24	1.015	1.030	
2022-061	148	Mission500	54	1.025	0.002	0.23	1.018	1.032	
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0						EVALUATION CRITERIA: TARGET VALUE 3 SD
2022-062	11	AMES NM10S	48	1.022	0.003	0.33	1.012	1.032	
2022-062	13	BAYER CLI	33	1.021	0.002	0.21	1.014	1.027	
2022-062	67	URISCAN	52	1.017	0.003	0.30	1.008	1.026	
2022-062	71	ATLAS	11	1.026	0.002	0.20	1.020	1.033	
2022-062	72	URS-9-TECO	96	1.022	0.003	0.28	1.013	1.030	
2022-062	80	ROCHE (CHE	38	1.013	0.003	0.29	1.004	1.022	
2022-062	89	AIMSTRIP	114	1.019	0.003	0.28	1.011	1.028	
2022-062	94	CLINITEK	106	1.021	0.003	0.26	1.013	1.029	
2022-062	102	ACON LAB	150	1.020	0.002	0.24	1.013	1.027	
2022-062	131	iCHEM VELO	29	1.026	0.001	0.09	1.023	1.029	
2022-062	135	Hybrido AU	12	1.024	0.001	0.12	1.021	1.028	
2022-062	138	URS-10T	10	1.021	0.004	0.41	1.008	1.033	
2022-062	140	MISSION A	53	1.020	0.003	0.34	1.009	1.030	
2022-062	145	CLINITEK	15	1.028	0.001	0.05	1.026	1.029	
2022-062	147	Mission120	34	1.022	0.003	0.27	1.014	1.030	
2022-062	148	Mission500	54	1.020	0.001	0.09	1.017	1.023	
2022-063	11	AMES NM10S	48	1.024	0.003	0.27	1.016	1.033	
2022-063	13	BAYER CLI	33	1.024	0.002	0.21	1.017	1.030	
2022-063	67	URISCAN	52	1.022	0.004	0.40	1.010	1.034	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-063	71	ATLAS	11	1.029	0.002	0.16	1.024	1.034
2022-063	72	URS-9-TECO	96	1.024	0.002	0.24	1.016	1.031
2022-063	80	ROCHE (CHE	38	1.015	0.000	0.00	1.015	1.015
2022-063	89	AIMSTRIP	114	1.022	0.003	0.26	1.014	1.030
2022-063	94	CLINITEK	106	1.024	0.002	0.21	1.018	1.031
2022-063	102	ACON LAB	150	1.023	0.003	0.28	1.014	1.031
2022-063	131	iCHEM VELO	29	1.025	0.001	0.08	1.022	1.027
2022-063	135	Hybrido AU	12	1.023	0.001	0.12	1.019	1.026
2022-063	138	URS-10T	10	1.025	0.004	0.34	1.014	1.035
2022-063	140	MISSION A	53	1.024	0.003	0.33	1.014	1.034
2022-063	145	CLINITEK	15	1.031	0.001	0.09	1.028	1.034
2022-063	147	Mission120	34	1.025	0.003	0.28	1.016	1.033
2022-063	148	Mission500	54	1.021	0.002	0.22	1.014	1.028
067	URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD			
2022-064	11	AMES NM10S	48	1.013	0.004	0.36	1.002	1.024
2022-064	13	BAYER CLI	33	1.013	0.003	0.32	1.003	1.023
2022-064	67	URISCAN	52	1.010	0.005	0.47	0.995	1.024
2022-064	71	ATLAS	11	1.028	0.004	0.43	1.015	1.041
2022-064	72	URS-9-TECO	96	1.015	0.004	0.40	1.003	1.027
2022-064	80	ROCHE (CHE	38	1.011	0.003	0.32	1.001	1.021
2022-064	89	AIMSTRIP	114	1.014	0.004	0.39	1.002	1.026
2022-064	94	CLINITEK	106	1.012	0.003	0.31	1.003	1.022
2022-064	102	ACON LAB	150	1.015	0.004	0.42	1.002	1.028
2022-064	131	iCHEM VELO	29	1.026	0.001	0.08	1.023	1.028
2022-064	135	Hybrido AU	12	1.024	0.001	0.12	1.020	1.028
2022-064	138	URS-10T	10	1.016	0.006	0.60	0.997	1.034
2022-064	140	MISSION A	53	1.015	0.004	0.42	1.002	1.028
2022-064	145	CLINITEK	15	1.031	0.001	0.08	1.029	1.034
2022-064	147	Mission120	34	1.017	0.003	0.27	1.009	1.026
2022-064	148	Mission500	54	1.017	0.003	0.34	1.007	1.028

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
067	URI-SPECIFIC GRAVITY	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD				
2022-065	11	AMES NM10S		48	1.018	0.003	0.30	1.009	1.027
2022-065	13	BAYER CLI		33	1.017	0.003	0.32	1.008	1.027
2022-065	67	URISCAN		52	1.014	0.003	0.31	1.004	1.023
2022-065	71	ATLAS		11	1.030	0.000	0.04	1.028	1.031
2022-065	72	URS-9-TECO		96	1.019	0.003	0.33	1.009	1.029
2022-065	80	ROCHE (CHE		38	1.011	0.003	0.33	1.001	1.022
2022-065	89	AIMSTRIP		114	1.016	0.003	0.34	1.006	1.027
2022-065	94	CLINITEK		106	1.017	0.003	0.27	1.009	1.026
2022-065	102	ACON LAB		150	1.017	0.004	0.35	1.007	1.028
2022-065	131	iCHEM VELO		29	1.028	0.001	0.08	1.026	1.031
2022-065	135	Hybrido AU		12	1.027	0.001	0.12	1.024	1.031
2022-065	138	URS-10T		10	1.022	0.004	0.38	1.010	1.033
2022-065	140	MISSION A		53	1.018	0.003	0.33	1.008	1.028
2022-065	145	CLINITEK		15	1.031	0.001	0.09	1.029	1.034
2022-065	147	Mission120		34	1.020	0.000	0.00	1.020	1.020
2022-065	148	Mission500		54	1.019	0.002	0.19	1.013	1.025
166	MICROALBUMIN		EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}			
2022-061	58	VITROS		44	6.023	0.151	2.50	1.000	11.000
2022-061	62	DADE DIM.		56	2.400	1.020	42.49	0	7.400
2022-061	62	DADE DIM.		56	2.616	1.057	40.41	0	7.600
2022-061	79	BECK. COUL		19	2.633	2.807	106.58	0	7.600
2022-061	85	Rx DAYTONA		19	1.532	2.036	132.92	0	6.500
2022-061	93	ARCHITECT		22	4.943	0.213	4.31	0	9.900
2022-061	95	INTEGRA		22	3.423	1.474	43.06	0	8.400
2022-061	113	ROCHE COBA		31	11.007	2.989	27.16	6.000	16.000
2022-061	139	S. EXL.200		27	2.833	1.188	41.93	0	7.800
2022-062	58	VITROS		44	880.863	59.117	6.71	660.600	1101.100
2022-062	62	DADE DIM.		56	860.138	53.769	6.25	645.100	1075.200

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-062	62	DADE DIM.		56	839.800	34.649	4.13	629.900	1049.800	
2022-062	79	BECK. COUL		19	840.921	69.005	8.21	630.700	1051.200	
2022-062	85	Rx DAYTONA		19	810.442	104.387	12.88	607.800	1013.100	
2022-062	93	ARCHITECT		22	858.895	32.754	3.81	644.200	1073.600	
2022-062	95	INTEGRA		22	887.581	37.788	4.26	665.700	1109.500	
2022-062	113	ROCHE COBA		31	839.927	31.586	3.76	629.900	1049.900	
2022-062	139	S. EXL.200		27	871.138	58.177	6.68	653.400	1088.900	
166 MICROALBUMIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2022-063	58	VITROS		44	884.209	62.241	7.04	663.200	1105.300	
2022-063	62	DADE DIM.		56	840.000	34.963	4.16	630.000	1050.000	
2022-063	62	DADE DIM.		56	857.651	53.464	6.23	643.200	1072.100	
2022-063	79	BECK. COUL		19	847.189	71.333	8.42	635.400	1059.000	
2022-063	85	Rx DAYTONA		19	796.368	100.514	12.62	597.300	995.500	
2022-063	93	ARCHITECT		22	850.848	32.403	3.81	638.100	1063.600	
2022-063	95	INTEGRA		22	880.162	36.450	4.14	660.100	1100.200	
2022-063	113	ROCHE COBA		31	832.267	37.205	4.47	624.200	1040.300	
2022-063	139	S. EXL.200		27	884.592	69.044	7.81	663.400	1105.700	
2022-064	58	VITROS		44	6.023	0.151	2.50	1.000	11.000	
2022-064	62	DADE DIM.		56	2.523	0.996	39.45	0	7.500	
2022-064	62	DADE DIM.		56	2.200	0.980	44.54	0	7.200	
2022-064	79	BECK. COUL		19	2.639	2.739	103.78	0	7.600	
2022-064	85	Rx DAYTONA		19	1.774	2.274	128.22	0	6.800	
2022-064	93	ARCHITECT		22	4.990	0.029	0.59	0.000	10.000	
2022-064	95	INTEGRA		22	2.973	1.147	38.58	0	8.000	
2022-064	113	ROCHE COBA		31	11.007	2.989	27.16	6.000	16.000	
2022-064	139	S. EXL.200		27	2.465	1.113	45.14	0	7.500	
2022-065	58	VITROS		44	866.974	57.709	6.66	650.200	1083.700	
2022-065	62	DADE DIM.		56	846.800	43.231	5.11	635.100	1058.500	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-065	62	DADE DIM.	56	858.219	53.104	6.19	643.700	1072.800
2022-065	79	BECK. COUL	19	832.268	74.196	8.91	624.200	1040.300
2022-065	85	Rx DAYTONA	19	778.237	100.569	12.92	583.700	972.800
2022-065	93	ARCHITECT	22	852.391	37.712	4.42	639.300	1065.500
2022-065	95	INTEGRA	22	874.471	36.427	4.17	655.900	1093.100
2022-065	113	ROCHE COBA	31	837.283	32.386	3.87	628.000	1046.600
2022-065	139	S. EXL.200	27	887.388	74.407	8.38	665.500	1109.200
167 CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2022-061	58	VITROS	51	3.226	0.197	6.10	0	8.200
2022-061	62	DADE DIM.	52	8.823	5.532	62.70	3.800	13.800
2022-061	79	BECK. COUL	17	1.435	3.153	219.69	0	6.400
2022-061	85	Rx DAYTONA	12	1.850	2.430	131.36	0	6.900
2022-061	93	ARCHITECT	21	4.940	0.218	4.41	0	9.900
2022-061	95	INTEGRA	19	0.189	0.297	156.84	0	5.200
2022-061	113	ROCHE COBA	33	3.575	1.153	32.24	0	8.600
2022-061	139	S. EXL.200	25	7.044	6.272	89.04	2.000	12.000
2022-062	58	VITROS	51	234.061	9.198	3.93	175.500	292.600
2022-062	62	DADE DIM.	52	242.351	9.485	3.91	181.800	302.900
2022-062	79	BECK. COUL	17	219.494	15.990	7.28	164.600	274.400
2022-062	85	Rx DAYTONA	12	227.942	20.870	9.16	171.000	284.900
2022-062	93	ARCHITECT	21	232.048	9.744	4.20	174.000	290.100
2022-062	95	INTEGRA	19	251.179	10.370	4.13	188.400	314.000
2022-062	113	ROCHE COBA	33	249.330	10.181	4.08	187.000	311.700
2022-062	139	S. EXL.200	25	242.112	7.858	3.25	181.600	302.600
2022-063	58	VITROS	51	3.222	0.201	6.25	0	8.200
2022-063	62	DADE DIM.	52	8.890	5.594	62.93	3.900	13.900
2022-063	79	BECK. COUL	17	1.535	3.110	202.58	0	6.500
2022-063	85	Rx DAYTONA	12	1.155	1.319	114.27	0	6.200

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-063	93	ARCHITECT		21	4.990	0.030	0.60	0.000	10.000	
2022-063	95	INTEGRA		19	0.363	0.299	82.47	0	5.400	
2022-063	113	ROCHE COBA		33	3.621	1.314	36.30	0	8.600	
2022-063	139	S. EXL.200		25	7.044	6.272	89.04	2.000	12.000	
167 CREATININE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2022-064	58	VITROS		51	238.471	13.261	5.56	178.900	298.100	
2022-064	62	DADE DIM.		52	235.763	9.083	3.85	176.800	294.700	
2022-064	79	BECK. COUL		17	215.294	16.006	7.43	161.500	269.100	
2022-064	85	Rx DAYTONA		12	223.533	22.203	9.93	167.700	279.400	
2022-064	93	ARCHITECT		21	227.648	8.860	3.89	170.700	284.600	
2022-064	95	INTEGRA		19	242.489	11.473	4.73	181.900	303.100	
2022-064	113	ROCHE COBA		33	245.882	9.663	3.93	184.400	307.400	
2022-064	139	S. EXL.200		25	236.248	7.845	3.32	177.200	295.300	
2022-065	58	VITROS		51	235.392	8.513	3.62	176.500	294.200	
2022-065	62	DADE DIM.		52	233.918	8.927	3.82	175.400	292.400	
2022-065	79	BECK. COUL		17	205.047	17.769	8.67	153.800	256.300	
2022-065	85	Rx DAYTONA		12	223.692	19.535	8.73	167.800	279.600	
2022-065	93	ARCHITECT		21	226.948	9.349	4.12	170.200	283.700	
2022-065	95	INTEGRA		19	240.100	10.357	4.31	180.100	300.100	
2022-065	113	ROCHE COBA		33	244.642	10.026	4.10	183.500	305.800	
2022-065	139	S. EXL.200		25	235.038	7.340	3.12	176.300	293.800	

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN												
2022-061	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	48	48	48	100
2022-061	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	35	35	35	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-061	067	URISCAN		057 057	057 057		057 - NEGATIVE	51	51	51	100	
2022-061	071	ATLAS		057 057	057 057		057 - NEGATIVE	10	10	10	100	
2022-061	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	94	94	94	100	
2022-061	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2022-061	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	117	117	117	100	
2022-061	094	CLINITEK		057 057	057 057		057 - NEGATIVE	104	104	104	100	
2022-061	102	ACON LAB		057 057	057 057		057 - NEGATIVE	145	145	145	100	
2022-061	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	28	28	28	100	
2022-061	135	Hybrido AU		057 057	057 057		057 - NEGATIVE	12	12	12	100	
2022-061	140	MISSION A		057 057	057 057		057 - NEGATIVE	52	52	52	100	
2022-061	145	CLINITEK		057 057	057 057		057 - NEGATIVE	15	15	15	100	
2022-061	147	Mission120		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2022-061	148	Mission500		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2022-061	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	10	10	10	100	
057 URINALYSIS-BILIRUBIN												
2022-062	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	48	48	48	100	
2022-062	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2022-062	067	URISCAN		057 057	057 057		057 - NEGATIVE	51	51	51	100	
2022-062	071	ATLAS		057 057	057 057		057 - NEGATIVE	10	10	10	100	
2022-062	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	94	94	94	100	
2022-062	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2022-062	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	117	117	117	100	
2022-062	094	CLINITEK		057 057	057 057		057 - NEGATIVE	104	104	104	100	
2022-062	102	ACON LAB		057 057	057 057		057 - NEGATIVE	145	145	145	100	
2022-062	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	28	28	28	100	
2022-062	135	Hybrido AU		057 057	057 057		057 - NEGATIVE	12	12	12	100	
2022-062	140	MISSION A		057 057	057 057		057 - NEGATIVE	52	52	52	100	
2022-062	145	CLINITEK		057 057	057 057		057 - NEGATIVE	15	15	15	100	
2022-062	147	Mission120		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2022-062	148	Mission500		057 057	057 057		057 - NEGATIVE	56	56	56	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-062	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	10	10	10	100	
057 URINALYSIS-BILIRUBIN													
2022-063	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	48	48	48	100	
2022-063	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	35	35	35	100	
2022-063	067	URISCAN		057	057	057	057	057 - NEGATIVE	51	51	51	100	
2022-063	071	ATLAS		057	057	057	057	057 - NEGATIVE	10	9	9	100	
2022-063	071	ATLAS		057	057	057	057	058 - TRACES, 1+	10	1	9	0	
2022-063	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	94	94	94	100	
2022-063	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2022-063	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	117	117	117	100	
2022-063	094	CLINITEK		057	057	057	057	057 - NEGATIVE	104	104	104	100	
2022-063	102	ACON LAB		057	057	057	057	057 - NEGATIVE	145	145	145	100	
2022-063	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	28	28	28	100	
2022-063	135	Hybrido AU		057	057	057	057	057 - NEGATIVE	12	12	12	100	
2022-063	140	MISSION A		057	057	057	057	057 - NEGATIVE	52	52	52	100	
2022-063	145	CLINITEK		057	057	057	057	057 - NEGATIVE	15	15	15	100	
2022-063	147	Mission120		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2022-063	148	Mission500		057	057	057	057	057 - NEGATIVE	56	56	56	100	
2022-063	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	10	10	10	100	
2022-064	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	48	48	48	100	
2022-064	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	35	35	35	100	
2022-064	067	URISCAN		057	057	057	057	057 - NEGATIVE	51	51	51	100	
2022-064	071	ATLAS		057	057	057	057	057 - NEGATIVE	10	10	10	100	
2022-064	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	94	94	94	100	
2022-064	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2022-064	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	117	117	117	100	
2022-064	094	CLINITEK		057	057	057	057	057 - NEGATIVE	104	104	104	100	
2022-064	102	ACON LAB		057	057	057	057	057 - NEGATIVE	145	145	145	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-064	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	28	28	28	100	
2022-064	135	Hybrido AU		057 057	057 057		057 - NEGATIVE	12	12	12	100	
2022-064	140	MISSION A		057 057	057 057		057 - NEGATIVE	52	52	52	100	
2022-064	145	CLINITEK		057 057	057 057		057 - NEGATIVE	15	15	15	100	
2022-064	147	Mission120		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2022-064	148	Mission500		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2022-064	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	10	10	10	100	
057 URINALYSIS-BILIRUBIN												
2022-065	011	AMES NM10S		058 060	057 059		058 - TRACES, 1+	48	8	48	100	
2022-065	011	AMES NM10S		058 060	057 059		059 - 2+	48	36	48	100	
2022-065	011	AMES NM10S		058 060	057 059		060 - 3+	48	4	48	100	
2022-065	013	BAYER CLI		058 060	057 059		058 - TRACES, 1+	35	6	35	100	
2022-065	013	BAYER CLI		058 060	057 059		059 - 2+	35	29	35	100	
2022-065	067	URISCAN		057 059	057 059		057 - NEGATIVE	51	3	51	100	
2022-065	067	URISCAN		057 059	057 059		058 - TRACES, 1+	51	38	51	100	
2022-065	067	URISCAN		057 059	057 059		059 - 2+	51	10	51	100	
2022-065	071	ATLAS		057 059	057 059		058 - TRACES, 1+	10	8	10	100	
2022-065	071	ATLAS		057 059	057 059		059 - 2+	10	2	10	100	
2022-065	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	94	1	94	100	
2022-065	072	URS-9-TECO		058 060	057 059		058 - TRACES, 1+	94	20	94	100	
2022-065	072	URS-9-TECO		058 060	057 059		059 - 2+	94	48	94	100	
2022-065	072	URS-9-TECO		058 060	057 059		060 - 3+	94	25	94	100	
2022-065	080	ROCHE (CHE		057 059	057 059		058 - TRACES, 1+	36	34	36	100	
2022-065	080	ROCHE (CHE		057 059	057 059		059 - 2+	36	2	36	100	
2022-065	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	117	3	112	100	
2022-065	089	AIMSTRIP		057 059	057 059		058 - TRACES, 1+	117	60	112	100	
2022-065	089	AIMSTRIP		057 059	057 059		059 - 2+	117	49	112	100	
2022-065	089	AIMSTRIP		057 059	057 059		060 - 3+	117	5	112	0	
2022-065	094	CLINITEK		058 060	057 059		058 - TRACES, 1+	104	20	104	100	
2022-065	094	CLINITEK		058 060	057 059		059 - 2+	104	81	104	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-065	094	CLINITEK		058 060	057 059		060 - 3+	104	3	104	100
2022-065	102	ACON LAB		057 059	057 059		057 - NEGATIVE	145	2	141	100
2022-065	102	ACON LAB		057 059	057 059		058 - TRACES, 1+	145	108	141	100
2022-065	102	ACON LAB		057 059	057 059		059 - 2+	145	31	141	100
2022-065	102	ACON LAB		057 059	057 059		060 - 3+	145	4	141	0
2022-065	131	ICHEM VELO		057 057	057 059		057 - NEGATIVE	28	28	28	100
2022-065	135	Hybrido AU		058 060	057 059		059 - 2+	12	12	12	100
2022-065	140	MISSION A		057 059	057 059		057 - NEGATIVE	52	2	51	100
2022-065	140	MISSION A		057 059	057 059		058 - TRACES, 1+	52	37	51	100
2022-065	140	MISSION A		057 059	057 059		059 - 2+	52	12	51	100
2022-065	140	MISSION A		057 059	057 059		060 - 3+	52	1	51	0
2022-065	145	CLINITEK		057 057	057 059		057 - NEGATIVE	15	15	15	100
2022-065	147	Mission120		057 059	057 059		058 - TRACES, 1+	36	26	36	100
2022-065	147	Mission120		057 059	057 059		059 - 2+	36	10	36	100
2022-065	148	Mission500		057 059	057 059		058 - TRACES, 1+	56	48	55	100
2022-065	148	Mission500		057 059	057 059		059 - 2+	56	7	55	100
2022-065	148	Mission500		057 059	057 059		060 - 3+	56	1	55	0
2022-065	151	Clari. Uro		058 060	057 059		058 - TRACES, 1+	10	4	10	100
2022-065	151	Clari. Uro		058 060	057 059		059 - 2+	10	6	10	100
058 URINALYSIS-GLUCOSE											
2022-061	011	AMES NM10S		074 076	074 076		074 - TRACES	48	16	48	100
2022-061	011	AMES NM10S		074 076	074 076		075 - 250mg/dl-+	48	30	48	100
2022-061	011	AMES NM10S		074 076	074 076		076 - 500mg/dl2+	48	2	48	100
2022-061	013	BAYER CLI		074 076	074 076		073 - NEGATIVE	33	1	32	0
2022-061	013	BAYER CLI		074 076	074 076		074 - TRACES	33	12	32	100
2022-061	013	BAYER CLI		074 076	074 076		075 - 250mg/dl-+	33	20	32	100
2022-061	067	URISCAN		074 076	074 076		074 - TRACES	51	3	45	100
2022-061	067	URISCAN		074 076	074 076		075 - 250mg/dl-+	51	23	45	100
2022-061	067	URISCAN		074 076	074 076		076 - 500mg/dl2+	51	19	45	100
2022-061	067	URISCAN		074 076	074 076		077 - 1000mg/dl	51	5	45	0

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-061	067	URISCAN		074 076	074 076		078 - 2000mg/dl	51	1	45	0		
2022-061	071	ATLAS		076 078	074 076		075 - 250mg/dl-+	11	1	11	100		
2022-061	071	ATLAS		076 078	074 076		076 - 500mg/dl2+	11	2	11	100		
2022-061	071	ATLAS		076 078	074 076		077 - 1000mg/dl	11	8	11	100		
2022-061	072	URS-9-TECO		074 076	074 076		073 - NEGATIVE	96	7	89	0		
2022-061	072	URS-9-TECO		074 076	074 076		074 - TRACES	96	37	89	100		
2022-061	072	URS-9-TECO		074 076	074 076		075 - 250mg/dl-+	96	49	89	100		
2022-061	072	URS-9-TECO		074 076	074 076		076 - 500mg/dl2+	96	3	89	100		
2022-061	080	ROCHE (CHE		076 078	074 076		075 - 250mg/dl-+	38	4	38	100		
2022-061	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	38	33	38	100		
2022-061	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	38	1	38	100		
2022-061	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	118	1	117	0		
2022-061	089	AIMSTRIP		074 076	074 076		074 - TRACES	118	23	117	100		
2022-061	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	118	94	117	100		
2022-061	094	CLINITEK		074 076	074 076		074 - TRACES	106	52	105	100		
2022-061	094	CLINITEK		074 076	074 076		075 - 250mg/dl-+	106	53	105	100		
2022-061	094	CLINITEK		074 076	074 076		078 - 2000mg/dl	106	1	105	0		
2022-061	102	ACON LAB		074 076	074 076		073 - NEGATIVE	148	1	147	0		
2022-061	102	ACON LAB		074 076	074 076		074 - TRACES	148	23	147	100		
2022-061	102	ACON LAB		074 076	074 076		075 - 250mg/dl-+	148	123	147	100		
2022-061	102	ACON LAB		074 076	074 076		076 - 500mg/dl2+	148	1	147	100		
2022-061	131	ICHEM VELO		075 077	074 076		074 - TRACES	29	1	29	100		
2022-061	131	ICHEM VELO		075 077	074 076		075 - 250mg/dl-+	29	1	29	100		
2022-061	131	ICHEM VELO		075 077	074 076		076 - 500mg/dl2+	29	25	29	100		
2022-061	131	ICHEM VELO		075 077	074 076		077 - 1000mg/dl	29	2	29	100		
2022-061	135	Hybrido AU		076 078	074 076		077 - 1000mg/dl	12	7	12	100		
2022-061	135	Hybrido AU		076 078	074 076		078 - 2000mg/dl	12	5	12	100		
2022-061	138	URS-10T		073 075	074 076		073 - NEGATIVE	10	1	10	100		
2022-061	138	URS-10T		073 075	074 076		074 - TRACES	10	6	10	100		
2022-061	138	URS-10T		073 075	074 076		075 - 250mg/dl-+	10	3	10	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-061	140	MISSION A		074 076	074 076		074 - TRACES	52	4	52	100	
2022-061	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	52	48	52	100	
2022-061	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	15	2	15	100	
2022-061	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	15	10	15	100	
2022-061	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	15	3	15	100	
2022-061	147	Mission120		074 076	074 076		074 - TRACES	34	2	34	100	
2022-061	147	Mission120		074 076	074 076		075 - 250mg/dl-+	34	32	34	100	
2022-061	148	Mission500		074 076	074 076		074 - TRACES	55	1	55	100	
2022-061	148	Mission500		074 076	074 076		075 - 250mg/dl-+	55	54	55	100	
058 URINALYSIS-GLUCOSE												
2022-062	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	48	48	48	100	
2022-062	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	33	33	33	100	
2022-062	067	URISCAN		073 073	073 073		073 - NEGATIVE	51	51	51	100	
2022-062	071	ATLAS		073 073	073 073		073 - NEGATIVE	11	11	11	100	
2022-062	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	96	96	96	100	
2022-062	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	38	38	38	100	
2022-062	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	118	117	117	100	
2022-062	089	AIMSTRIP		073 073	073 073		074 - TRACES	118	1	117	0	
2022-062	094	CLINITEK		073 073	073 073		073 - NEGATIVE	106	106	106	100	
2022-062	102	ACON LAB		073 073	073 073		073 - NEGATIVE	148	148	148	100	
2022-062	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	29	29	29	100	
2022-062	135	Hybrido AU		073 073	073 073		073 - NEGATIVE	12	12	12	100	
2022-062	138	URS-10T		073 073	073 073		073 - NEGATIVE	10	10	10	100	
2022-062	140	MISSION A		073 073	073 073		073 - NEGATIVE	52	52	52	100	
2022-062	145	CLINITEK		073 073	073 073		073 - NEGATIVE	15	15	15	100	
2022-062	147	Mission120		073 073	073 073		073 - NEGATIVE	34	34	34	100	
2022-062	148	Mission500		073 073	073 073		073 - NEGATIVE	55	54	54	100	
2022-062	148	Mission500		073 073	073 073		077 - 1000mg/dl	55	1	54	0	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
058 URINALYSIS-GLUCOSE													
2022-063	011	AMES NM10S		076 078	076 078		073 - NEGATIVE	48	1	45	0		
2022-063	011	AMES NM10S		076 078	076 078		075 - 250mg/dl-+	48	2	45	0		
2022-063	011	AMES NM10S		076 078	076 078		076 - 500mg/dl2+	48	11	45	100		
2022-063	011	AMES NM10S		076 078	076 078		077 - 1000mg/dl	48	34	45	100		
2022-063	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	33	13	33	100		
2022-063	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	33	20	33	100		
2022-063	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	51	4	51	100		
2022-063	067	URISCAN		077 078	076 078		077 - 1000mg/dl	51	15	51	100		
2022-063	067	URISCAN		077 078	076 078		078 - 2000mg/dl	51	32	51	100		
2022-063	071	ATLAS		076 078	076 078		074 - TRACES	11	1	10	0		
2022-063	071	ATLAS		076 078	076 078		077 - 1000mg/dl	11	9	10	100		
2022-063	071	ATLAS		076 078	076 078		078 - 2000mg/dl	11	1	10	100		
2022-063	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	96	34	96	100		
2022-063	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	96	60	96	100		
2022-063	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	96	2	96	100		
2022-063	080	ROCHE (CHE		076 078	076 078		076 - 500mg/dl2+	38	1	38	100		
2022-063	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	38	36	38	100		
2022-063	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	38	1	38	100		
2022-063	089	AIMSTRIP		075 077	076 078		075 - 250mg/dl-+	118	6	118	100		
2022-063	089	AIMSTRIP		075 077	076 078		076 - 500mg/dl2+	118	64	118	100		
2022-063	089	AIMSTRIP		075 077	076 078		077 - 1000mg/dl	118	48	118	100		
2022-063	094	CLINITEK		076 078	076 078		076 - 500mg/dl2+	106	32	106	100		
2022-063	094	CLINITEK		076 078	076 078		077 - 1000mg/dl	106	70	106	100		
2022-063	094	CLINITEK		076 078	076 078		078 - 2000mg/dl	106	4	106	100		
2022-063	102	ACON LAB		075 077	076 078		075 - 250mg/dl-+	148	2	148	100		
2022-063	102	ACON LAB		075 077	076 078		076 - 500mg/dl2+	148	84	148	100		
2022-063	102	ACON LAB		075 077	076 078		077 - 1000mg/dl	148	62	148	100		
2022-063	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	29	27	29	100		
2022-063	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	29	2	29	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-063	135	Hybrido AU		076 078	076 078		077 - 1000mg/dl	12	8	12	100		
2022-063	135	Hybrido AU		076 078	076 078		078 - 2000mg/dl	12	4	12	100		
2022-063	138	URS-10T		076 078	076 078		076 - 500mg/dl2+	10	3	10	100		
2022-063	138	URS-10T		076 078	076 078		077 - 1000mg/dl	10	7	10	100		
2022-063	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	52	16	52	100		
2022-063	140	MISSION A		076 078	076 078		077 - 1000mg/dl	52	32	52	100		
2022-063	140	MISSION A		076 078	076 078		078 - 2000mg/dl	52	4	52	100		
2022-063	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	15	1	15	100		
2022-063	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	15	11	15	100		
2022-063	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	15	3	15	100		
2022-063	147	Mission120		076 078	076 078		076 - 500mg/dl2+	34	3	34	100		
2022-063	147	Mission120		076 078	076 078		077 - 1000mg/dl	34	27	34	100		
2022-063	147	Mission120		076 078	076 078		078 - 2000mg/dl	34	4	34	100		
2022-063	148	Mission500		075 077	076 078		076 - 500mg/dl2+	55	31	55	100		
2022-063	148	Mission500		075 077	076 078		077 - 1000mg/dl	55	23	55	100		
2022-063	148	Mission500		075 077	076 078		078 - 2000mg/dl	55	1	55	100		
058 URINALYSIS-GLUCOSE													
2022-064	011	AMES NM10S		076 078	075 077		076 - 500mg/dl2+	48	11	48	100		
2022-064	011	AMES NM10S		076 078	075 077		077 - 1000mg/dl	48	37	48	100		
2022-064	013	BAYER CLI		076 078	075 077		076 - 500mg/dl2+	33	12	33	100		
2022-064	013	BAYER CLI		076 078	075 077		077 - 1000mg/dl	33	21	33	100		
2022-064	067	URISCAN		077 078	075 077		075 - 250mg/dl-+	51	1	51	100		
2022-064	067	URISCAN		077 078	075 077		076 - 500mg/dl2+	51	4	51	100		
2022-064	067	URISCAN		077 078	075 077		077 - 1000mg/dl	51	17	51	100		
2022-064	067	URISCAN		077 078	075 077		078 - 2000mg/dl	51	29	51	100		
2022-064	071	ATLAS		075 077	075 077		076 - 500mg/dl2+	11	10	11	100		
2022-064	071	ATLAS		075 077	075 077		077 - 1000mg/dl	11	1	11	100		
2022-064	072	URS-9-TECO		076 078	075 077		073 - NEGATIVE	96	2	94	0		
2022-064	072	URS-9-TECO		076 078	075 077		076 - 500mg/dl2+	96	35	94	100		
2022-064	072	URS-9-TECO		076 078	075 077		077 - 1000mg/dl	96	59	94	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-064	080	ROCHE (CHE		076 078	075 077		075 - 250mg/dl-+	38	4	38	100	
2022-064	080	ROCHE (CHE		076 078	075 077		076 - 500mg/dl2+	38	1	38	100	
2022-064	080	ROCHE (CHE		076 078	075 077		077 - 1000mg/dl	38	32	38	100	
2022-064	080	ROCHE (CHE		076 078	075 077		078 - 2000mg/dl	38	1	38	100	
2022-064	089	AIMSTRIP		075 077	075 077		076 - 500mg/dl2+	118	60	116	100	
2022-064	089	AIMSTRIP		075 077	075 077		077 - 1000mg/dl	118	56	116	100	
2022-064	089	AIMSTRIP		075 077	075 077		078 - 2000mg/dl	118	2	116	0	
2022-064	094	CLINITEK		076 078	075 077		073 - NEGATIVE	106	1	105	0	
2022-064	094	CLINITEK		076 078	075 077		075 - 250mg/dl-+	106	2	105	100	
2022-064	094	CLINITEK		076 078	075 077		076 - 500mg/dl2+	106	35	105	100	
2022-064	094	CLINITEK		076 078	075 077		077 - 1000mg/dl	106	64	105	100	
2022-064	094	CLINITEK		076 078	075 077		078 - 2000mg/dl	106	4	105	100	
2022-064	102	ACON LAB		075 077	075 077		075 - 250mg/dl-+	148	2	145	100	
2022-064	102	ACON LAB		075 077	075 077		076 - 500mg/dl2+	148	73	145	100	
2022-064	102	ACON LAB		075 077	075 077		077 - 1000mg/dl	148	70	145	100	
2022-064	102	ACON LAB		075 077	075 077		078 - 2000mg/dl	148	3	145	0	
2022-064	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	29	27	29	100	
2022-064	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	29	2	29	100	
2022-064	135	Hybrido AU		076 078	075 077		077 - 1000mg/dl	12	8	12	100	
2022-064	135	Hybrido AU		076 078	075 077		078 - 2000mg/dl	12	4	12	100	
2022-064	138	URS-10T		075 077	075 077		076 - 500mg/dl2+	10	6	10	100	
2022-064	138	URS-10T		075 077	075 077		077 - 1000mg/dl	10	4	10	100	
2022-064	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	52	10	52	100	
2022-064	140	MISSION A		076 078	075 077		077 - 1000mg/dl	52	34	52	100	
2022-064	140	MISSION A		076 078	075 077		078 - 2000mg/dl	52	8	52	100	
2022-064	145	CLINITEK		075 077	075 077		076 - 500mg/dl2+	15	15	15	100	
2022-064	147	Mission120		076 078	075 077		073 - NEGATIVE	34	1	33	0	
2022-064	147	Mission120		076 078	075 077		076 - 500mg/dl2+	34	3	33	100	
2022-064	147	Mission120		076 078	075 077		077 - 1000mg/dl	34	23	33	100	
2022-064	147	Mission120		076 078	075 077		078 - 2000mg/dl	34	7	33	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-064	148	Mission500		076 078	075 077		073 - NEGATIVE	55	1	54	0	
2022-064	148	Mission500		076 078	075 077		076 - 500mg/dl2+	55	19	54	100	
2022-064	148	Mission500		076 078	075 077		077 - 1000mg/dl	55	29	54	100	
2022-064	148	Mission500		076 078	075 077		078 - 2000mg/dl	55	6	54	100	
058 URINALYSIS-GLUCOSE												
2022-065	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	48	48	48	100	
2022-065	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	33	33	33	100	
2022-065	067	URISCAN		073 073	073 073		073 - NEGATIVE	51	51	51	100	
2022-065	071	ATLAS		073 073	073 073		073 - NEGATIVE	11	11	11	100	
2022-065	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	96	95	95	100	
2022-065	072	URS-9-TECO		073 073	073 073		077 - 1000mg/dl	96	1	95	0	
2022-065	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	38	38	38	100	
2022-065	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	118	118	118	100	
2022-065	094	CLINITEK		073 073	073 073		073 - NEGATIVE	106	106	106	100	
2022-065	102	ACON LAB		073 073	073 073		073 - NEGATIVE	148	148	148	100	
2022-065	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	29	29	29	100	
2022-065	135	Hybrido AU		073 073	073 073		073 - NEGATIVE	12	12	12	100	
2022-065	138	URS-10T		073 073	073 073		073 - NEGATIVE	10	10	10	100	
2022-065	140	MISSION A		073 073	073 073		073 - NEGATIVE	52	52	52	100	
2022-065	145	CLINITEK		073 073	073 073		073 - NEGATIVE	15	15	15	100	
2022-065	147	Mission120		073 073	073 073		073 - NEGATIVE	34	34	34	100	
2022-065	148	Mission500		073 073	073 073		073 - NEGATIVE	55	53	53	100	
2022-065	148	Mission500		073 073	073 073		074 - TRACES	55	1	53	0	
2022-065	148	Mission500		073 073	073 073		077 - 1000mg/dl	55	1	53	0	
059 URINALYS.HG.OR BLOOD												
2022-061	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	48	48	48	100	
2022-061	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2022-061	067	URISCAN		066 066	066 066		066 - NEGATIVE	51	51	51	100	
2022-061	071	ATLAS		066 066	066 066		066 - NEGATIVE	11	11	11	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-061	072	URS-9-TECO		066	066	066	066	96	96	96	100	
2022-061	080	ROCHE (CHE		066	066	066	066	38	37	37	100	
2022-061	080	ROCHE (CHE		066	066	066	066	38	1	37	0	
2022-061	089	AIMSTRIP		066	066	066	066	118	118	118	100	
2022-061	094	CLINITEK		066	066	066	066	106	105	105	100	
2022-061	094	CLINITEK		066	066	066	066	106	1	105	0	
2022-061	102	ACON LAB		066	066	066	066	149	149	149	100	
2022-061	131	icHEM VELO		066	066	066	066	29	29	29	100	
2022-061	135	Hybrido AU		066	066	066	066	12	12	12	100	
2022-061	138	URS-10T		066	066	066	066	10	10	10	100	
2022-061	140	MISSION A		066	066	066	066	51	51	51	100	
2022-061	145	CLINITEK		066	066	066	066	15	15	15	100	
2022-061	147	Mission120		066	066	066	066	35	35	35	100	
2022-061	148	Mission500		066	066	066	066	54	54	54	100	
059 URINALYS.HG.OR BLOOD												
2022-062	011	AMES NM10S		068	069	068	069	48	1	48	100	
2022-062	011	AMES NM10S		068	069	068	069	48	47	48	100	
2022-062	013	BAYER CLI		068	069	068	069	33	33	33	100	
2022-062	067	URISCAN		068	069	068	069	51	2	51	100	
2022-062	067	URISCAN		068	069	068	069	51	49	51	100	
2022-062	071	ATLAS		068	069	068	069	11	11	11	100	
2022-062	072	URS-9-TECO		068	069	068	069	96	6	96	100	
2022-062	072	URS-9-TECO		068	069	068	069	96	90	96	100	
2022-062	080	ROCHE (CHE		068	069	068	069	38	3	38	100	
2022-062	080	ROCHE (CHE		068	069	068	069	38	35	38	100	
2022-062	089	AIMSTRIP		068	069	068	069	118	1	117	0	
2022-062	089	AIMSTRIP		068	069	068	069	118	1	117	100	
2022-062	089	AIMSTRIP		068	069	068	069	118	116	117	100	
2022-062	094	CLINITEK		068	069	068	069	106	3	106	100	
2022-062	094	CLINITEK		068	069	068	069	106	103	106	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-062	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	149	1	149	100	
2022-062	102	ACON LAB		068 069	068 069		069 - POS.(3+)	149	148	149	100	
2022-062	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	29	2	29	100	
2022-062	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	29	27	29	100	
2022-062	135	Hybrido AU		068 069	068 069		068 - POS.(1-2+)	12	2	12	100	
2022-062	135	Hybrido AU		068 069	068 069		069 - POS.(3+)	12	10	12	100	
2022-062	138	URS-10T		068 069	068 069		069 - POS.(3+)	10	10	10	100	
2022-062	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	51	1	51	100	
2022-062	140	MISSION A		068 069	068 069		069 - POS.(3+)	51	50	51	100	
2022-062	145	CLINITEK		068 069	068 069		066 - NEGATIVE	15	1	14	0	
2022-062	145	CLINITEK		068 069	068 069		069 - POS.(3+)	15	14	14	100	
2022-062	147	Mission120		068 069	068 069		069 - POS.(3+)	35	35	35	100	
2022-062	148	Mission500		068 069	068 069		068 - POS.(1-2+)	54	1	54	100	
2022-062	148	Mission500		068 069	068 069		069 - POS.(3+)	54	53	54	100	
059 URINALYS.HG.OR BLOOD												
2022-063	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	48	2	48	100	
2022-063	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	48	46	48	100	
2022-063	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	33	33	33	100	
2022-063	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	51	4	51	100	
2022-063	067	URISCAN		068 069	068 069		069 - POS.(3+)	51	47	51	100	
2022-063	071	ATLAS		068 069	068 069		069 - POS.(3+)	11	11	11	100	
2022-063	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	96	6	96	100	
2022-063	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	96	90	96	100	
2022-063	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	38	3	38	100	
2022-063	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	38	35	38	100	
2022-063	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	118	8	118	100	
2022-063	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	118	110	118	100	
2022-063	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	2	106	100	
2022-063	094	CLINITEK		068 069	068 069		069 - POS.(3+)	106	104	106	100	
2022-063	102	ACON LAB		068 069	068 069		066 - NEGATIVE	149	1	148	0	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-063	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	149	1	148	100	
2022-063	102	ACON LAB		068 069	068 069		069 - POS.(3+)	149	147	148	100	
2022-063	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	29	2	29	100	
2022-063	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	29	27	29	100	
2022-063	135	Hybrido AU		068 069	068 069		069 - POS.(3+)	12	12	12	100	
2022-063	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	10	1	10	100	
2022-063	138	URS-10T		068 069	068 069		069 - POS.(3+)	10	9	10	100	
2022-063	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	51	1	51	100	
2022-063	140	MISSION A		068 069	068 069		069 - POS.(3+)	51	50	51	100	
2022-063	145	CLINITEK		068 069	068 069		069 - POS.(3+)	15	15	15	100	
2022-063	147	Mission120		068 069	068 069		068 - POS.(1-2+)	35	2	35	100	
2022-063	147	Mission120		068 069	068 069		069 - POS.(3+)	35	33	35	100	
2022-063	148	Mission500		068 069	068 069		069 - POS.(3+)	54	54	54	100	
059 URINALYS.HG.OR BLOOD												
2022-064	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	48	47	47	100	
2022-064	011	AMES NM10S		066 066	066 066		067 - TRACES	48	1	47	0	
2022-064	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2022-064	067	URISCAN		066 066	066 066		066 - NEGATIVE	51	50	50	100	
2022-064	067	URISCAN		066 066	066 066		067 - TRACES	51	1	50	0	
2022-064	071	ATLAS		066 066	066 066		066 - NEGATIVE	11	11	11	100	
2022-064	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	96	95	95	100	
2022-064	072	URS-9-TECO		066 066	066 066		068 - POS.(1-2+)	96	1	95	0	
2022-064	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2022-064	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	118	117	117	100	
2022-064	089	AIMSTRIP		066 066	066 066		067 - TRACES	118	1	117	0	
2022-064	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100	
2022-064	102	ACON LAB		066 066	066 066		066 - NEGATIVE	149	149	149	100	
2022-064	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	29	28	28	100	
2022-064	131	iCHEM VELO		066 066	066 066		068 - POS.(1-2+)	29	1	28	0	
2022-064	135	Hybrido AU		066 066	066 066		066 - NEGATIVE	12	12	12	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-064	138	URS-10T		066 066	066 066		066 - NEGATIVE	10	10	10	100	
2022-064	140	MISSION A		066 066	066 066		066 - NEGATIVE	51	51	51	100	
2022-064	145	CLINITEK		066 066	066 066		066 - NEGATIVE	15	15	15	100	
2022-064	147	Mission120		066 066	066 066		066 - NEGATIVE	35	35	35	100	
2022-064	148	Mission500		066 066	066 066		066 - NEGATIVE	54	54	54	100	
059 URINALYS.HG.OR BLOOD												
2022-065	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	48	11	48	100	
2022-065	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	48	37	48	100	
2022-065	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	33	5	33	100	
2022-065	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	33	28	33	100	
2022-065	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	51	6	51	100	
2022-065	067	URISCAN		068 069	068 069		069 - POS.(3+)	51	45	51	100	
2022-065	071	ATLAS		068 069	068 069		068 - POS.(1-2+)	11	4	11	100	
2022-065	071	ATLAS		068 069	068 069		069 - POS.(3+)	11	7	11	100	
2022-065	072	URS-9-TECO		068 069	068 069		066 - NEGATIVE	96	1	95	0	
2022-065	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	96	28	95	100	
2022-065	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	96	67	95	100	
2022-065	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	38	2	38	100	
2022-065	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	38	36	38	100	
2022-065	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	118	2	118	100	
2022-065	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	118	116	118	100	
2022-065	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	23	106	100	
2022-065	094	CLINITEK		068 069	068 069		069 - POS.(3+)	106	83	106	100	
2022-065	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	149	1	149	100	
2022-065	102	ACON LAB		068 069	068 069		069 - POS.(3+)	149	148	149	100	
2022-065	131	iCHEM VELO		067 069	068 069		067 - TRACES	29	1	29	100	
2022-065	131	iCHEM VELO		067 069	068 069		068 - POS.(1-2+)	29	21	29	100	
2022-065	131	iCHEM VELO		067 069	068 069		069 - POS.(3+)	29	7	29	100	
2022-065	135	Hybrido AU		067 069	068 069		068 - POS.(1-2+)	12	12	12	100	
2022-065	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	10	3	10	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-065	138	URS-10T		068 069	068 069		069 - POS.(3+))	10	7	10	100	
2022-065	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	51	1	51	100	
2022-065	140	MISSION A		068 069	068 069		069 - POS.(3+))	51	50	51	100	
2022-065	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	15	5	15	100	
2022-065	145	CLINITEK		068 069	068 069		069 - POS.(3+))	15	10	15	100	
2022-065	147	Mission120		068 069	068 069		069 - POS.(3+))	35	35	35	100	
2022-065	148	Mission500		068 069	068 069		069 - POS.(3+))	54	54	54	100	
060 URINALYSIS-KETONES												
2022-061	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	48	3	48	100	
2022-061	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	48	33	48	100	
2022-061	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	48	12	48	100	
2022-061	013	BAYER CLI		092 094	092 094		090 - NEGATIVE	33	1	32	0	
2022-061	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	33	4	32	100	
2022-061	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	33	28	32	100	
2022-061	067	URISCAN		092 094	092 094		092 - SMALL (1+)	51	6	51	100	
2022-061	067	URISCAN		092 094	092 094		093 - MOD. (2+)	51	37	51	100	
2022-061	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	51	8	51	100	
2022-061	071	ATLAS		092 094	092 094		092 - SMALL (1+)	11	3	11	100	
2022-061	071	ATLAS		092 094	092 094		093 - MOD. (2+)	11	8	11	100	
2022-061	072	URS-9-TECO		092 094	092 094		091 - TRACE	96	2	94	0	
2022-061	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	96	6	94	100	
2022-061	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	96	45	94	100	
2022-061	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	96	43	94	100	
2022-061	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	38	13	38	100	
2022-061	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	38	16	38	100	
2022-061	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	38	9	38	100	
2022-061	089	AIMSTRIP		092 094	092 094		090 - NEGATIVE	117	2	114	0	
2022-061	089	AIMSTRIP		092 094	092 094		091 - TRACE	117	1	114	0	
2022-061	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	117	12	114	100	
2022-061	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	117	56	114	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-061	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	117	46	114	100
2022-061	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	106	3	105	100
2022-061	094	CLINITEK		092 094	092 094		091 - TRACE	106	1	105	0
2022-061	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	106	17	105	100
2022-061	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	106	85	105	100
2022-061	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	148	11	148	100
2022-061	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	148	82	148	100
2022-061	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	148	55	148	100
2022-061	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	29	18	29	100
2022-061	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	29	8	29	100
2022-061	131	iCHEM VELO		091 093	092 094		094 - LARGE-3-4+	29	3	29	100
2022-061	135	Hybrido AU		092 094	092 094		093 - MOD. (2+)	12	12	12	100
2022-061	138	URS-10T		092 094	092 094		092 - SMALL (1+)	10	1	10	100
2022-061	138	URS-10T		092 094	092 094		093 - MOD. (2+)	10	7	10	100
2022-061	138	URS-10T		092 094	092 094		094 - LARGE-3-4+	10	2	10	100
2022-061	140	MISSION A		093 094	092 094		092 - SMALL (1+)	54	1	54	100
2022-061	140	MISSION A		093 094	092 094		093 - MOD. (2+)	54	17	54	100
2022-061	140	MISSION A		093 094	092 094		094 - LARGE-3-4+	54	36	54	100
2022-061	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	15	10	15	100
2022-061	145	CLINITEK		092 094	092 094		094 - LARGE-3-4+	15	5	15	100
2022-061	147	Mission120		093 094	092 094		093 - MOD. (2+)	34	2	34	100
2022-061	147	Mission120		093 094	092 094		094 - LARGE-3-4+	34	32	34	100
2022-061	148	Mission500		093 094	092 094		092 - SMALL (1+)	54	1	54	100
2022-061	148	Mission500		093 094	092 094		093 - MOD. (2+)	54	26	54	100
2022-061	148	Mission500		093 094	092 094		094 - LARGE-3-4+	54	27	54	100
060 URINALYSIS-KETONES											
2022-062	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	48	48	48	100
2022-062	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	33	33	33	100
2022-062	067	URISCAN		090 090	090 090		090 - NEGATIVE	51	51	51	100
2022-062	071	ATLAS		090 090	090 090		090 - NEGATIVE	11	11	11	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-062	072	URS-9-TECO		090	090	090	090	96	96	96	100	
2022-062	080	ROCHE (CHE		090	090	090	090	38	38	38	100	
2022-062	089	AIMSTRIP		090	090	090	090	117	117	117	100	
2022-062	094	CLINITEK		090	090	090	090	106	106	106	100	
2022-062	102	ACON LAB		090	090	090	090	148	148	148	100	
2022-062	131	ICHEM VELO		090	090	090	090	29	29	29	100	
2022-062	135	Hybrido AU		090	090	090	090	12	12	12	100	
2022-062	138	URS-10T		090	090	090	090	10	10	10	100	
2022-062	140	MISSION A		090	090	090	090	54	54	54	100	
2022-062	145	CLINITEK		090	090	090	090	15	15	15	100	
2022-062	147	Mission120		090	090	090	090	34	34	34	100	
2022-062	148	Mission500		090	090	090	090	54	54	54	100	
060 URINALYSIS-KETONES												
2022-063	011	AMES NM10S		090	090	090	090	48	48	48	100	
2022-063	013	BAYER CLI		090	090	090	090	33	33	33	100	
2022-063	067	URISCAN		090	090	090	090	51	51	51	100	
2022-063	071	ATLAS		090	090	090	090	11	11	11	100	
2022-063	072	URS-9-TECO		090	090	090	090	96	96	96	100	
2022-063	080	ROCHE (CHE		090	090	090	090	38	38	38	100	
2022-063	089	AIMSTRIP		090	090	090	090	117	117	117	100	
2022-063	094	CLINITEK		090	090	090	090	106	106	106	100	
2022-063	102	ACON LAB		090	090	090	090	148	148	148	100	
2022-063	131	ICHEM VELO		090	090	090	090	29	29	29	100	
2022-063	135	Hybrido AU		090	090	090	090	12	12	12	100	
2022-063	138	URS-10T		090	090	090	090	10	10	10	100	
2022-063	140	MISSION A		090	090	090	090	54	53	53	100	
2022-063	140	MISSION A		090	090	090	094 - LARGE-3-4+	54	1	53	0	
2022-063	145	CLINITEK		090	090	090	090	15	15	15	100	
2022-063	147	Mission120		090	090	090	090	34	34	34	100	
2022-063	148	Mission500		090	090	090	090	54	54	54	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
060 URINALYSIS-KETONES												
2022-064	011	AMES NM10S		090	090	090	090	090 - NEGATIVE	48	48	48	100
2022-064	013	BAYER CLI		090	090	090	090	090 - NEGATIVE	33	33	33	100
2022-064	067	URISCAN		090	090	090	090	090 - NEGATIVE	51	51	51	100
2022-064	071	ATLAS		090	090	090	090	090 - NEGATIVE	11	11	11	100
2022-064	072	URS-9-TECO		090	090	090	090	090 - NEGATIVE	96	95	95	100
2022-064	072	URS-9-TECO		090	090	090	090	094 - LARGE-3-4+	96	1	95	0
2022-064	080	ROCHE (CHE		090	090	090	090	090 - NEGATIVE	38	38	38	100
2022-064	089	AIMSTRIP		090	090	090	090	090 - NEGATIVE	117	117	117	100
2022-064	094	CLINITEK		090	090	090	090	090 - NEGATIVE	106	106	106	100
2022-064	102	ACON LAB		090	090	090	090	090 - NEGATIVE	148	148	148	100
2022-064	131	iCHEM VELO		090	090	090	090	090 - NEGATIVE	29	29	29	100
2022-064	135	Hybrido AU		090	090	090	090	090 - NEGATIVE	12	12	12	100
2022-064	138	URS-10T		090	090	090	090	090 - NEGATIVE	10	10	10	100
2022-064	140	MISSION A		090	090	090	090	090 - NEGATIVE	54	54	54	100
2022-064	145	CLINITEK		090	090	090	090	090 - NEGATIVE	15	15	15	100
2022-064	147	Mission120		090	090	090	090	090 - NEGATIVE	34	34	34	100
2022-064	148	Mission500		090	090	090	090	090 - NEGATIVE	54	54	54	100
2022-065	011	AMES NM10S		093	094	093	094	093 - MOD. (2+)	48	3	48	100
2022-065	011	AMES NM10S		093	094	093	094	094 - LARGE-3-4+	48	45	48	100
2022-065	013	BAYER CLI		093	094	093	094	093 - MOD. (2+)	33	1	33	100
2022-065	013	BAYER CLI		093	094	093	094	094 - LARGE-3-4+	33	32	33	100
2022-065	067	URISCAN		093	094	093	094	093 - MOD. (2+)	51	17	51	100
2022-065	067	URISCAN		093	094	093	094	094 - LARGE-3-4+	51	34	51	100
2022-065	071	ATLAS		093	094	093	094	094 - LARGE-3-4+	11	11	11	100
2022-065	072	URS-9-TECO		093	094	093	094	090 - NEGATIVE	96	1	95	0
2022-065	072	URS-9-TECO		093	094	093	094	093 - MOD. (2+)	96	6	95	100
2022-065	072	URS-9-TECO		093	094	093	094	094 - LARGE-3-4+	96	89	95	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-065	080	ROCHE (CHE		093	094	093	094	093 - MOD. (2+)	38	6	38	100
2022-065	080	ROCHE (CHE		093	094	093	094	094 - LARGE-3-4+	38	32	38	100
2022-065	089	AIMSTRIP		093	094	093	094	093 - MOD. (2+)	117	1	117	100
2022-065	089	AIMSTRIP		093	094	093	094	094 - LARGE-3-4+	117	116	117	100
2022-065	094	CLINITEK		093	094	093	094	093 - MOD. (2+)	106	2	106	100
2022-065	094	CLINITEK		093	094	093	094	094 - LARGE-3-4+	106	104	106	100
2022-065	102	ACON LAB		093	094	093	094	092 - SMALL (1+)	148	1	147	0
2022-065	102	ACON LAB		093	094	093	094	093 - MOD. (2+)	148	6	147	100
2022-065	102	ACON LAB		093	094	093	094	094 - LARGE-3-4+	148	141	147	100
2022-065	131	iCHEM VELO		092	094	093	094	093 - MOD. (2+)	29	17	29	100
2022-065	131	iCHEM VELO		092	094	093	094	094 - LARGE-3-4+	29	12	29	100
2022-065	135	Hybrido AU		093	094	093	094	094 - LARGE-3-4+	12	12	12	100
2022-065	138	URS-10T		093	094	093	094	093 - MOD. (2+)	10	1	10	100
2022-065	138	URS-10T		093	094	093	094	094 - LARGE-3-4+	10	9	10	100
2022-065	140	MISSION A		093	094	093	094	093 - MOD. (2+)	54	1	54	100
2022-065	140	MISSION A		093	094	093	094	094 - LARGE-3-4+	54	53	54	100
2022-065	145	CLINITEK		093	094	093	094	094 - LARGE-3-4+	15	15	15	100
2022-065	147	Mission120		093	094	093	094	094 - LARGE-3-4+	34	34	34	100
2022-065	148	Mission500		093	094	093	094	094 - LARGE-3-4+	54	54	54	100
061 URINALYSIS-NITRATE												
2022-061	011	AMES NM10S		071	072	071	072	072 - POSITIVE	48	48	48	100
2022-061	013	BAYER CLI		071	072	071	072	072 - POSITIVE	33	33	33	100
2022-061	067	URISCAN		071	072	071	072	072 - POSITIVE	51	51	51	100
2022-061	071	ATLAS		071	072	071	072	072 - POSITIVE	11	11	11	100
2022-061	072	URS-9-TECO		071	072	071	072	071 - WEAK POS.	96	1	96	100
2022-061	072	URS-9-TECO		071	072	071	072	072 - POSITIVE	96	95	96	100
2022-061	080	ROCHE (CHE		071	072	071	072	072 - POSITIVE	38	38	38	100
2022-061	089	AIMSTRIP		071	072	071	072	071 - WEAK POS.	118	1	118	100
2022-061	089	AIMSTRIP		071	072	071	072	072 - POSITIVE	118	117	118	100
2022-061	094	CLINITEK		071	072	071	072	072 - POSITIVE	106	106	106	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-061	102	ACON LAB		071 072	071 072		072 - POSITIVE	148	148	148	100	
2022-061	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	29	29	29	100	
2022-061	135	Hybrido AU		071 072	071 072		072 - POSITIVE	12	12	12	100	
2022-061	138	URS-10T		071 072	071 072		072 - POSITIVE	10	10	10	100	
2022-061	140	MISSION A		071 072	071 072		072 - POSITIVE	52	52	52	100	
2022-061	145	CLINITEK		071 072	071 072		072 - POSITIVE	15	15	15	100	
2022-061	147	Mission120		071 072	071 072		072 - POSITIVE	35	35	35	100	
2022-061	148	Mission500		071 072	071 072		072 - POSITIVE	54	54	54	100	
061 URINALYSIS-NITRATE												
2022-062	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	48	48	48	100	
2022-062	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2022-062	067	URISCAN		070 070	070 070		070 - NEGATIVE	51	51	51	100	
2022-062	071	ATLAS		070 070	070 070		070 - NEGATIVE	11	11	11	100	
2022-062	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	96	96	96	100	
2022-062	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2022-062	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	118	118	118	100	
2022-062	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100	
2022-062	102	ACON LAB		070 070	070 070		070 - NEGATIVE	148	148	148	100	
2022-062	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	29	29	29	100	
2022-062	135	Hybrido AU		070 070	070 070		070 - NEGATIVE	12	12	12	100	
2022-062	138	URS-10T		070 070	070 070		070 - NEGATIVE	10	10	10	100	
2022-062	140	MISSION A		070 070	070 070		070 - NEGATIVE	52	52	52	100	
2022-062	145	CLINITEK		070 070	070 070		070 - NEGATIVE	15	15	15	100	
2022-062	147	Mission120		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2022-062	148	Mission500		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2022-063	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	48	48	48	100	
2022-063	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2022-063	067	URISCAN		070 070	070 070		070 - NEGATIVE	51	51	51	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
2022-063	071	ATLAS		070	070	070	070	070	-	NEGATIVE	11	11	11	100
2022-063	072	URS-9-TECO		070	070	070	070	070	-	NEGATIVE	96	96	96	100
2022-063	080	ROCHE (CHE		070	070	070	070	070	-	NEGATIVE	38	38	38	100
2022-063	089	AIMSTRIP		070	070	070	070	070	-	NEGATIVE	118	118	118	100
2022-063	094	CLINITEK		070	070	070	070	070	-	NEGATIVE	106	106	106	100
2022-063	102	ACON LAB		070	070	070	070	070	-	NEGATIVE	148	148	148	100
2022-063	131	iCHEM VELO		070	070	070	070	070	-	NEGATIVE	29	29	29	100
2022-063	135	Hybrido AU		070	070	070	070	070	-	NEGATIVE	12	12	12	100
2022-063	138	URS-10T		070	070	070	070	070	-	NEGATIVE	10	10	10	100
2022-063	140	MISSION A		070	070	070	070	070	-	NEGATIVE	52	52	52	100
2022-063	145	CLINITEK		070	070	070	070	070	-	NEGATIVE	15	15	15	100
2022-063	147	Mission120		070	070	070	070	070	-	NEGATIVE	35	35	35	100
2022-063	148	Mission500		070	070	070	070	070	-	NEGATIVE	54	54	54	100
061 URINALYSIS-NITRATE														
2022-064	011	AMES NM10S		070	070	070	070	070	-	NEGATIVE	48	48	48	100
2022-064	013	BAYER CLI		070	070	070	070	070	-	NEGATIVE	33	33	33	100
2022-064	067	URISCAN		070	070	070	070	070	-	NEGATIVE	51	51	51	100
2022-064	071	ATLAS		070	070	070	070	070	-	NEGATIVE	11	11	11	100
2022-064	072	URS-9-TECO		070	070	070	070	070	-	NEGATIVE	96	96	96	100
2022-064	080	ROCHE (CHE		070	070	070	070	070	-	NEGATIVE	38	38	38	100
2022-064	089	AIMSTRIP		070	070	070	070	070	-	NEGATIVE	118	118	118	100
2022-064	094	CLINITEK		070	070	070	070	070	-	NEGATIVE	106	106	106	100
2022-064	102	ACON LAB		070	070	070	070	070	-	NEGATIVE	148	148	148	100
2022-064	131	iCHEM VELO		070	070	070	070	070	-	NEGATIVE	29	29	29	100
2022-064	135	Hybrido AU		070	070	070	070	070	-	NEGATIVE	12	12	12	100
2022-064	138	URS-10T		070	070	070	070	070	-	NEGATIVE	10	10	10	100
2022-064	140	MISSION A		070	070	070	070	070	-	NEGATIVE	52	52	52	100
2022-064	145	CLINITEK		070	070	070	070	070	-	NEGATIVE	15	15	15	100
2022-064	147	Mission120		070	070	070	070	070	-	NEGATIVE	35	35	35	100
2022-064	148	Mission500		070	070	070	070	070	-	NEGATIVE	54	54	54	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
061 URINALYSIS-NITRATE													
2022-065	011	AMES NM10S		070	070	070	070	070 - NEGATIVE	48	48	48	100	
2022-065	013	BAYER CLI		070	070	070	070	070 - NEGATIVE	33	33	33	100	
2022-065	067	URISCAN		070	070	070	070	070 - NEGATIVE	51	51	51	100	
2022-065	071	ATLAS		070	070	070	070	070 - NEGATIVE	11	11	11	100	
2022-065	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	96	96	96	100	
2022-065	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2022-065	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	118	118	118	100	
2022-065	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	105	105	100	
2022-065	094	CLINITEK		070	070	070	070	072 - POSITIVE	106	1	105	0	
2022-065	102	ACON LAB		070	070	070	070	070 - NEGATIVE	148	148	148	100	
2022-065	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	29	29	29	100	
2022-065	135	Hybrido AU		070	070	070	070	070 - NEGATIVE	12	12	12	100	
2022-065	138	URS-10T		070	070	070	070	070 - NEGATIVE	10	10	10	100	
2022-065	140	MISSION A		070	070	070	070	070 - NEGATIVE	52	52	52	100	
2022-065	145	CLINITEK		070	070	070	070	070 - NEGATIVE	15	15	15	100	
2022-065	147	Mission120		070	070	070	070	070 - NEGATIVE	35	35	35	100	
2022-065	148	Mission500		070	070	070	070	070 - NEGATIVE	54	54	54	100	
062 URINALYSIS-pH													
2022-061	011	AMES NM10S		081	085	080	084	082 - 5.0	48	17	48	100	
2022-061	011	AMES NM10S		081	085	080	084	083 - 5.5	48	24	48	100	
2022-061	011	AMES NM10S		081	085	080	084	084 - 6.0	48	7	48	100	
2022-061	013	BAYER CLI		081	085	080	084	082 - 5.0	34	13	34	100	
2022-061	013	BAYER CLI		081	085	080	084	083 - 5.5	34	18	34	100	
2022-061	013	BAYER CLI		081	085	080	084	084 - 6.0	34	3	34	100	
2022-061	067	URISCAN		080	084	080	084	082 - 5.0	51	35	51	100	
2022-061	067	URISCAN		080	084	080	084	083 - 5.5	51	14	51	100	
2022-061	067	URISCAN		080	084	080	084	084 - 6.0	51	2	51	100	
2022-061	071	ATLAS		081	085	080	084	082 - 5.0	11	2	11	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-061	071	ATLAS		081 085	080 084		083 - 5.5	11	8	11	100
2022-061	071	ATLAS		081 085	080 084		084 - 6.0	11	1	11	100
2022-061	072	URS-9-TECO		082 086	080 084		082 - 5.0	95	17	95	100
2022-061	072	URS-9-TECO		082 086	080 084		083 - 5.5	95	10	95	100
2022-061	072	URS-9-TECO		082 086	080 084		084 - 6.0	95	68	95	100
2022-061	080	ROCHE (CHE		080 084	080 084		082 - 5.0	38	31	38	100
2022-061	080	ROCHE (CHE		080 084	080 084		083 - 5.5	38	1	38	100
2022-061	080	ROCHE (CHE		080 084	080 084		084 - 6.0	38	6	38	100
2022-061	089	AIMSTRIP		080 084	080 084		082 - 5.0	117	57	117	100
2022-061	089	AIMSTRIP		080 084	080 084		083 - 5.5	117	30	117	100
2022-061	089	AIMSTRIP		080 084	080 084		084 - 6.0	117	30	117	100
2022-061	094	CLINITEK		081 085	080 084		082 - 5.0	106	28	106	100
2022-061	094	CLINITEK		081 085	080 084		083 - 5.5	106	61	106	100
2022-061	094	CLINITEK		081 085	080 084		084 - 6.0	106	17	106	100
2022-061	102	ACON LAB		082 086	080 084		082 - 5.0	148	44	148	100
2022-061	102	ACON LAB		082 086	080 084		083 - 5.5	148	31	148	100
2022-061	102	ACON LAB		082 086	080 084		084 - 6.0	148	73	148	100
2022-061	131	ICHEM VELO		080 084	080 084		082 - 5.0	29	29	29	100
2022-061	135	Hybrido AU		080 084	080 084		082 - 5.0	12	8	12	100
2022-061	135	Hybrido AU		080 084	080 084		083 - 5.5	12	4	12	100
2022-061	138	URS-10T		081 085	080 084		082 - 5.0	10	3	10	100
2022-061	138	URS-10T		081 085	080 084		083 - 5.5	10	4	10	100
2022-061	138	URS-10T		081 085	080 084		084 - 6.0	10	2	10	100
2022-061	138	URS-10T		081 085	080 084		085 - 6.5	10	1	10	100
2022-061	140	MISSION A		081 085	080 084		082 - 5.0	54	15	54	100
2022-061	140	MISSION A		081 085	080 084		083 - 5.5	54	20	54	100
2022-061	140	MISSION A		081 085	080 084		084 - 6.0	54	19	54	100
2022-061	145	CLINITEK		080 084	080 084		082 - 5.0	15	8	15	100
2022-061	145	CLINITEK		080 084	080 084		083 - 5.5	15	7	15	100
2022-061	147	Mission120		081 085	080 084		082 - 5.0	34	10	34	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-061	147	Mission120		081 085	080 084		083 - 5.5	34	22	34	100	
2022-061	147	Mission120		081 085	080 084		084 - 6.0	34	2	34	100	
2022-061	148	Mission500		082 086	080 084		082 - 5.0	54	1	54	100	
2022-061	148	Mission500		082 086	080 084		083 - 5.5	54	10	54	100	
2022-061	148	Mission500		082 086	080 084		084 - 6.0	54	43	54	100	
062 URINALYSIS-pH												
2022-062	011	AMES NM10S		085 088	084 088		086 - 7.0	48	23	48	100	
2022-062	011	AMES NM10S		085 088	084 088		087 - 7.5	48	25	48	100	
2022-062	013	BAYER CLI		085 088	084 088		086 - 7.0	34	14	34	100	
2022-062	013	BAYER CLI		085 088	084 088		087 - 7.5	34	20	34	100	
2022-062	067	URISCAN		084 088	084 088		085 - 6.5	51	6	51	100	
2022-062	067	URISCAN		084 088	084 088		086 - 7.0	51	42	51	100	
2022-062	067	URISCAN		084 088	084 088		087 - 7.5	51	3	51	100	
2022-062	071	ATLAS		084 088	084 088		086 - 7.0	11	10	11	100	
2022-062	071	ATLAS		084 088	084 088		087 - 7.5	11	1	11	100	
2022-062	072	URS-9-TECO		084 088	084 088		085 - 6.5	95	1	95	100	
2022-062	072	URS-9-TECO		084 088	084 088		086 - 7.0	95	89	95	100	
2022-062	072	URS-9-TECO		084 088	084 088		087 - 7.5	95	4	95	100	
2022-062	072	URS-9-TECO		084 088	084 088		088 - 8.0OR MORE	95	1	95	100	
2022-062	080	ROCHE (CHE		084 088	084 088		086 - 7.0	38	38	38	100	
2022-062	089	AIMSTRIP		084 088	084 088		082 - 5.0	117	1	116	0	
2022-062	089	AIMSTRIP		084 088	084 088		086 - 7.0	117	88	116	100	
2022-062	089	AIMSTRIP		084 088	084 088		087 - 7.5	117	28	116	100	
2022-062	094	CLINITEK		085 088	084 088		086 - 7.0	106	42	106	100	
2022-062	094	CLINITEK		085 088	084 088		087 - 7.5	106	64	106	100	
2022-062	102	ACON LAB		084 088	084 088		086 - 7.0	148	128	148	100	
2022-062	102	ACON LAB		084 088	084 088		087 - 7.5	148	20	148	100	
2022-062	131	iCHEM VELO		084 088	084 088		086 - 7.0	29	29	29	100	
2022-062	135	Hybrido AU		084 088	084 088		086 - 7.0	12	8	12	100	
2022-062	135	Hybrido AU		084 088	084 088		087 - 7.5	12	4	12	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-062	138	URS-10T		084 088	084 088		084 - 6.0	10	1	10	100	
2022-062	138	URS-10T		084 088	084 088		085 - 6.5	10	1	10	100	
2022-062	138	URS-10T		084 088	084 088		086 - 7.0	10	8	10	100	
2022-062	140	MISSION A		084 088	084 088		085 - 6.5	54	2	54	100	
2022-062	140	MISSION A		084 088	084 088		086 - 7.0	54	49	54	100	
2022-062	140	MISSION A		084 088	084 088		087 - 7.5	54	3	54	100	
2022-062	145	CLINITEK		084 088	084 088		086 - 7.0	15	11	15	100	
2022-062	145	CLINITEK		084 088	084 088		087 - 7.5	15	4	15	100	
2022-062	147	Mission120		084 088	084 088		085 - 6.5	34	1	34	100	
2022-062	147	Mission120		084 088	084 088		086 - 7.0	34	33	34	100	
2022-062	148	Mission500		084 088	084 088		086 - 7.0	54	54	54	100	
062 URINALYSIS-pH												
2022-063	011	AMES NM10S		084 088	083 087		085 - 6.5	48	10	48	100	
2022-063	011	AMES NM10S		084 088	083 087		086 - 7.0	48	38	48	100	
2022-063	013	BAYER CLI		084 088	083 087		085 - 6.5	34	4	34	100	
2022-063	013	BAYER CLI		084 088	083 087		086 - 7.0	34	30	34	100	
2022-063	067	URISCAN		083 087	083 087		084 - 6.0	51	7	51	100	
2022-063	067	URISCAN		083 087	083 087		085 - 6.5	51	43	51	100	
2022-063	067	URISCAN		083 087	083 087		086 - 7.0	51	1	51	100	
2022-063	071	ATLAS		083 087	083 087		085 - 6.5	11	8	11	100	
2022-063	071	ATLAS		083 087	083 087		086 - 7.0	11	3	11	100	
2022-063	072	URS-9-TECO		083 087	083 087		084 - 6.0	95	7	95	100	
2022-063	072	URS-9-TECO		083 087	083 087		085 - 6.5	95	59	95	100	
2022-063	072	URS-9-TECO		083 087	083 087		086 - 7.0	95	29	95	100	
2022-063	080	ROCHE (CHE		083 087	083 087		085 - 6.5	38	38	38	100	
2022-063	089	AIMSTRIP		083 087	083 087		084 - 6.0	117	14	117	100	
2022-063	089	AIMSTRIP		083 087	083 087		085 - 6.5	117	55	117	100	
2022-063	089	AIMSTRIP		083 087	083 087		086 - 7.0	117	48	117	100	
2022-063	094	CLINITEK		084 088	083 087		085 - 6.5	106	8	106	100	
2022-063	094	CLINITEK		084 088	083 087		086 - 7.0	106	98	106	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-063	102	ACON LAB		083 087	083 087		084 - 6.0	148	15	148	100	
2022-063	102	ACON LAB		083 087	083 087		085 - 6.5	148	102	148	100	
2022-063	102	ACON LAB		083 087	083 087		086 - 7.0	148	31	148	100	
2022-063	131	iCHEM VELO		082 086	083 087		084 - 6.0	29	26	29	100	
2022-063	131	iCHEM VELO		082 086	083 087		086 - 7.0	29	3	29	100	
2022-063	135	Hybrido AU		083 087	083 087		085 - 6.5	12	7	12	100	
2022-063	135	Hybrido AU		083 087	083 087		086 - 7.0	12	5	12	100	
2022-063	138	URS-10T		083 087	083 087		085 - 6.5	10	7	10	100	
2022-063	138	URS-10T		083 087	083 087		086 - 7.0	10	3	10	100	
2022-063	140	MISSION A		083 087	083 087		084 - 6.0	54	5	54	100	
2022-063	140	MISSION A		083 087	083 087		085 - 6.5	54	44	54	100	
2022-063	140	MISSION A		083 087	083 087		086 - 7.0	54	5	54	100	
2022-063	145	CLINITEK		083 087	083 087		085 - 6.5	15	11	15	100	
2022-063	145	CLINITEK		083 087	083 087		086 - 7.0	15	4	15	100	
2022-063	147	Mission120		083 087	083 087		085 - 6.5	34	34	34	100	
2022-063	148	Mission500		083 087	083 087		085 - 6.5	54	49	54	100	
2022-063	148	Mission500		083 087	083 087		086 - 7.0	54	5	54	100	
062 URINALYSIS-pH												
2022-064	011	AMES NM10S		086 088	086 088		087 - 7.5	48	5	48	100	
2022-064	011	AMES NM10S		086 088	086 088		088 - 8.0OR MORE	48	43	48	100	
2022-064	013	BAYER CLI		086 088	086 088		087 - 7.5	34	5	34	100	
2022-064	013	BAYER CLI		086 088	086 088		088 - 8.0OR MORE	34	29	34	100	
2022-064	067	URISCAN		086 088	086 088		086 - 7.0	51	1	51	100	
2022-064	067	URISCAN		086 088	086 088		087 - 7.5	51	15	51	100	
2022-064	067	URISCAN		086 088	086 088		088 - 8.0OR MORE	51	35	51	100	
2022-064	071	ATLAS		086 088	086 088		087 - 7.5	11	4	11	100	
2022-064	071	ATLAS		086 088	086 088		088 - 8.0OR MORE	11	7	11	100	
2022-064	072	URS-9-TECO		085 088	086 088		088 - 8.0OR MORE	95	21	95	100	
2022-064	072	URS-9-TECO		085 088	086 088		086 - 7.0	95	11	95	100	
2022-064	072	URS-9-TECO		085 088	086 088		087 - 7.5	95	63	95	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-064	080	ROCHE (CHE		086	088	086	088	086 - 7.0	38	10	38	100
2022-064	080	ROCHE (CHE		086	088	086	088	088 - 8.0OR MORE	38	28	38	100
2022-064	089	AIMSTRIP		086	088	086	088	087 - 7.5	117	8	117	100
2022-064	089	AIMSTRIP		086	088	086	088	088 - 8.0OR MORE	117	109	117	100
2022-064	094	CLINITEK		086	088	086	088	086 - 7.0	106	1	106	100
2022-064	094	CLINITEK		086	088	086	088	087 - 7.5	106	14	106	100
2022-064	094	CLINITEK		086	088	086	088	088 - 8.0OR MORE	106	91	106	100
2022-064	102	ACON LAB		086	088	086	088	087 - 7.5	148	14	148	100
2022-064	102	ACON LAB		086	088	086	088	088 - 8.0OR MORE	148	134	148	100
2022-064	131	iCHEM VELO		086	088	086	088	086 - 7.0	29	1	29	100
2022-064	131	iCHEM VELO		086	088	086	088	088 - 8.0OR MORE	29	28	29	100
2022-064	135	Hybrido AU		086	088	086	088	088 - 8.0OR MORE	12	12	12	100
2022-064	138	URS-10T		085	088	086	088	086 - 7.0	10	1	10	100
2022-064	138	URS-10T		085	088	086	088	087 - 7.5	10	8	10	100
2022-064	138	URS-10T		085	088	086	088	088 - 8.0OR MORE	10	1	10	100
2022-064	140	MISSION A		086	088	086	088	086 - 7.0	54	2	54	100
2022-064	140	MISSION A		086	088	086	088	087 - 7.5	54	6	54	100
2022-064	140	MISSION A		086	088	086	088	088 - 8.0OR MORE	54	46	54	100
2022-064	145	CLINITEK		086	088	086	088	088 - 8.0OR MORE	15	15	15	100
2022-064	147	Mission120		086	088	086	088	087 - 7.5	34	6	34	100
2022-064	147	Mission120		086	088	086	088	088 - 8.0OR MORE	34	28	34	100
2022-064	148	Mission500		086	088	086	088	087 - 7.5	54	1	54	100
2022-064	148	Mission500		086	088	086	088	088 - 8.0OR MORE	54	53	54	100
062 URINALYSIS-pH												
2022-065	011	AMES NM10S		086	088	086	088	087 - 7.5	48	9	48	100
2022-065	011	AMES NM10S		086	088	086	088	088 - 8.0OR MORE	48	39	48	100
2022-065	013	BAYER CLI		086	088	086	088	087 - 7.5	34	11	34	100
2022-065	013	BAYER CLI		086	088	086	088	088 - 8.0OR MORE	34	23	34	100
2022-065	067	URISCAN		085	088	086	088	086 - 7.0	51	3	51	100
2022-065	067	URISCAN		085	088	086	088	087 - 7.5	51	40	51	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-065	067	URISCAN		085 088	086 088		088 - 8.00R MORE	51	8	51	100	
2022-065	071	ATLAS		085 088	086 088		087 - 7.5	11	10	11	100	
2022-065	071	ATLAS		085 088	086 088		088 - 8.00R MORE	11	1	11	100	
2022-065	072	URS-9-TECO		085 088	086 088		085 - 6.5	95	1	95	100	
2022-065	072	URS-9-TECO		085 088	086 088		086 - 7.0	95	16	95	100	
2022-065	072	URS-9-TECO		085 088	086 088		087 - 7.5	95	65	95	100	
2022-065	072	URS-9-TECO		085 088	086 088		088 - 8.00R MORE	95	13	95	100	
2022-065	080	ROCHE (CHE		084 088	086 088		086 - 7.0	38	22	38	100	
2022-065	080	ROCHE (CHE		084 088	086 088		088 - 8.00R MORE	38	16	38	100	
2022-065	089	AIMSTRIP		086 088	086 088		086 - 7.0	117	1	117	100	
2022-065	089	AIMSTRIP		086 088	086 088		087 - 7.5	117	40	117	100	
2022-065	089	AIMSTRIP		086 088	086 088		088 - 8.00R MORE	117	76	117	100	
2022-065	094	CLINITEK		086 088	086 088		086 - 7.0	106	1	106	100	
2022-065	094	CLINITEK		086 088	086 088		087 - 7.5	106	24	106	100	
2022-065	094	CLINITEK		086 088	086 088		088 - 8.00R MORE	106	81	106	100	
2022-065	102	ACON LAB		086 088	086 088		087 - 7.5	148	48	148	100	
2022-065	102	ACON LAB		086 088	086 088		088 - 8.00R MORE	148	100	148	100	
2022-065	131	iCHEM VELO		084 088	086 088		086 - 7.0	29	18	29	100	
2022-065	131	iCHEM VELO		084 088	086 088		088 - 8.00R MORE	29	11	29	100	
2022-065	135	Hybrido AU		086 088	086 088		087 - 7.5	12	1	12	100	
2022-065	135	Hybrido AU		086 088	086 088		088 - 8.00R MORE	12	11	12	100	
2022-065	138	URS-10T		085 088	086 088		086 - 7.0	10	1	10	100	
2022-065	138	URS-10T		085 088	086 088		087 - 7.5	10	9	10	100	
2022-065	140	MISSION A		086 088	086 088		087 - 7.5	54	24	54	100	
2022-065	140	MISSION A		086 088	086 088		088 - 8.00R MORE	54	30	54	100	
2022-065	145	CLINITEK		085 088	086 088		087 - 7.5	15	11	15	100	
2022-065	145	CLINITEK		085 088	086 088		088 - 8.00R MORE	15	4	15	100	
2022-065	147	Mission120		086 088	086 088		087 - 7.5	34	16	34	100	
2022-065	147	Mission120		086 088	086 088		088 - 8.00R MORE	34	18	34	100	
2022-065	148	Mission500		086 088	086 088		086 - 7.0	54	1	54	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-065	148	Mission500		086 088	086 088		087 - 7.5	54	13	54	100		
2022-065	148	Mission500		086 088	086 088		088 - 8.0OR MORE	54	40	54	100		
064 URIN-PROTEIN QUALI.													
2022-061	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	49	48	48	100		
2022-061	011	AMES NM10S		051 051	051 051		052 - TRACES	49	1	48	0		
2022-061	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	33	33	33	100		
2022-061	067	URISCAN		051 051	051 051		051 - NEGATIVE	51	50	50	100		
2022-061	067	URISCAN		051 051	051 051		052 - TRACES	51	1	50	0		
2022-061	071	ATLAS		051 051	051 051		051 - NEGATIVE	11	11	11	100		
2022-061	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	96	96	96	100		
2022-061	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	38	37	37	100		
2022-061	080	ROCHE (CHE		051 051	051 051		052 - TRACES	38	1	37	0		
2022-061	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	116	116	116	100		
2022-061	094	CLINITEK		051 051	051 051		051 - NEGATIVE	105	105	105	100		
2022-061	102	ACON LAB		051 051	051 051		051 - NEGATIVE	147	147	147	100		
2022-061	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	29	29	29	100		
2022-061	135	Hybrido AU		051 051	051 051		051 - NEGATIVE	12	12	12	100		
2022-061	138	URS-10T		051 051	051 051		051 - NEGATIVE	10	10	10	100		
2022-061	140	MISSION A		051 051	051 051		051 - NEGATIVE	53	53	53	100		
2022-061	145	CLINITEK		051 051	051 051		051 - NEGATIVE	15	15	15	100		
2022-061	147	Mission120		051 051	051 051		051 - NEGATIVE	35	35	35	100		
2022-061	148	Mission500		051 051	051 051		051 - NEGATIVE	54	54	54	100		
2022-062	011	AMES NM10S		053 055	053 055		054 - 2+	49	28	49	100		
2022-062	011	AMES NM10S		053 055	053 055		053 - 1+	49	1	49	100		
2022-062	011	AMES NM10S		053 055	053 055		055 - 3+	49	20	49	100		
2022-062	013	BAYER CLI		053 055	053 055		055 - 3+	33	11	33	100		
2022-062	013	BAYER CLI		053 055	053 055		054 - 2+	33	22	33	100		
2022-062	067	URISCAN		053 055	053 055		054 - 2+	51	42	51	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-062	067	URISCAN		053 055	053 055		053 - 1+	51	7	51	100
2022-062	067	URISCAN		053 055	053 055		055 - 3+	51	2	51	100
2022-062	071	ATLAS		053 055	053 055		054 - 2+	11	9	11	100
2022-062	071	ATLAS		053 055	053 055		053 - 1+	11	2	11	100
2022-062	072	URS-9-TECO		054 056	053 055		054 - 2+	96	43	96	100
2022-062	072	URS-9-TECO		054 056	053 055		053 - 1+	96	1	96	100
2022-062	072	URS-9-TECO		054 056	053 055		055 - 3+	96	52	96	100
2022-062	080	ROCHE (CHE		053 055	053 055		054 - 2+	38	29	38	100
2022-062	080	ROCHE (CHE		053 055	053 055		055 - 3+	38	9	38	100
2022-062	089	AIMSTRIP		053 055	053 055		054 - 2+	116	63	112	100
2022-062	089	AIMSTRIP		053 055	053 055		053 - 1+	116	2	112	100
2022-062	089	AIMSTRIP		053 055	053 055		055 - 3+	116	47	112	100
2022-062	089	AIMSTRIP		053 055	053 055		056 - 4+	116	4	112	0
2022-062	094	CLINITEK		053 055	053 055		054 - 2+	105	84	104	100
2022-062	094	CLINITEK		053 055	053 055		053 - 1+	105	3	104	100
2022-062	094	CLINITEK		053 055	053 055		055 - 3+	105	17	104	100
2022-062	094	CLINITEK		053 055	053 055		056 - 4+	105	1	104	0
2022-062	102	ACON LAB		054 056	053 055		056 - 4+	147	2	147	100
2022-062	102	ACON LAB		054 056	053 055		054 - 2+	147	59	147	100
2022-062	102	ACON LAB		054 056	053 055		055 - 3+	147	86	147	100
2022-062	131	iCHEM VELO		053 055	053 055		054 - 2+	29	25	29	100
2022-062	131	iCHEM VELO		053 055	053 055		055 - 3+	29	4	29	100
2022-062	135	Hybrido AU		053 055	053 055		054 - 2+	12	11	12	100
2022-062	135	Hybrido AU		053 055	053 055		055 - 3+	12	1	12	100
2022-062	138	URS-10T		054 056	053 055		054 - 2+	10	4	10	100
2022-062	138	URS-10T		054 056	053 055		055 - 3+	10	6	10	100
2022-062	140	MISSION A		053 055	053 055		054 - 2+	53	34	53	100
2022-062	140	MISSION A		053 055	053 055		053 - 1+	53	1	53	100
2022-062	140	MISSION A		053 055	053 055		055 - 3+	53	18	53	100
2022-062	145	CLINITEK		054 056	053 055		054 - 2+	15	7	15	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-062	145	CLINITEK		054 056	053 055		055 - 3+	15	8	15	100	
2022-062	147	Mission120		053 055	053 055		054 - 2+	35	28	35	100	
2022-062	147	Mission120		053 055	053 055		053 - 1+	35	6	35	100	
2022-062	147	Mission120		053 055	053 055		055 - 3+	35	1	35	100	
2022-062	148	Mission500		054 056	053 055		054 - 2+	54	17	54	100	
2022-062	148	Mission500		054 056	053 055		055 - 3+	54	36	54	100	
2022-062	148	Mission500		054 056	053 055		056 - 4+	54	1	54	100	
064 URIN-PROTEIN QUALI.												
2022-063	011	AMES NM10S		053 055	053 055		054 - 2+	49	34	49	100	
2022-063	011	AMES NM10S		053 055	053 055		053 - 1+	49	2	49	100	
2022-063	011	AMES NM10S		053 055	053 055		055 - 3+	49	13	49	100	
2022-063	013	BAYER CLI		053 055	053 055		054 - 2+	33	25	33	100	
2022-063	013	BAYER CLI		053 055	053 055		055 - 3+	33	8	33	100	
2022-063	067	URISCAN		053 055	053 055		054 - 2+	51	32	49	100	
2022-063	067	URISCAN		053 055	053 055		051 - NEGATIVE	51	1	49	0	
2022-063	067	URISCAN		053 055	053 055		052 - TRACES	51	1	49	0	
2022-063	067	URISCAN		053 055	053 055		053 - 1+	51	15	49	100	
2022-063	067	URISCAN		053 055	053 055		055 - 3+	51	2	49	100	
2022-063	071	ATLAS		053 055	053 055		054 - 2+	11	10	11	100	
2022-063	071	ATLAS		053 055	053 055		053 - 1+	11	1	11	100	
2022-063	072	URS-9-TECO		053 055	053 055		054 - 2+	96	68	95	100	
2022-063	072	URS-9-TECO		053 055	053 055		051 - NEGATIVE	96	1	95	0	
2022-063	072	URS-9-TECO		053 055	053 055		053 - 1+	96	3	95	100	
2022-063	072	URS-9-TECO		053 055	053 055		055 - 3+	96	24	95	100	
2022-063	080	ROCHE (CHE		053 055	053 055		054 - 2+	38	31	38	100	
2022-063	080	ROCHE (CHE		053 055	053 055		053 - 1+	38	1	38	100	
2022-063	080	ROCHE (CHE		053 055	053 055		055 - 3+	38	6	38	100	
2022-063	089	AIMSTRIP		053 055	053 055		054 - 2+	116	82	113	100	
2022-063	089	AIMSTRIP		053 055	053 055		053 - 1+	116	4	113	100	
2022-063	089	AIMSTRIP		053 055	053 055		055 - 3+	116	27	113	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2022-063	089	AIMSTRIP		053 055	053 055		056 - 4+	116	3	113	0		
2022-063	094	CLINITEK		053 055	053 055		054 - 2+	105	89	104	100		
2022-063	094	CLINITEK		053 055	053 055		053 - 1+	105	6	104	100		
2022-063	094	CLINITEK		053 055	053 055		055 - 3+	105	9	104	100		
2022-063	094	CLINITEK		053 055	053 055		056 - 4+	105	1	104	0		
2022-063	102	ACON LAB		053 055	053 055		054 - 2+	147	90	145	100		
2022-063	102	ACON LAB		053 055	053 055		053 - 1+	147	2	145	100		
2022-063	102	ACON LAB		053 055	053 055		055 - 3+	147	53	145	100		
2022-063	102	ACON LAB		053 055	053 055		056 - 4+	147	2	145	0		
2022-063	131	ICHEM VELO		053 055	053 055		054 - 2+	29	29	29	100		
2022-063	135	Hybrido AU		053 055	053 055		054 - 2+	12	11	12	100		
2022-063	135	Hybrido AU		053 055	053 055		055 - 3+	12	1	12	100		
2022-063	138	URS-10T		053 055	053 055		054 - 2+	10	6	10	100		
2022-063	138	URS-10T		053 055	053 055		053 - 1+	10	1	10	100		
2022-063	138	URS-10T		053 055	053 055		055 - 3+	10	3	10	100		
2022-063	140	MISSION A		053 055	053 055		054 - 2+	53	39	53	100		
2022-063	140	MISSION A		053 055	053 055		053 - 1+	53	3	53	100		
2022-063	140	MISSION A		053 055	053 055		055 - 3+	53	11	53	100		
2022-063	145	CLINITEK		053 055	053 055		054 - 2+	15	15	15	100		
2022-063	147	Mission120		053 055	053 055		054 - 2+	35	29	35	100		
2022-063	147	Mission120		053 055	053 055		053 - 1+	35	5	35	100		
2022-063	147	Mission120		053 055	053 055		055 - 3+	35	1	35	100		
2022-063	148	Mission500		053 055	053 055		054 - 2+	54	39	53	100		
2022-063	148	Mission500		053 055	053 055		055 - 3+	54	14	53	100		
2022-063	148	Mission500		053 055	053 055		056 - 4+	54	1	53	0		
064 URIN-PROTEIN QUALI.													
2022-064	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	49	47	47	100		
2022-064	011	AMES NM10S		051 051	051 051		052 - TRACES	49	1	47	0		
2022-064	011	AMES NM10S		051 051	051 051		053 - 1+	49	1	47	0		
2022-064	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	33	33	33	100		

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-064	067	URISCAN		051 051	051 051		051 - NEGATIVE	51	50	50	100
2022-064	067	URISCAN		051 051	051 051		053 - 1+	51	1	50	0
2022-064	071	ATLAS		051 051	051 051		051 - NEGATIVE	11	11	11	100
2022-064	072	URS-9-TECO		051 051	051 051		054 - 2+	96	2	93	0
2022-064	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	96	93	93	100
2022-064	072	URS-9-TECO		051 051	051 051		053 - 1+	96	1	93	0
2022-064	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	38	37	37	100
2022-064	080	ROCHE (CHE		051 051	051 051		052 - TRACES	38	1	37	0
2022-064	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	116	109	109	100
2022-064	089	AIMSTRIP		051 051	051 051		052 - TRACES	116	7	109	0
2022-064	094	CLINITEK		051 051	051 051		051 - NEGATIVE	105	105	105	100
2022-064	102	ACON LAB		051 051	051 051		051 - NEGATIVE	147	137	137	100
2022-064	102	ACON LAB		051 051	051 051		052 - TRACES	147	10	137	0
2022-064	131	ICHEM VELO		051 051	051 051		051 - NEGATIVE	29	29	29	100
2022-064	135	Hybrido AU		051 051	051 051		051 - NEGATIVE	12	12	12	100
2022-064	138	URS-10T		051 051	051 051		051 - NEGATIVE	10	10	10	100
2022-064	140	MISSION A		051 051	051 051		051 - NEGATIVE	53	49	49	100
2022-064	140	MISSION A		051 051	051 051		052 - TRACES	53	3	49	0
2022-064	140	MISSION A		051 051	051 051		053 - 1+	53	1	49	0
2022-064	145	CLINITEK		051 051	051 051		051 - NEGATIVE	15	15	15	100
2022-064	147	Mission120		051 051	051 051		051 - NEGATIVE	35	35	35	100
2022-064	148	Mission500		051 051	051 051		051 - NEGATIVE	54	49	49	100
2022-064	148	Mission500		051 051	051 051		052 - TRACES	54	5	49	0
064 URIN-PROTEIN QUALI.											
2022-065	011	AMES NM10S		053 055	053 055		054 - 2+	49	28	49	100
2022-065	011	AMES NM10S		053 055	053 055		053 - 1+	49	1	49	100
2022-065	011	AMES NM10S		053 055	053 055		055 - 3+	49	20	49	100
2022-065	013	BAYER CLI		053 055	053 055		054 - 2+	33	20	33	100
2022-065	013	BAYER CLI		053 055	053 055		055 - 3+	33	13	33	100
2022-065	067	URISCAN		053 055	053 055		054 - 2+	51	41	50	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-065	067	URISCAN		053 055	053 055		053 - 1+	51	4	50	100
2022-065	067	URISCAN		053 055	053 055		055 - 3+	51	5	50	100
2022-065	067	URISCAN		053 055	053 055		056 - 4+	51	1	50	0
2022-065	071	ATLAS		053 055	053 055		054 - 2+	11	10	11	100
2022-065	071	ATLAS		053 055	053 055		053 - 1+	11	1	11	100
2022-065	072	URS-9-TECO		054 056	053 055		054 - 2+	96	46	95	100
2022-065	072	URS-9-TECO		054 056	053 055		051 - NEGATIVE	96	1	95	0
2022-065	072	URS-9-TECO		054 056	053 055		055 - 3+	96	49	95	100
2022-065	080	ROCHE (CHE		053 055	053 055		054 - 2+	38	30	37	100
2022-065	080	ROCHE (CHE		053 055	053 055		051 - NEGATIVE	38	1	37	0
2022-065	080	ROCHE (CHE		053 055	053 055		055 - 3+	38	7	37	100
2022-065	089	AIMSTRIP		054 056	053 055		054 - 2+	116	45	116	100
2022-065	089	AIMSTRIP		054 056	053 055		053 - 1+	116	2	116	100
2022-065	089	AIMSTRIP		054 056	053 055		055 - 3+	116	65	116	100
2022-065	089	AIMSTRIP		054 056	053 055		056 - 4+	116	4	116	100
2022-065	094	CLINITEK		053 055	053 055		054 - 2+	105	80	103	100
2022-065	094	CLINITEK		053 055	053 055		053 - 1+	105	3	103	100
2022-065	094	CLINITEK		053 055	053 055		055 - 3+	105	20	103	100
2022-065	094	CLINITEK		053 055	053 055		056 - 4+	105	2	103	0
2022-065	102	ACON LAB		054 056	053 055		054 - 2+	147	53	147	100
2022-065	102	ACON LAB		054 056	053 055		055 - 3+	147	92	147	100
2022-065	102	ACON LAB		054 056	053 055		056 - 4+	147	2	147	100
2022-065	131	iCHEM VELO		053 055	053 055		054 - 2+	29	20	27	100
2022-065	131	iCHEM VELO		053 055	053 055		055 - 3+	29	7	27	100
2022-065	131	iCHEM VELO		053 055	053 055		056 - 4+	29	2	27	0
2022-065	135	Hybrido AU		053 055	053 055		054 - 2+	12	11	12	100
2022-065	135	Hybrido AU		053 055	053 055		055 - 3+	12	1	12	100
2022-065	138	URS-10T		054 056	053 055		054 - 2+	10	5	10	100
2022-065	138	URS-10T		054 056	053 055		055 - 3+	10	5	10	100
2022-065	140	MISSION A		053 055	053 055		054 - 2+	53	29	53	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-065	140	MISSION A		053 055	053 055		053 - 1+	53	1	53	100	
2022-065	140	MISSION A		053 055	053 055		055 - 3+	53	23	53	100	
2022-065	145	CLINITEK		054 056	053 055		054 - 2+	15	6	15	100	
2022-065	145	CLINITEK		054 056	053 055		055 - 3+	15	9	15	100	
2022-065	147	Mission120		053 055	053 055		054 - 2+	35	24	35	100	
2022-065	147	Mission120		053 055	053 055		053 - 1+	35	5	35	100	
2022-065	147	Mission120		053 055	053 055		055 - 3+	35	6	35	100	
2022-065	148	Mission500		054 056	053 055		054 - 2+	54	10	54	100	
2022-065	148	Mission500		054 056	053 055		055 - 3+	54	42	54	100	
2022-065	148	Mission500		054 056	053 055		056 - 4+	54	2	54	100	
066 URINAL.-UROBILINOGEN												
2022-061	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	
2022-061	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2022-061	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	51	51	51	100	
2022-061	071	ATLAS		061 061	061 061		061 - NORMAL,NEG	11	11	11	100	
2022-061	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	96	96	96	100	
2022-061	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2022-061	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	116	116	116	100	
2022-061	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2022-061	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2022-061	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	29	29	29	100	
2022-061	135	Hybrido AU		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
2022-061	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2022-061	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	53	53	53	100	
2022-061	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	15	15	15	100	
2022-061	147	Mission120		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2022-061	148	Mission500		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2022-062	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-062	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	33	33	33	100
2022-062	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	51	51	51	100
2022-062	071	ATLAS		061 061	061 061		061 - NORMAL,NEG	11	11	11	100
2022-062	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	96	96	96	100
2022-062	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100
2022-062	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	116	116	116	100
2022-062	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100
2022-062	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	146	146	146	100
2022-062	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	29	29	29	100
2022-062	135	Hybrido AU		061 061	061 061		061 - NORMAL,NEG	12	12	12	100
2022-062	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100
2022-062	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	53	53	53	100
2022-062	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	15	15	15	100
2022-062	147	Mission120		061 061	061 061		061 - NORMAL,NEG	35	35	35	100
2022-062	148	Mission500		061 061	061 061		061 - NORMAL,NEG	54	54	54	100
066 URINAL.-UROBILINOGEN											
2022-063	011	AMES NMI0S		061 061	061 061		061 - NORMAL,NEG	49	49	49	100
2022-063	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	33	33	33	100
2022-063	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	51	51	51	100
2022-063	071	ATLAS		061 061	061 061		061 - NORMAL,NEG	11	11	11	100
2022-063	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	96	95	95	100
2022-063	072	URS-9-TECO		061 061	061 061		062 - 2	96	1	95	0
2022-063	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100
2022-063	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	116	116	116	100
2022-063	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100
2022-063	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	146	146	146	100
2022-063	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	29	29	29	100
2022-063	135	Hybrido AU		061 061	061 061		061 - NORMAL,NEG	12	12	12	100
2022-063	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100
2022-063	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	53	53	53	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-063	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	15	15	15	100	
2022-063	147	Mission120		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2022-063	148	Mission500		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
066 URINAL.-UROBILINOGEN												
2022-064	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	
2022-064	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2022-064	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	51	51	51	100	
2022-064	071	ATLAS		061 061	061 061		061 - NORMAL,NEG	11	11	11	100	
2022-064	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	96	95	95	100	
2022-064	072	URS-9-TECO		061 061	061 061		062 - 2	96	1	95	0	
2022-064	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2022-064	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	116	116	116	100	
2022-064	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2022-064	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2022-064	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	29	29	29	100	
2022-064	135	Hybrido AU		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
2022-064	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2022-064	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	53	53	53	100	
2022-064	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	15	15	15	100	
2022-064	147	Mission120		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2022-064	148	Mission500		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2022-065	011	AMES NM10S		061 063	061 063		061 - NORMAL,NEG	49	5	47	100	
2022-065	011	AMES NM10S		061 063	061 063		062 - 2	49	27	47	100	
2022-065	011	AMES NM10S		061 063	061 063		063 - 4	49	15	47	100	
2022-065	011	AMES NM10S		061 063	061 063		064 - 8	49	2	47	0	
2022-065	013	BAYER CLI		061 063	061 063		063 - 4	33	3	33	100	
2022-065	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	33	10	33	100	
2022-065	013	BAYER CLI		061 063	061 063		062 - 2	33	20	33	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-065	067	URISCAN			061 063		061 - NORMAL,NEG	51	15	51	100
2022-065	067	URISCAN			061 063		062 - 2	51	6	51	100
2022-065	067	URISCAN			061 063		063 - 4	51	30	51	100
2022-065	071	ATLAS		061 063	061 063		062 - 2	11	10	11	100
2022-065	071	ATLAS		061 063	061 063		063 - 4	11	1	11	100
2022-065	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	96	23	93	100
2022-065	072	URS-9-TECO		061 063	061 063		062 - 2	96	57	93	100
2022-065	072	URS-9-TECO		061 063	061 063		063 - 4	96	13	93	100
2022-065	072	URS-9-TECO		061 063	061 063		064 - 8	96	3	93	0
2022-065	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	38	34	38	100
2022-065	080	ROCHE (CHE		061 061	061 063		062 - 2	38	4	38	100
2022-065	089	AIMSTRIP			061 063		063 - 4	116	6	115	100
2022-065	089	AIMSTRIP			061 063		064 - 8	116	1	115	0
2022-065	089	AIMSTRIP			061 063		061 - NORMAL,NEG	116	71	115	100
2022-065	089	AIMSTRIP			061 063		062 - 2	116	38	115	100
2022-065	094	CLINITEK		061 063	061 063		061 - NORMAL,NEG	106	19	106	100
2022-065	094	CLINITEK		061 063	061 063		062 - 2	106	54	106	100
2022-065	094	CLINITEK		061 063	061 063		063 - 4	106	33	106	100
2022-065	102	ACON LAB		061 061	061 063		061 - NORMAL,NEG	146	123	146	100
2022-065	102	ACON LAB		061 061	061 063		062 - 2	146	23	146	100
2022-065	131	iCHEM VELO		062 064	061 063		063 - 4	29	29	29	100
2022-065	135	Hybrido AU		061 063	061 063		061 - NORMAL,NEG	12	2	12	100
2022-065	135	Hybrido AU		061 063	061 063		062 - 2	12	10	12	100
2022-065	138	URS-10T			061 063		061 - NORMAL,NEG	10	6	10	100
2022-065	138	URS-10T			061 063		062 - 2	10	3	10	100
2022-065	138	URS-10T			061 063		063 - 4	10	1	10	100
2022-065	140	MISSION A		061 061	061 063		063 - 4	53	1	53	100
2022-065	140	MISSION A		061 061	061 063		061 - NORMAL,NEG	53	48	53	100
2022-065	140	MISSION A		061 061	061 063		062 - 2	53	4	53	100
2022-065	145	CLINITEK		061 063	061 063		062 - 2	15	15	15	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-065	147	Mission120		061 061	061 063		061 - NORMAL,NEG	35	34	35	100
2022-065	147	Mission120		061 061	061 063		062 - 2	35	1	35	100
2022-065	148	Mission500		061 061	061 063		061 - NORMAL,NEG	54	50	54	100
2022-065	148	Mission500		061 061	061 063		062 - 2	54	3	54	100
2022-065	148	Mission500		061 061	061 063		063 - 4	54	1	54	100
184 URINALYSIS LEUKOCYTE											
2022-061	011	AMES NM10S		002 004	003 005		003 - Small	45	40	45	100
2022-061	011	AMES NM10S		002 004	003 005		004 - Moderate	45	5	45	100
2022-061	013	BAYER CLI		002 004	003 005		003 - Small	33	29	33	100
2022-061	013	BAYER CLI		002 004	003 005		004 - Moderate	33	4	33	100
2022-061	067	URISCAN		004 005	003 005		005 - Large	51	29	50	100
2022-061	067	URISCAN		004 005	003 005		002 - Traces	51	1	50	0
2022-061	067	URISCAN		004 005	003 005		004 - Moderate	51	21	50	100
2022-061	071	ATLAS		003 005	003 005		003 - Small	11	1	11	100
2022-061	071	ATLAS		003 005	003 005		004 - Moderate	11	10	11	100
2022-061	072	URS-9-TECO		003 005	003 005		001 - Negative	89	1	87	0
2022-061	072	URS-9-TECO		003 005	003 005		002 - Traces	89	1	87	0
2022-061	072	URS-9-TECO		003 005	003 005		003 - Small	89	37	87	100
2022-061	072	URS-9-TECO		003 005	003 005		004 - Moderate	89	49	87	100
2022-061	072	URS-9-TECO		003 005	003 005		005 - Large	89	1	87	100
2022-061	080	ROCHE (CHE		004 005	003 005		003 - Small	35	2	35	100
2022-061	080	ROCHE (CHE		004 005	003 005		004 - Moderate	35	3	35	100
2022-061	080	ROCHE (CHE		004 005	003 005		005 - Large	35	30	35	100
2022-061	089	AIMSTRIP		002 004	003 005		002 - Traces	114	3	114	100
2022-061	089	AIMSTRIP		002 004	003 005		003 - Small	114	81	114	100
2022-061	089	AIMSTRIP		002 004	003 005		004 - Moderate	114	26	114	100
2022-061	089	AIMSTRIP		002 004	003 005		005 - Large	114	4	114	100
2022-061	094	CLINITEK		002 004	003 005		002 - Traces	107	2	107	100
2022-061	094	CLINITEK		002 004	003 005		003 - Small	107	100	107	100
2022-061	094	CLINITEK		002 004	003 005		004 - Moderate	107	4	107	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-061	094	CLINITEK		002 004	003 005		005 - Large	107	1	107	100
2022-061	102	ACON LAB		002 004	003 005		001 - Negative	133	2	131	0
2022-061	102	ACON LAB		002 004	003 005		002 - Traces	133	7	131	100
2022-061	102	ACON LAB		002 004	003 005		003 - Small	133	75	131	100
2022-061	102	ACON LAB		002 004	003 005		004 - Moderate	133	48	131	100
2022-061	102	ACON LAB		002 004	003 005		005 - Large	133	1	131	100
2022-061	131	iCHEM VELO		004 005	003 005		004 - Moderate	29	3	29	100
2022-061	131	iCHEM VELO		004 005	003 005		005 - Large	29	26	29	100
2022-061	135	Hybrido AU		004 005	003 005		005 - Large	12	12	12	100
2022-061	138	URS-10T		002 004	003 005		002 - Traces	10	1	10	100
2022-061	138	URS-10T		002 004	003 005		003 - Small	10	8	10	100
2022-061	138	URS-10T		002 004	003 005		004 - Moderate	10	1	10	100
2022-061	140	MISSION A		002 004	003 005		002 - Traces	60	3	60	100
2022-061	140	MISSION A		002 004	003 005		003 - Small	60	40	60	100
2022-061	140	MISSION A		002 004	003 005		004 - Moderate	60	17	60	100
2022-061	145	CLINITEK		003 005	003 005		003 - Small	15	1	15	100
2022-061	145	CLINITEK		003 005	003 005		004 - Moderate	15	14	15	100
2022-061	147	Mission120		002 004	003 005		002 - Traces	34	6	34	100
2022-061	147	Mission120		002 004	003 005		003 - Small	34	26	34	100
2022-061	147	Mission120		002 004	003 005		004 - Moderate	34	1	34	100
2022-061	147	Mission120		002 004	003 005		005 - Large	34	1	34	100
2022-061	148	Mission500		002 004	003 005		003 - Small	53	35	53	100
2022-061	148	Mission500		002 004	003 005		004 - Moderate	53	18	53	100
184 URINALYSIS LEUKOCYTE											
2022-062	011	AMES NM10S		001 001	001 001		001 - Negative	45	45	45	100
2022-062	013	BAYER CLI		001 001	001 001		001 - Negative	33	33	33	100
2022-062	067	URISCAN		001 001	001 001		001 - Negative	51	51	51	100
2022-062	071	ATLAS		001 001	001 001		001 - Negative	11	11	11	100
2022-062	072	URS-9-TECO		001 001	001 001		001 - Negative	89	89	89	100
2022-062	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-062	089	AIMSTRIP		001 001	001 001		001 - Negative	114	114	114	100	
2022-062	094	CLINITEK		001 001	001 001		001 - Negative	107	107	107	100	
2022-062	102	ACON LAB		001 001	001 001		001 - Negative	133	133	133	100	
2022-062	131	iCHEM VELO		001 001	001 001		001 - Negative	29	29	29	100	
2022-062	135	Hybrido AU		001 001	001 001		001 - Negative	12	12	12	100	
2022-062	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100	
2022-062	140	MISSION A		001 001	001 001		001 - Negative	60	60	60	100	
2022-062	145	CLINITEK		001 001	001 001		001 - Negative	15	15	15	100	
2022-062	147	Mission120		001 001	001 001		001 - Negative	34	34	34	100	
2022-062	148	Mission500		001 001	001 001		001 - Negative	53	53	53	100	
184 URINALYSIS LEUKOCYTE												
2022-063	011	AMES NM10S		001 001	001 001		001 - Negative	45	44	44	100	
2022-063	011	AMES NM10S		001 001	001 001		002 - Traces	45	1	44	0	
2022-063	013	BAYER CLI		001 001	001 001		001 - Negative	33	33	33	100	
2022-063	067	URISCAN		001 001	001 001		001 - Negative	51	51	51	100	
2022-063	071	ATLAS		001 001	001 001		001 - Negative	11	11	11	100	
2022-063	072	URS-9-TECO		001 001	001 001		001 - Negative	89	89	89	100	
2022-063	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100	
2022-063	089	AIMSTRIP		001 001	001 001		001 - Negative	114	114	114	100	
2022-063	094	CLINITEK		001 001	001 001		001 - Negative	107	107	107	100	
2022-063	102	ACON LAB		001 001	001 001		001 - Negative	133	133	133	100	
2022-063	131	iCHEM VELO		001 001	001 001		001 - Negative	29	29	29	100	
2022-063	135	Hybrido AU		001 001	001 001		001 - Negative	12	12	12	100	
2022-063	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100	
2022-063	140	MISSION A		001 001	001 001		001 - Negative	60	60	60	100	
2022-063	145	CLINITEK		001 001	001 001		001 - Negative	15	15	15	100	
2022-063	147	Mission120		001 001	001 001		001 - Negative	34	34	34	100	
2022-063	148	Mission500		001 001	001 001		001 - Negative	53	53	53	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
184 URINALYSIS LEUKOCYTE													
2022-064	011	AMES NM10S		001	001	001	001	001 - Negative	45	45	45	100	
2022-064	013	BAYER CLI		001	001	001	001	001 - Negative	33	33	33	100	
2022-064	067	URISCAN		001	001	001	001	001 - Negative	51	51	51	100	
2022-064	071	ATLAS		001	001	001	001	001 - Negative	11	11	11	100	
2022-064	072	URS-9-TECO		001	001	001	001	001 - Negative	89	89	89	100	
2022-064	080	ROCHE (CHE		001	001	001	001	001 - Negative	35	35	35	100	
2022-064	089	AIMSTRIP		001	001	001	001	001 - Negative	114	113	113	100	
2022-064	089	AIMSTRIP		001	001	001	001	003 - Small	114	1	113	0	
2022-064	094	CLINITEK		001	001	001	001	001 - Negative	107	107	107	100	
2022-064	102	ACON LAB		001	001	001	001	001 - Negative	133	133	133	100	
2022-064	131	iCHEM VELO		001	001	001	001	001 - Negative	29	29	29	100	
2022-064	135	Hybrido AU		001	001	001	001	001 - Negative	12	12	12	100	
2022-064	138	URS-10T		001	001	001	001	001 - Negative	10	10	10	100	
2022-064	140	MISSION A		001	001	001	001	001 - Negative	60	60	60	100	
2022-064	145	CLINITEK		001	001	001	001	001 - Negative	15	15	15	100	
2022-064	147	Mission120		001	001	001	001	001 - Negative	34	34	34	100	
2022-064	148	Mission500		001	001	001	001	001 - Negative	53	53	53	100	
2022-065	011	AMES NM10S		001	001	001	001	001 - Negative	45	45	45	100	
2022-065	013	BAYER CLI		001	001	001	001	001 - Negative	33	33	33	100	
2022-065	067	URISCAN		001	001	001	001	001 - Negative	51	51	51	100	
2022-065	071	ATLAS		001	001	001	001	001 - Negative	11	11	11	100	
2022-065	072	URS-9-TECO		001	001	001	001	001 - Negative	89	89	89	100	
2022-065	080	ROCHE (CHE		001	001	001	001	001 - Negative	35	35	35	100	
2022-065	089	AIMSTRIP		001	001	001	001	001 - Negative	114	113	113	100	
2022-065	089	AIMSTRIP		001	001	001	001	002 - Traces	114	1	113	0	
2022-065	094	CLINITEK		001	001	001	001	001 - Negative	107	107	107	100	
2022-065	102	ACON LAB		001	001	001	001	001 - Negative	133	133	133	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-065	131	iCHEM VELO		001 001	001 001		001 - Negative	29	29	29	100
2022-065	135	Hybrido AU		001 001	001 001		001 - Negative	12	12	12	100
2022-065	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100
2022-065	140	MISSION A		001 001	001 001		001 - Negative	60	60	60	100
2022-065	145	CLINITEK		001 001	001 001		001 - Negative	15	15	15	100
2022-065	147	Mission120		001 001	001 001		001 - Negative	34	34	34	100
2022-065	148	Mission500		001 001	001 001		001 - Negative	53	53	53	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
063 URI-PREGNANCY TEST													
2022-061	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2022-061	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100	
2022-062	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100	
2022-062	101	HCG Alere		002	002	002	002	002 - POSITIVE	23	23	23	100	
2022-063	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2022-063	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100	
2022-064	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100	
2022-064	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100	
2022-065	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100	
2022-065	101	HCG Alere		002	002	002	002	002 - POSITIVE	23	23	23	100	

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2022-071					013	013	013 - AMORPHOUS	881	873	873	100
2022-071					013	013	020 - SODIUM UR.	881	1	873	0
2022-071					013	013	024 - AMMONIUM B	881	1	873	0
2022-071					013	013	025 - AMORPHOUS	881	6	873	0
2022-072					007	007	002 - FATTY CAST	881	23	857	0
2022-072					007	007	003 - GRANULAR C	881	1	857	0
2022-072					007	007	007 - WHITE CELL	881	857	857	100
2022-073					011	011	001 - E.C. CAST	881	6	874	0
2022-073					011	011	011 - SQUAMOUS E	881	874	874	100
2022-073					011	011	012 - TRANSITIO.	881	1	874	0
2022-074					043	043	007 - WHITE CELL	882	2	793	0
2022-074					043	043	012 - TRANSITIO.	882	1	793	0
2022-074					043	043	041 - T. vagina.	882	86	793	0
2022-074					043	043	043 - Giardia la	882	793	793	100
2022-075					042	042	007 - WHITE CELL	882	2	856	0
2022-075					042	042	008 - ERYTHROCYT	882	1	856	0
2022-075					042	042	009 - LEUKOCYTE	882	23	856	0
2022-075					042	042	042 - WBC in clu	882	856	856	100

Participant Summary

MONTH 2 OF YEAR 2022

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD								
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
154 FECAL OCCULT BLOOD														
2022-081	001	PEROXIDASE		001	001	001	001	001	-	NEGATIVE	428	427	427	100
2022-081	001	PEROXIDASE		001	001	001	001	002	-	POSITIVE	428	1	427	0
2022-081	002	INMMUASSAY		001	001	001	001	001	-	NEGATIVE	711	710	710	100
2022-081	002	INMMUASSAY		001	001	001	001	002	-	POSITIVE	711	1	710	0
2022-082	001	PEROXIDASE		001	001	001	001	001	-	NEGATIVE	428	427	427	100
2022-082	001	PEROXIDASE		001	001	001	001	002	-	POSITIVE	428	1	427	0
2022-082	002	INMMUASSAY		001	001	001	001	001	-	NEGATIVE	711	711	711	100
2022-083	001	PEROXIDASE		002	002	002	002	001	-	NEGATIVE	428	1	427	0
2022-083	001	PEROXIDASE		002	002	002	002	002	-	POSITIVE	428	427	427	100
2022-083	002	INMMUASSAY		002	002	002	002	002	-	POSITIVE	711	711	711	100
2022-084	001	PEROXIDASE		002	002	002	002	001	-	NEGATIVE	428	2	426	0
2022-084	001	PEROXIDASE		002	002	002	002	002	-	POSITIVE	428	426	426	100
2022-084	002	INMMUASSAY		002	002	002	002	001	-	NEGATIVE	711	1	710	0
2022-084	002	INMMUASSAY		002	002	002	002	002	-	POSITIVE	711	710	710	100
2022-085	001	PEROXIDASE		001	001	001	001	001	-	NEGATIVE	428	427	427	100
2022-085	001	PEROXIDASE		001	001	001	001	002	-	POSITIVE	428	1	427	0
2022-085	002	INMMUASSAY		001	001	001	001	001	-	NEGATIVE	711	709	709	100
2022-085	002	INMMUASSAY		001	001	001	001	002	-	POSITIVE	711	2	709	0
SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST								

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
068	CARCINOE. ANTIG. CEA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}			
2022-031	29 VITROS			12	10.500	0.422	4.02	9.200	11.800
2022-031	38 ROCHE E			21	9.490	0.332	3.50	8.500	10.500
2022-031	44 BECK.COUL.			16	10.881	0.574	5.27	9.200	12.600
2022-031	50 ARC			10	11.310	0.617	5.46	9.500	13.200
2022-032	29 VITROS			12	30.667	1.341	4.37	26.600	34.700
2022-032	38 ROCHE E			21	25.662	0.749	2.92	23.400	27.900
2022-032	44 BECK.COUL.			16	32.075	2.006	6.25	26.100	38.100
2022-032	50 ARC			10	31.330	1.474	4.71	26.900	35.800
2022-033	29 VITROS			12	34.083	1.383	4.06	29.900	38.200
2022-033	38 ROCHE E			21	28.076	0.853	3.04	25.500	30.600
2022-033	44 BECK.COUL.			16	34.988	1.464	4.18	30.600	39.400
2022-033	50 ARC			10	34.660	1.449	4.18	30.300	39.000
2022-034	29 VITROS			12	0.309	0.029	9.30	0.200	0.400
2022-034	38 ROCHE E			21	0.665	0.149	22.44	0.500	0.800
2022-034	44 BECK.COUL.			16	0.550	0.050	9.09	0.400	0.700
2022-034	50 ARC			10	1.030	0.550	53.36	0.800	1.300
2022-035	29 VITROS			12	5.325	0.201	3.77	4.700	5.900
2022-035	38 ROCHE E			21	5.176	0.220	4.25	4.500	5.800
2022-035	44 BECK.COUL.			16	5.631	0.301	5.35	4.700	6.500
2022-035	50 ARC			10	5.660	0.353	6.23	4.600	6.700
069	PROS. SPEC-ANTIG-PSA								
2022-031	29 VITROS			38	4.926	0.209	4.23	4.300	5.600
2022-031	36 TOSOH AIA			13	6.646	0.521	7.84	5.100	8.200
2022-031	38 ROCHE E			51	9.049	0.667	7.37	7.000	11.100
2022-031	39 DIMENS.RXL			44	7.807	0.417	5.34	6.600	9.100

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-031	44	BECK.COUL.		54	8.700	0.425	4.89	7.400	10.000	
2022-031	50	ARC		22	6.982	0.514	7.36	5.400	8.500	
2022-031	57	S. EXL 200		27	7.696	0.494	6.42	6.200	9.200	
069	PROS. SPEC-ANTIG-PSA		CLIA TEST ID #: 0							EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}
2022-032	29	VITROS		38	14.166	0.764	5.40	11.900	16.500	
2022-032	36	TOSOH AIA		13	18.677	1.269	6.80	14.900	22.500	
2022-032	38	ROCHE E		51	25.731	1.611	6.26	20.900	30.600	
2022-032	39	DIMENS.RXL		44	22.884	1.230	5.37	19.200	26.600	
2022-032	44	BECK.COUL.		54	25.425	1.334	5.25	21.400	29.400	
2022-032	50	ARC		22	20.668	1.143	5.53	17.200	24.100	
2022-032	57	S. EXL 200		27	22.656	1.513	6.68	18.100	27.200	
2022-033	29	VITROS		38	15.605	0.848	5.44	13.100	18.100	
2022-033	36	TOSOH AIA		13	20.785	1.340	6.45	16.800	24.800	
2022-033	38	ROCHE E		51	28.454	1.900	6.68	22.800	34.200	
2022-033	39	DIMENS.RXL		44	25.284	1.579	6.24	20.500	30.000	
2022-033	44	BECK.COUL.		54	28.145	1.343	4.77	24.100	32.200	
2022-033	50	ARC		22	23.105	1.636	7.08	18.200	28.000	
2022-033	57	S. EXL 200		27	24.908	1.626	6.53	20.000	29.800	
2022-034	29	VITROS		38	0.100	0.000	0.00	0.100	0.100	
2022-034	36	TOSOH AIA		13	0.069	0.046	66.67	0.100	0.100	
2022-034	38	ROCHE E		51	0.024	0.081	339.12	0.000	0.000	
2022-034	39	DIMENS.RXL		44	0.082	0.039	47.14	0.100	0.100	
2022-034	44	BECK.COUL.		54	0.000	0.000	0.00	0.000	0.000	
2022-034	50	ARC		22	0.000	0.000	0.00	0.000	0.000	
2022-034	57	S. EXL 200		27	0.059	0.049	82.92	0.000	0.100	
2022-035	29	VITROS		38	2.608	0.148	5.66	2.200	3.100	
2022-035	36	TOSOH AIA		13	3.300	0.266	8.06	2.500	4.100	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 90 SPECIAL TEST

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-035	38	ROCHE E	51	4.527	0.294	6.49	3.600	5.400
2022-035	39	DIMENS.RXL	44	3.844	0.203	5.27	3.200	4.500
2022-035	44	BECK.COUL.	54	4.292	0.243	5.65	3.600	5.000
2022-035	50	ARC	22	3.409	0.219	6.43	2.800	4.100
2022-035	57	S. EXL 200	27	3.773	0.262	6.96	3.000	4.600
071 VITAMIN B 12		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}				
2022-031	29	VITROS	23	460.318	19.172	4.17	403.000	518.000
2022-031	38	ROCHE E	29	435.172	60.509	13.90	326.000	544.000
2022-031	44	BECK.COUL.	27	342.556	18.935	5.53	286.000	399.000
2022-031	50	ARC	20	426.400	39.245	9.20	320.000	533.000
2022-031	57	S. EXL 200	16	456.938	37.136	8.13	346.000	568.000
2022-032	29	VITROS	23	845.261	50.576	5.98	694.000	997.000
2022-032	38	ROCHE E	29	969.690	64.163	6.62	777.000	1162.000
2022-032	44	BECK.COUL.	27	659.667	39.997	6.06	540.000	780.000
2022-032	50	ARC	20	846.789	52.732	6.23	689.000	1005.000
2022-032	57	S. EXL 200	16	908.688	83.526	9.19	682.000	1136.000
2022-033	29	VITROS	23	842.000	59.028	7.01	665.000	1019.000
2022-033	38	ROCHE E	29	1049.483	52.891	5.04	891.000	1208.000
2022-033	44	BECK.COUL.	27	714.222	41.512	5.81	590.000	839.000
2022-033	50	ARC	20	905.842	57.065	6.30	735.000	1077.000
2022-033	57	S. EXL 200	16	977.063	83.707	8.57	733.000	1221.000
2022-034	29	VITROS	23	233.909	9.839	4.21	204.000	263.000
2022-034	38	ROCHE E	29	198.786	41.702	20.98	149.000	248.000
2022-034	44	BECK.COUL.	27	160.704	10.036	6.25	131.000	191.000
2022-034	50	ARC	20	204.650	25.709	12.56	153.000	256.000
2022-034	57	S. EXL 200	16	238.125	25.632	10.76	179.000	298.000

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
071 VITAMIN B 12		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}				
2022-035	29 VITROS			23	333.545	8.742	2.62	307.000	360.000	
2022-035	38 ROCHE E			29	312.379	53.151	17.01	234.000	390.000	
2022-035	44 BECK.COUL.			27	252.593	11.183	4.43	219.000	286.000	
2022-035	50 ARC			20	312.250	33.991	10.89	234.000	390.000	
2022-035	57 S. EXL 200			16	355.625	24.884	7.00	281.000	430.000	

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
146 GLYCOHEMOGLOBIN										
2022-041	12 COBAS/INT.			30	6.500	1.000	15.38	4.900	8.100	
2022-041	12 COBAS/INT.			30	6.645	0.234	3.53	5.900	7.300	
2022-041	14 IMMUNOTUR.			12	6.855	0.468	6.82	5.500	8.300	
2022-041	22 VITROS			45	6.702	0.169	2.53	6.200	7.200	
2022-041	30 DAYTONA			12	6.933	0.330	4.76	5.900	7.900	
2022-041	31 IMMUNOTURB			32	6.574	0.168	2.56	6.100	7.100	
2022-041	40 SIEMENS DI			80	6.782	0.135	1.99	6.400	7.200	
2022-041	40 SIEMENS DI			80	6.500	1.000	15.38	4.900	8.100	
2022-041	46 ARCHITECT			17	6.424	0.100	1.56	6.100	6.700	
2022-042	12 COBAS/INT.			30	6.062	0.230	3.79	5.400	6.800	
2022-042	12 COBAS/INT.			30	5.600	1.000	17.86	4.200	7.000	
2022-042	14 IMMUNOTUR.			12	6.200	0.245	3.95	5.500	6.900	
2022-042	22 VITROS			45	6.060	0.153	2.52	5.600	6.500	
2022-042	30 DAYTONA			12	6.050	0.318	5.25	5.100	7.000	
2022-042	31 IMMUNOTURB			32	6.003	0.120	2.01	5.600	6.400	
2022-042	40 SIEMENS DI			80	5.600	1.000	17.86	4.200	7.000	
2022-042	40 SIEMENS DI			80	6.151	0.130	2.12	5.800	6.500	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-042	46	ARCHITECT		17	5.753	0.098	1.70	5.500	6.000	
146	GLYCOHEMOGLOBIN			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2022-043	12	COBAS/INT.		30	6.500	1.000	15.38	4.900	8.100	
2022-043	12	COBAS/INT.		30	6.713	0.320	4.77	5.800	7.700	
2022-043	14	IMMUNOTUR.		12	6.909	0.552	7.99	5.300	8.600	
2022-043	22	VITROS		45	6.680	0.171	2.56	6.200	7.200	
2022-043	30	DAYTONA		12	6.967	0.431	6.18	5.700	8.300	
2022-043	31	IMMUNOTURB		32	6.597	0.140	2.13	6.200	7.000	
2022-043	40	SIEMENS DI		80	6.782	0.123	1.81	6.400	7.200	
2022-043	40	SIEMENS DI		80	6.500	1.000	15.38	4.900	8.100	
2022-043	46	ARCHITECT		17	6.435	0.103	1.59	6.100	6.700	
2022-044	12	COBAS/INT.		30	10.348	0.330	3.19	9.400	11.300	
2022-044	12	COBAS/INT.		30	10.100	1.000	9.90	7.600	12.600	
2022-044	14	IMMUNOTUR.		12	10.445	0.955	9.14	7.800	13.100	
2022-044	22	VITROS		45	10.184	0.517	5.07	8.600	11.700	
2022-044	30	DAYTONA		12	11.117	0.740	6.66	8.900	13.300	
2022-044	31	IMMUNOTURB		32	10.177	0.241	2.36	9.500	10.900	
2022-044	40	SIEMENS DI		80	10.100	1.000	9.90	7.600	12.600	
2022-044	40	SIEMENS DI		80	10.073	0.275	2.73	9.200	10.900	
2022-044	46	ARCHITECT		17	10.156	0.180	1.77	9.600	10.700	
2022-045	12	COBAS/INT.		30	5.600	1.000	17.86	4.200	7.000	
2022-045	12	COBAS/INT.		30	6.055	0.185	3.05	5.500	6.600	
2022-045	14	IMMUNOTUR.		12	6.255	0.382	6.11	5.100	7.400	
2022-045	22	VITROS		45	6.066	0.138	2.28	5.700	6.500	
2022-045	30	DAYTONA		12	6.083	0.372	6.11	5.000	7.200	
2022-045	31	IMMUNOTURB		32	6.023	0.113	1.87	5.700	6.400	
2022-045	40	SIEMENS DI		80	6.171	0.142	2.29	5.700	6.600	
2022-045	40	SIEMENS DI		80	5.600	1.000	17.86	4.200	7.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022-045	46	ARCHITECT		17	5.753	0.114	1.99	5.400	6.100	
SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 99 Vitamin D				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
178	Vitamin D	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %							
2022-261	3	VITROS		41	78.825	6.745	8.56	63.000	95.000	
2022-261	3	VITROS		41	64.750	2.586	3.99	52.000	78.000	
2022-261	5	ROCHE E		39	101.250	9.934	9.81	81.000	122.000	
2022-261	5	ROCHE E		39	50.316	5.804	11.54	40.000	60.000	
2022-261	9	BECK.COUL.		47	101.250	9.934	9.81	81.000	122.000	
2022-261	9	BECK.COUL.		47	78.696	6.820	8.67	63.000	94.000	
2022-261	11	ARC		20	73.950	3.278	4.43	59.000	89.000	
2022-261	25	S. DIME		28	53.370	2.328	4.36	43.000	64.000	
2022-262	3	VITROS		41	29.000	1.000	3.45	23.000	35.000	
2022-262	3	VITROS		41	31.610	5.170	16.35	25.000	38.000	
2022-262	5	ROCHE E		39	24.324	4.369	17.96	19.000	29.000	
2022-262	5	ROCHE E		39	39.500	4.770	12.08	32.000	47.000	
2022-262	9	BECK.COUL.		47	33.717	4.052	12.02	27.000	40.000	
2022-262	9	BECK.COUL.		47	39.500	4.770	12.08	32.000	47.000	
2022-262	11	ARC		20	31.750	1.220	3.84	25.000	38.000	
2022-262	25	S. DIME		28	25.741	1.174	4.56	21.000	31.000	
2022-263	3	VITROS		41	57.854	6.698	11.58	46.000	69.000	
2022-263	3	VITROS		41	47.500	5.315	11.19	38.000	57.000	
2022-263	5	ROCHE E		39	81.750	5.262	6.44	65.000	98.000	
2022-263	5	ROCHE E		39	41.421	5.985	14.45	33.000	50.000	
2022-263	9	BECK.COUL.		47	81.750	5.262	6.44	65.000	98.000	

Participant Summary

MONTH 2 OF YEAR 2022

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 99 Vitamin D			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022-263	9	BECK.COUL.		47	64.022	5.799	9.06	51.000	77.000
2022-263	11	ARC		20	59.950	2.958	4.93	48.000	72.000
2022-263	25	S. DIME		28	44.333	1.905	4.30	35.000	53.000
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %					
2022-264	3	VITROS		41	23.000	1.225	5.32	18.000	28.000
2022-264	3	VITROS		41	24.049	4.108	17.08	19.000	29.000
2022-264	5	ROCHE E		39	21.111	2.622	12.42	17.000	25.000
2022-264	5	ROCHE E		39	35.250	3.897	11.06	28.000	42.000
2022-264	9	BECK.COUL.		47	28.739	3.172	11.04	23.000	34.000
2022-264	9	BECK.COUL.		47	35.250	3.897	11.06	28.000	42.000
2022-264	11	ARC		20	28.050	1.359	4.85	22.000	34.000
2022-264	25	S. DIME		28	22.963	1.401	6.10	18.000	28.000
2022-265	3	VITROS		41	42.171	5.094	12.08	34.000	51.000
2022-265	3	VITROS		41	37.250	2.165	5.81	30.000	45.000
2022-265	5	ROCHE E		39	58.750	3.832	6.52	47.000	71.000
2022-265	5	ROCHE E		39	34.500	7.687	22.28	28.000	41.000
2022-265	9	BECK.COUL.		47	58.750	3.832	6.52	47.000	71.000
2022-265	9	BECK.COUL.		47	47.500	4.740	9.98	38.000	57.000
2022-265	11	ARC		20	46.250	2.447	5.29	37.000	56.000
2022-265	25	S. DIME		28	35.000	1.678	4.79	28.000	42.000